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Chapter 1
Introduction and outline of this thesis
Treatment of failing gas exchange in children.

1
9
Introduction and outline of this thesis
And he [Elisha] went up, and lay upon the child, and put his 
mouth upon his mouth, … and the flesh of the child waxed warm. 
(II Kings 4:34, King James version) 
This is probably the first written example of successful treatment of failing gas exchange. 
In the present day, providing adequate gas exchange and oxygen delivery remains 
one of the cornerstones of intensive care medicine. Many things have been changed, 
improved and scientifically proven since ancient times but numerous questions and 
challenges remain to be explored and proven to be of benefit. 
In 1929 Drinker and Shaw produced the first widely used external negative pressure 
mechanical ventilator, named the ”Drinker respirator”. The first patient treated with this 
’iron lung’ was an eight-year-old polio patient [1]. The Danish anesthesiologist Ibsen was 
one of the first to use positive pressure ventilation for diseased lungs outside the operat-
ing room, during the great poliomyelitis epidemic in Copenhagen in 1952 [2]. After that 
turning point in the history of intensive care permanent intensive care units were estab-
lished and patients were ventilated with positive pressure ventilation. Today, ventilation 
worldwide is mostly performed with any form of positive pressure ventilation.
In the pediatric intensive care unit this type of ventilation is basically a form of 
time cycled variation of positive pressure levels, resulting in tidal volume changes in 
the lungs. Despite the benefits of positive pressure ventilation, many patients still die 
after initiation of mechanical ventilation either from therapy failure or from progres-
sive deterioration of pulmonary functions. Moreover, mechanical ventilation might in 
itself be detrimental as since its beginning detrimental side effects of this therapy have 
been published. Multiple factors have been implicated for these effects such as oxygen 
toxicity, volume-trauma and barotrauma. Nowadays this negative effect of mechanical 
ventilation on the lung itself is referred to as ventilator-induced lung injury [3]. 
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In 1992 Burkhard Lachmann published an editorial entitled Open up the lung and keep 
the lung open [4] in which he proposed a ventilator strategy aiming to protect the lung 
by reducing or even preventing therapy- or ventilator-induced lung injury. Since then 
many studies on ventilator-induced lung injury have been published, paying attention 
to issues such as pathogenesis, evaluation of ventilation strategies and alternatives to 
mechanical ventilation. Recently (2015) Amato et al. confirmed the original ideas of 
Burkhard Lachmann that ventilation of a diseased lung with high pressure differences 
can induce further damage to the lungs and can contribute to increased mortality and 
morbidity [5].
Ventilator settings are therefore important for adequate gas exchange with minimal 
secondary injury. Furthermore the underlying disease is of equal importance since me-
chanical ventilation can only provide sufficient gas exchange if enough well-perfused 
aeriated alveoli are present. In patients with severe respiratory failure with limited or in-
sufficient alveoli even frantic efforts to maintain gas exchange, also with high ventilator 
pressures, will result in respiratory failure and death. Equally important is an adequate 
pulmonary blood flow. Severe pulmonary hypertension may reduce the pulmonary 
blood flow, increase ventilation and perfusion mismatch and thereby severely impede 
gas exchange even when alveoli are adequately ventilated.
An alternative approach to delivering sufficient gas exchange is that of gas exchange 
outside the body using artificial lungs and blood pumps. This is a technique developed 
in the early 1970s in which venous blood from the patient is pumped through an artificial 
lung where the blood is oxygenated and carbon dioxide is extracted before it is returned 
to the patient either via a vein or an artery. The variant in which the oxygenated blood 
is returned via a vein is called veno-venous (VV) extracorporeal membrane oxygenation 
(ECMO) and supports pulmonary functions; in the other variant – veno-arterial (VA)
ECMO – the blood is returned in the arterial system and this technique functions as a 
cardiopulmonary bypass supporting both the respiration and circulation.
Since its introduction in the intensive care unit in 1972, this type of gas exchange in 
combination with mechanical ventilation has become an alternative treatment option 
in severe cardiorespiratory failure [6]. The use of ECMO was widely embraced in neonatal 
care as well. The first reported use in neonatal care dates from 1977 [7]. Since then over 
36,000 neonates have been treated with ECMO. The use of ECMO for pediatric patients is 
increasing and more than 18,000 pediatric patients have been treated with ECMO until 
now. ECMO has become a reliable option allowing for intrinsic recovery of the lungs and 
potentially reducing secondary damage due to high pressure mechanical ventilation [8]. 
The Extracorporeal Life Support Organization (ELSO), Ann Arbor, Michigan, was 
formed in 1989 as a non-profit organization that aids centers using extracorporeal life 
support in the management of cardiopulmonary failure unresponsive to conventional 
medical and surgical therapies. The ELSO maintains a registry of extracorporeal life sup-
1
11
Introduction and outline of this thesis
port cases and provides annual Extracorporeal Life Support (ECLS) survival information 
and center-based performance reports. Figure 1. shows a summary report of all patients 
in the registry up to January 2016.
Despite the many patients treated, many questions regarding the use of ECMO remain. 
Changes in ECMO materials such as devices and cannulas as well as other advances in 
the fi eld have greatly altered ECMO indications and utility of ECMO in diff erent popula-
tions. Changes in the underlying pathology in ECMO patients, the concept of minimal 
ventilation to prevent or reduce ventilator induced lung injury and the use of VV ECMO 
with double lumen single catheter cannulas have come with many challenges. With the 
shift from neonatal to pediatric and adult ECMO, clear insight from research is needed to 
reach consensus on contraindications for ECMO, the timing of ECMO initiation, optimal 
management strategies for subgroups of ECMO patients, diagnostic criteria and time 
estimates on recoverability of lung function.
figure 1: International summary of extracorporeal life support cases in the ESLO registry.
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1
12
OutlinE Of tHE tHEsis
The general aim of this thesis is to provide scientifically valid data that will help to guide 
the treatment of failing gas exchange in pediatric patients. This thesis is in two parts.
Part 1. Mechanical ventilation for failing gas exchange in children
In chapter 2 we analyze the existing literature on ventilator modes in children aged 
from 28 days to 18 years, and we perform a search for articles comparing two different 
modes of ventilation. We discuss the reported differences between modes of ventilation 
with regard to length of ventilation, oxygenation, mortality, chronic lung disease and 
weaning.
After a search in the PubMed and EMBASE databases and the screening of 461 poten-
tially relevant articles, nine full text articles were retrieved and assessed for eligibility. 
Four randomized controlled trials (RCTs) were excluded, however, for any of the follow-
ing reasons: focus on triggering instead of ventilation; inclusion of infants below 37 
weeks of gestational age; or not comparing two ventilation modes. chapter 2 contains 
the results of analysis of the pooled data of the remaining five RCTs [9].
With the knowledge obtained in chapter 2 we developed an invasive ventilation 
algorithm. The algorithm distinguishes between the presence of lung disease, in which 
pressure control is considered as the preferred mode, and the absence of lung disease, 
in which situation pressure-regulated volume control is preferred. In chapter 3 we 
evaluate physician adherence to this new protocol [10].
In chapter 4 we describe the use of extracorporeal membrane oxygenation (ECMO) 
in pediatric patients [11]. In this chapter we discuss the available evidence for the use of 
pediatric ECMO in respiratory and circulatory failure, focusing on indications and contra-
indications and choice of ECMO mode.
Part 2. Aspects in the use of Extracorporeal Membrane Oxygenation to assist 
gas exchange in children
In chapter 5 we present data on the use of arterial lactate for predicting mortality in 
children requiring ECMO [12]. We show that static arterial lactate measurements and, to 
a lesser extent, dynamic arterial lactate indices predict mortality in pediatric, but not in 
neonatal ECMO patients.
In chapter 6 we present a retrospective analysis of the role of preoperative ECMO in 
neonates born with transposition of the great arteries with severe hypoxemia, despite 
conventional measures like balloon atrioseptostomy, ventilation, nitric oxide inhalation 
and inotropic support.
In chapter 7 we describe prolonged use of ECMO defined as an ECMO run of more 
than 21 days in pediatric patients in particular. An analysis is performed on survival; the 
1
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occurrence and nature of complications; and the need for interventional and diagnostic 
procedures. 
chapter 8 reports on the benefits and drawbacks of open lung biopsy in neonatal and 
pediatric patients on ECMO. We describe all open lung biopsies performed during ECMO 
in the Netherlands in the period 1990-2014.
In chapter 9 we investigated the feasibility of surgical correction of congenital dia-
phragmatic hernia while the patient is on ECMO and report on the surgical bleeding 
complications associated with this procedure [13].
We describe our findings on the pharmacological aspects during ECMO in chapter 10.
In chapter 11 we present a multicenter study on the use of a new diagonal pump for 
the use in ECMO. We pooled the patient data from seven European pediatric centers on 
a new miniaturized third generation diagonal centrifugal pump, to evaluate the feasibil-
ity, efficacy, complication-, and survival rate.
In chapter 12 we discuss the current status of the use of perfluorocarbons (PFC’s) in 
respiratory failure.
Lastly, the implications of our findings are discussed and compared to the available 
literature in chapter 13 [14].
chapter 14 contains the summary of this thesis.
Introduction and outline of this thesis
1
14
REfEREncEs
 1. Drinker P, McKhann CF: The use of a new apparatus for the prolonged administration of artificial 
respiration: I. a fatal case of poliomyelitis. JAMA 255: 1473-5, 1986
 2. Ibsen B: The anaesthetist’s viewpoint on the treatment of respiratory complications in poliomy-
elitis during the epidemic in Copenhagen, 1952. Proceedings of the Royal Society of Medicine 47: 
72-4, 1954
 3. Slutsky AS, Ranieri VM: Ventilator-Induced Lung Injury. New England Journal of Medicine 369: 
2126-36, 2013
 4. Lachmann B: Open up the lung and keep the lung open. Intensive Care Med 18: 319-21, 1992
 5. Amato MB, Meade MO, Slutsky AS, et al: Driving pressure and survival in the acute respiratory 
distress syndrome. The New England journal of medicine 372: 747-55, 2015
 6. Hill JD, O’Brien TG, Murray JJ, et al: Prolonged extracorporeal oxygenation for acute post-traumatic 
respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. The New England 
journal of medicine 286: 629-34, 1972
 7. Bartlett RH, Gazzaniga AB, Huxtable RF, et al: Extracorporeal circulation (ECMO) in neonatal 
respiratory failure. J Thorac Cardiovasc Surg 74: 826-33, 1977
 8. Peek GJ, Mugford M, Tiruvoipati R, et al: Efficacy and economic assessment of conventional venti-
latory support versus extracorporeal membrane oxygenation for severe adult respiratory failure 
(CESAR): a multicentre randomised controlled trial. Lancet 374: 1351-63, 2009
 9. Duyndam A, Ista E, Houmes RJ, et al: Invasive ventilation modes in children: a systematic review 
and meta-analysis. Crit Care 15: R24, 2011
 10. Duyndam A, Houmes RJ, van Dijk M, et al: How to achieve adherence to a ventilation algorithm 
for critically ill children? Nurs Crit Care, 2014
 11. Houmes RJ, Wildschut E, Pokorna P, et al: Challenges in non-neonatal extracorporeal membrane 
oxygenation. Minerva Pediatr 64: 439-45, 2012
 12. Buijs E, Houmes RJ, Rizopoulos D, et al: Arterial lactate for predicting mortality in children requir-
ing extracorporeal membrane oxygenation. Minerva anestesiologica, 2014
 13. Keijzer R, Wilschut DE, Houmes RJ, et al: Congenital diaphragmatic hernia: to repair on or off 
extracorporeal membrane oxygenation? J Pediatr Surg 47: 631-6, 201214
 14. Snoek KG, Houmes RJ, Tibboel D: Liquid ventilation in congenital diaphragmatic hernia: back on 
stage? Pediatr Crit Care Med 15: 914-915, 2014


Part 1
Mechanical ventilation for failing gas 
exchange in children
Quality means doing it right 
when no one is looking 
(Henry Ford 1863-1947)

Chapter 2
Invasive ventilation modes in children: 
a systematic review and meta-analysis
Anita Duyndam, Erwin Ista, Robert Jan Houmes, Bionda van Driel, Irwin Reiss, Dick 
Tibboel
Crit Care. 2011;15(1):R24.
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AbstRAct
introduction
The purpose of this study was to critically review the existing body of evidence on ven-
tilation modes for infants and children up to the age of 18 years.
Methods 
The databases PubMed and EMBASE were searched using the search terms: ‘artificial 
respiration’, ‘instrumentation’, ‘device’, ‘devices’, ‘mode’, ‘modes’. The review included only 
studies comparing two ventilation modes in a randomized controlled study (RCT) and 
reporting one of the following outcome measures: length of ventilation (LOV), oxygen-
ation, mortality, chronic lung disease and weaning. We quantitatively pooled the results 
of trials where suitable. 
Results 
Five trials met the inclusion criteria. They addressed six different ventilation modes in 
421 children: high frequency oscillation (HFO), pressure control (PC), pressure support 
(PS), volume support (VS), volume diffusive respirator (VDR) and biphasic positive airway 
pressure. Overall there were no significant differences in LOV and mortality or survival 
rate associated with the different ventilation modes. Two trials compared HFO versus 
conventional ventilation. In the pooled analysis, mortality rate did not differ between 
these modes (odds ratio (OR) 0.83, 95% confidence interval (CI) 0.30 to 1.91). High-
frequency ventilation (HFO and VDR) was associated with a better oxygenation after 72 
hours than was conventional ventilation. One study found a significantly higher PaO2/
FiO2 ratio with the use of VDR versus PC ventilation in children with burns. Weaning was 
studied in 182 children assigned to either a PS protocol, VS protocol or no protocol. Most 
children could be weaned within two days and weaning time did not significantly differ 
between the groups.
conclusion 
The literature provides scarce data for the best ventilation mode in critically ill children 
beyond the newborn period. However, there is no evidence that high-frequency ventila-
tion reduced mortality and LOV. Longer-term outcome measures such as pulmonary 
function, neurocognitive development, and cost-effectiveness should be considered in 
future studies.
Invasive ventilation modes in children: a systematic review and meta-analysis 
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intROductiOn
Ventilator-induced lung injury in critically ill children suffering from acute respiratory 
failure should be counteracted by adapting ventilation management to the cause of re-
spiratory failure [1]. Ideally, management should be based on proven effective strategies. 
In a multicenter study bronchiolitis was the most frequent cause of respiratory failure in 
infants (43.6%); pneumonia that in older children (24.8%) [2]. Mortality in that study was 
rare (1.6%); the median duration of ventilation was 7 days. Randolph et al. [1] suggested 
that in pediatric clinical trials, long-term morbidity would be a more sensitive indicator of 
the effects of clinical ventilation interventions than mortality or duration of ventilation. 
Pediatric intensive care units (PICUs) worldwide use a wide variety of ventilation modes: 
high frequency oscillation (HFO), pressure control (PC), synchronized intermittent manda-
tory ventilation (SIMV), pressure support (PS), pressure regulated volume control (PRVC) 
and, more recently, neurally adjusted ventilator assist (NAVA) [3, 4]. The ventilation mode 
is often not targeted specifically to the underlying disease but rather determined by the 
intensive care physician’s experience, local PICU policy and protocols, or outcomes of stud-
ies in adults [1, 2, 5]. An unambiguous international guideline is still lacking [1, 5]. 
The objective of this article is to systematically review the randomized controlled trials 
(RCTs) comparing ventilation modes used in critically ill children (term born up to 18 
years of age) on the following outcome measures: length of ventilation, oxygenation, 
mortality, chronic lung disease and weaning. We aimed to answer the question whether 
there is sufficient evidence to decide on the better mode.
MEtHOds
search and selection
A systematic search was performed in PubMed and EMBASE in September 2010. MeSH 
terms and keywords searched for in the titles, abstracts and keywords areas were: 
‘artificial respiration’, ‘instrumentation’, ‘device’, ‘devices’, ‘mode’, ‘modes’, combined with 
Boolean operators AND, OR. (Additional file 1 provides the complete search strategy). 
The search was limited to RCTs or quasi-experimental studies, with age limit > 28 days 
until 18 years. Only articles comparing at least two ventilation modes were selected for 
review. Articles on non-invasive ventilation, studies in premature neonates (< 37 weeks), 
and articles in other languages than English or Dutch were excluded. No limits were 
imposed on publication date. 
Two authors (AvD, EI) independently reviewed abstracts and full-text articles to 
identify eligible studies. Reference lists of retrieved studies were hand searched for ad-
ditional articles.
Invasive ventilation modes in children: a systematic review and meta-analysis 
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Quality assessment
Study quality and level of evidence were assessed on criteria established by the Dutch 
Institute for Healthcare Improvement CBO in collaboration with the Dutch Cochrane li-
brary (See Additional file 2 and Table 1) [6]. The major criteria were: 1) was assignment to 
study group randomized?; 2) were investigators blinded?; 3) was it an intention-to-treat 
analysis?; 4) were the study groups comparable?; and 5) was there appropriate report of 
outcome results for each group and the estimated effect size. Consensus between the 
authors on the interpretation of the extracted data was achieved.
data abstraction
Authors AvD and EI each independently recorded patient characteristics (sample size, 
age, respiratory failure), details of the ventilation mode and period over which outcome 
variables were measured. Outcome variables considered were the following: length of 
ventilation (LOV), oxygenation, chronic lung disease (CLD), mortality and weaning.
statistical methods
We quantitatively pooled the results of individual trials, where suitable. We expressed 
the treatment effect as an odds ratio (OR) for dichotomous outcomes and as a weighted 
mean difference (WMD) for continuous outcomes with 95% confidence intervals. The 
pooled OR was estimated with the Mantel-Haenszel method which is generally the most 
robust model [7]. Differences were considered statistically significant if p < 0.05 or if the 
95% confidence interval did not include the value 1. The analyses were performed with 
Microsoft ® Excel, Office 2007 for Windows.
table 1: Level of Evidence
Level Description of evidence
1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1+ Well-conducted meta analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1- Meta analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2++ High-quality systematic reviews of case–control or cohort or studies High-quality case–control
or cohort studies with a very low risk of confounding, bias, or chance and a high probability
that the relationship is causal
2+ Well-conducted case–control or cohort studies with a low risk of confounding, bias, or chance and 
a moderate probability that the relationship is causal
2- Case–control or cohort studies with a high risk of confounding, bias, or chance and a significant 
probability that the relationship is not causal
3 Non-analytic studies, e.g. case reports, case series
4 Expert opinion
Invasive ventilation modes in children: a systematic review and meta-analysis 
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REsults
search and selection
After filtering out duplicate studies, titles and abstracts of 461 potentially relevant ar-
ticles were screened (Figure 1). The reference lists yielded one other study that had been 
missed because the keywords were not in the title or abstract. Eventually, nine full-text 
articles were retrieved and assessed for eligibility. Four RCTs were excluded for any of 
the following reasons: focus on triggering instead of ventilation; inclusion of infants 
below 37 weeks of gestational age; not comparing two ventilation modes [8-11]. This 
review therefore includes five RCTs [12-16]. 
Tabulated details of these five RCTs are presented in Tables 2 and 3.
length of ventilation 
Length of ventilation (LOV) served as outcome measure in four studies (Table 2). First, 
Arnold and colleagues [12] in a multi center trial compared HFO and conventional ven-
figure 1: Search results. RCT, randomized controlled trial.
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tilation (CV) in 58 children with either diffuse alveolar disease and/or air leak syndrome; 
29 had been randomized to HFO; 29 to CV. During the first 72 hours of study the mean 
airway pressure was significantly (p<0.001) higher in the HFO group. The HFO strategy 
entailed aggressive increases in mean airway pressure to attain the ideal lung volume 
and to achieve an arterial oxygen saturation of > 90% with FiO2 < 0.6. The CV strategy 
entailed stepping up the end-expiratory pressure and inspiratory time to increase mean 
airway pressure and to limit peak inspiratory pressure increases. Crossover to the alter-
nate ventilator was required if the patient met defined criteria for treatment failure. LOV 
did not significantly differ between the CV and HFO groups (weighted mean difference 
(WMD) 2.0 days, 95% confidence interval (CI) -9.61 to 13.61). 
Second, Dobyns et al. [14] in a multi center study compared HFO and CV in 99 children 
with acute hypoxemic respiratory failure. Seventy-three were treated with CV (38 with-
out iNO, 35 with iNO); 26 with HFO (12 without iNO, 14 with iNO). Mechanical ventila-
tion and FiO2 were adjusted to maintain SaO2 at 90% and pCO2 between 45 and 55 
mmHg. Higher pCO2 values were tolerated as long as the arterial pH was 7.20. In the CV 
strategy the positive end-expiratory pressure was increased incrementally to improve 
oxygenation while avoiding clinical and radiographic signs of lung hyperinflation. The 
peak airway pressure was maintained at < 35–40 cm H2O by limiting the level of tidal 
volume and positive end-expiratory pressure. The initial HFO settings were: FiO2 of 1.0, 
33% inspiratory time, frequency of 10 Hz, and mean airway pressure set at 2–4 cm H2O 
above that used on CV. Pressure amplitude was set to achieve perceptible chest wall 
motion and was adjusted if possible to optimize ventilation. 
table 3: Included randomized controlled trials- weaning
Reference
Study 
population Intervention/ mode
Outcome measures 
Level of 
evidence
Duration 
of weaning 
(days)*
Extubation 
failure rate Oxygenation
Randolph 
et al. [15]
182 children 
(age 0-17 
years) with 
weaning of 
ventilation 
support for 
more than 24 
hours and who 
failed a test 
for extubation 
readiness on 
minimal PS
Multi-center study (10 
centers) to evaluate 
weaning protocols 
comparing VS 
(continuous automated 
adjustment of PS by the 
ventilator) (n=59)
-  PS (adjustment by 
clinicians) (n=61)
-  to standard care (no 
protocol) (n=59)
PS: 1.6 (0.9-
4.1); VS: 1.8 
(1.0-3.2); no 
protocol: 
2.0 
(0.9-2.9), 
(p=0.75)
PS (15%), VS 
(24%); no 
protocol (17%) 
(p=0.44)
Male children 
more 
frequently 
failed 
extubation 
(OR, 7.86 95% 
CI = 2.36-26.2; 
p<.001)
ND 1++
 *Data presented as median (interquartile range). CI, confidence interval; ND, no data; OR, odds ratio; PS, 
pressure support; VS, volume support.
Invasive ventilation modes in children: a systematic review and meta-analysis 
2
26
In this study HFO did not lead to a significantly shorter LOV (Table 2). However, for 
the two ventilation groups without iNO, LOV significantly differed between CV and HFO 
(WMD -30.0 days, 95%CI -45.89 to -14.11). Third, Carman et al. [16] compared the Volume 
Diffusive Respirator (VDR) with PC ventilation in burned children with inhalation injury. 
The VDR is a high-frequency, time cycled pressure ventilator that can ventilate, oxygen-
ate and promote secretion removal. SaO2 was maintained at or above 90%; PaCO2 at <55 
mmHg. Thirty-two children with a mean age of 5.5 years (SD±0.9) were treated with VDR; 
32 children with a mean age of 9.4 years (SD±1.0) with PC ventilation (p=0.04 for mean 
age). LOV was significantly different between the study groups (WMD -1.0 days, 95%CI 
-1.98 to -0.02). Fourth, Jaarsma et al. [13] randomized 18 children with respiratory failure 
to either BIPAP (n=11) or PSV (n=7); their median age was 4 months (range 4 weeks 
to 10 years). Initial ventilator settings depended on age and the cause of respiratory 
failure and were adjusted according to thoracic excursions and measured tidal volume. 
Adjustments were made afterwards aiming at a pCO2 of 4–5 kPa and a pO2 of 8–11 kPa. 
LOV did not significantly differ between BIPAP (9.8 ± 9.2 days) and PS (6.4 ± 5.8 days). 
Pooled analysis resulted in a significantly shorter LOV after CV in comparison with HFO 
(WMD -2.3 days, 95%CI= -3. 63, -1.04) (Table 4).
Oxygenation 
Three studies addressed the effects of different ventilation modes on oxygenation. 
In the study by Dobyns et al. [14] the PaO2/FiO2 (PF) ratio improved most in HFO mode 
with iNO after 4 hrs (136mmHg ±21 vs. CV 96±6; p=0.2)) and 12 hrs (HFOV+iNO 184mmHg 
±45 vs. CV 107mmHg ±8 and CV+iNO 115mmHg ±9, p=0.023; HFOV 136mmHg ±32). 
After 24 hrs, HFO treatment both with and without iNO provided better oxygenation 
than CV both with and without iNO (p<0.05). After 72 hrs, HFO treatment was associated 
with the best improvement in PF ratio (HFO 259 mmHg ±60 vs. CV 148mmHg ±15 and 
table 4: Meta-analysis of trials comparing high-frequency ventilation with conventional ventilation: length 
of ventilation
Study
CV HFOV
WMD (95%CI) Z value (p-value)Mean (SD) N Mean (SD) N
Length of ventilation
Arnold et al [12] 22 (17) 29 20 (27) 29 2 [-9.61, 13.61] -0.338 (p=0.74)
Dobyns et al [14] 22 (4) 38 52 (28) 12 -30 [-45.89, -14.11] 3.699 (p=0.0002)
Subtotal 67 41 -11.51 [-15.14, -7.88] -6.221 (p<0.0001)
Carman et al (VDR) [16] 11 (2) 32 12 (2) 32 -1 [-1.98, -0.02] -2.0 (p=0.046)
Overall 99 73 -2.34 [-3.63, -1.04] -3.542 (p=0.0004)
CI, confidence interval; CV, conventional ventilation; HFOV, High-frequency oscillation ventilation; SD, stan-
dard deviation; VDR, volume diffusive respirator (high-frequency time-cycled pressure ventilator); WMD, 
weight mean difference.
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CV+iNO 150 mmHg ±19, p=0.027; HFOV+iNO 213 mmHg ±9). The two therapies did 
not differ in failure rate. Arnold et al. [12] reported a significant (p=0.001) relationship 
between time and a decreasing oxygenation index in the HFO group but not in the CV 
group. After crossover (19 patients crossed over from CV to HFO and 11 patients crossed 
over from HFO to CV) this relationship was significant in both crossover groups (p=0.03 
crossover to CV; p=0.02 crossover to HFO). 
Carman et al. [16] reported a significantly higher PF ratio in the VDR mode compared 
with PC (563 mmHg ± 15 vs. 507 mmHg ± 13, p<0.05) but did not specify the time point 
at which the best PF ratio was measured. As the oxygenation parameters in these three 
studies were not uniform it was not possible to pool the data.
Mortality, survival
Three studies focused on the outcome measure mortality or survival.
None found a significant difference in mortality between patients treated with HFO 
and those treated with CV. Arnold et al. [12] reported a mortality rate of 34% (10/29) for 
HFO versus 41% (12/29) for CV (OR 0.75, 95%CI 0.26 to 2.16). However, the mortality rate 
in patients not crossed over to CV from HFO or to HFO from CV was significantly better 
(p=0.003) than that in patients managed with CV only.
Dobyns et al. [14] showed that the survival rate for patients treated with HFO in com-
bination with iNO was higher than that for patients treated with HFO only or with CV 
(71% vs. 58% in CV, 53% in CV +iNO and 58% in HFO). These differences did not achieve 
statistical significance. These authors speculated that the improved lung recruitment by 
HFO enhances the effects of low dose iNO on gas exchange. The mortality rate for HFO 
without iNO was 42% (5/12) versus 42% (16/38) for CV without iNO (OR 0.98, 95%CI 0.26 
to 3.66) [14]. In the study of Carman et al. [16] five of 32 (16%) patients in the PCV group 
died versus two of 32 (6%) in the VDR group (OR 0.36, 95%CI 0.06 to 2.01). 
In the pooled analysis, the mortality rates in HFO mode and CV did not differ (OR 0.70, 
95%CI 0.33 to 1.47) (Table 5).
table 5: Meta-analysis of trials comparing high frequency ventilation to conventional ventilation: Mortality
Study Conventional ventilation High-frequency oscillation ventilation OR (95%CI)
Mortality
Arnold et al [12] 12/29 10/29 0.75 (0.26, 2.16)
Dobyns et al [14] 6/38 5/12 0.98 (0.26, 3.66)
Subtotal Mantel-Haenszel 67 41 0.83 (0.30,1.91)
Carman et al (VDR)[16] 5/32 2/32
Overall Mantel-Haenszel 99 73 0.70 (0.33, 1.47)
Data presented as number/total. VDR, volume diffusive respirator (high-frequency time-cycled pressure 
ventilator).
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chronic lung disease 
Chronic lung disease was examined only in the study of Arnold et al. [12]. The proportion 
of patients treated with HFO and requiring supplemental oxygen at 30 days was lower 
than that of patients managed with CV (p=0.039; OR 5.4, 95% CI 1.2 to 23.2).
Weaning
Randolph et al. [15] randomized 182 children aged from 0 to 17 years to either a Pressure 
support (PS) protocol (n=62), Volume support (VS) protocol (n=60) or a no ventilation 
weaning protocol in which weaning was at the discretion of the physician (n=60) (Table 
3). The VS and PS protocols dictated that FiO2 and PEEP be adjusted to maintain SpO2 
at 95% or higher. In the PS protocol, the amount of pressure support was adjusted to 
achieve an exhaled tidal volume goal of 5 to 7 ml/kg. In the VS protocol, the ventilator 
automatically adjusted the level of pressure support to achieve an exhaled tidal volume 
of 5 to 7 ml/kg. Two outcome measures were assessed: weaning time and extubation 
failure (i.e. any invasive or non-invasive ventilator support within 48 hours of extuba-
tion). It was hypothesized that VS would result in shorter weaning time as the inspiratory 
pressures automatically decrease with improvement of lung compliance. Most children 
could be weaned within two days and weaning time did not significantly differ for the 
protocols used: PS (1.6 days), VS (1.8 days) and no protocol (2.0 days). Extubation failure 
rates were not significantly different for PS (15%), VS (24%) and no protocol (17%).
Quality of studies
These five studies compared six different ventilation modes in 421 children [12-14, 16]. 
Two studies, based on intention to treat analysis, met all CBO quality criteria [14, 15]. 
Blinding was not possible in any of these studies, because ventilator displays cannot be 
masked. In four studies patient characteristics and prognostic variables did not differ be-
tween the intervention groups. In the study of Carman et al. [16] the mean age differed 
significantly. Only one study calculated the estimated effect sizes (relative risk of odds 
ratio) for continuous outcome variables such as LOV, survival or weaning failure [15]. The 
study by Dobyns et al. [14] is of limited quality because it is a secondary analysis of data 
obtained from a previous multicenter, randomized trial on iNO treatment in pediatric 
acute hypoxemic respiratory failure [8]. The mode of ventilation was determined by 
the attending physician on the guidance of guidelines to maximize oxygenation. The 
patient was then randomized to treatment with or without iNO [14]. Levels of evidence 
for the different studies are presented in Tables 2 and 3.
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discussiOn
This review aimed at identifying the various ventilation modes used in children over 
the last three decades and searching for any data that would favour a particular mode 
for pediatric ventilation. The five RCTs included in this review varied in the investigated 
modes of ventilations, in outcomes and in patient groups. 
High-frequency ventilators may use different ventilation modes. Two studies included 
in this review concerned high-frequency oscillation ventilation [12, 14]; a third con-
cerned the volume diffusive respirator (high-frequency time cycled pressure ventilator) 
[16]. The evidence from these studies does not allow making a recommendation on 
preferred type of high frequency ventilator. Two RCTs compared HFO with CV on the 
outcomes oxygenation, LOV and mortality. Neither study found significant differences 
in mortality and LOV. However, analysis of the pooled data revealed a significantly lower 
LOV for the conventional ventilation groups. A confounding factor for this finding is the 
threefold sample size of conventionally ventilated patients in the study of Dobyns et al. 
[14]. On the other hand, this analysis only concerned the patients treated with HFO and 
CV without iNO. 
In all studies, oxygenation significantly improved over 72 hours for patients treated 
with high-frequency oscillators [12, 14, 16]. However, lack of uniform data on oxygen-
ation prevented analysis of pooled data. This finding is in contrast with that reported 
for preterm neonates. The systematic reviews and meta analyses overall provide no 
evidence that HFO as the initial ventilation strategy offers important advantages over 
CV in terms of preventing chronic lung disease in preterm infants with acute pulmonary 
dysfunction [17-22]. 
The level of evidence proved moderate to good in three studies [12, 14, 15]. The study 
of Jaarsma et al. [13] was stopped halfway as both physicians and nurses preferred BIPAP. 
This, was assigned a 1- level of evidence because of the high risk of bias. Likewise, the 
study of Carman et al. [16] was assigned a 1- level of evidence because the randomiza-
tion failed for the demographic variable age. 
The strengths of the present review include a comprehensive search strategy, broad 
inclusion criteria (resulting in a representative, heterogeneous population), and assess-
ment of clinically important outcomes. In addition, we have pooled the data. This sta-
tistical approach is also allowed for quasi-experimental, non-randomized studies, such 
as the study of Dobyns et al. [14] in which randomization of groups was not possible 
or failed [23]. Meta-analytic techniques in the analysis of nonrandomized studies have 
been criticized for their potential to perpetuate the individual biases of each study and 
give a false impression of cohesion in the literature thus discouraging further research 
[24]. The counter-argument is that statistical quantification and pooling of results from 
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many studies helps to identify reasons for variability, inconsistency or heterogeneity in 
the literature,
and thus may encourage further research [23, 25]. Nevertheless, the pooled results 
of this study should be interpreted cautiously in view of the diversity in patient groups, 
sample sizes, randomization methods, types of ventilators and ventilation strategies.
The reviewed RCTs cannot easily be compared owing to the heterogeneity in age, 
underlying disease and study outcomes. Therefore, we would recommend to set up 
studies investigating the best ventilation strategy for specific age categories or un-
derlying pathology [1]. Furthermore, as mortality is rather low, longer-term outcome 
measures others than the short-term outcome measures studied in this review should 
be considered, such as pulmonary function, neurocognitive development and cost-
effectiveness. Internationally consensus on the most appropriate outcome measures 
should be reached.
cOnclusiOn
The available literature does not provide sufficient evidence on the best ventilation 
mode in critically ill children beyond the newborn period. High-frequency ventilation 
(HFO and VDR) provided better oxygenation after 72 hours than did conventional ven-
tilation. There is no evidence that high-frequency ventilation would reduce mortality 
and LOV.
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AdditiOnAl filE 1: sEARcH stRAtEgy 
PubMed
(artificial respiration[mesh] OR artificial respir*[tw] OR mechanical ventil*[tw] OR high 
frequency respirat*[tw] OR liquid ventilat*[tw] OR pressure respirat*[tw] OR positive 
airway pressure*[tw] OR pressure breath*[tw] OR pressure ventilat*[tw] OR ventilator 
wean*[tw] OR ventilation wean*[tw] OR ventilators, mechanical[mesh] OR pulmonary 
ventilat*[tw] OR respirator*[tw] OR ventilator*[tw]) AND (instrument*[tw] OR device*[tw] 
OR mode[tw] OR modes[tw]) AND (infan*[tw] OR child*[tw] OR adolescen*[tw] NOT 
adult[mesh]) AND (randomized controlled trial*[tw] OR randomized controlled trial*[pt] 
OR rct[tw])
Hits: n=403
EMBASE
(artificial AND ‘ventilation’/exp OR (artificial OR mechanical OR ‘high frequency’ OR 
‘liquid ventilation’ OR ‘liquid ventilator’ OR pressure OR ‘positive airway pressure’ OR 
wean* OR pulmonary) NEAR/3 (breath* OR ventilat* OR respirat*) OR respirator*:de,ab,ti 
OR ventilator*:de,ab,ti) AND (instrument*:de,ab,ti OR device*:de,ab,ti OR mode:de,ab,ti 
OR modes:de,ab,ti) AND ([randomized controlled trial]/lim OR ‘randomized controlled 
trial’:ti,ab,de OR rct:ti,ab,de) AND ([newborn]/lim OR [infant]/lim OR [preschool]/lim OR 
[school]/lim OR [child]/lim OR [adolescent]/lim) NOT [adult]/lim NOT [aged]/lim AND 
[humans]/lim
Hits: n=250
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AdditiOnAl filE 2: EVAluAtiOn fORM Of Rcts
Assessment of the quality of a randomized controlled trial (Rct)
1. Was the intervention assignment truly random?
2. The person who includes subjects in the study should be unaware of the randomiza-
tion order; was that the case?
3. Were patients blinded to treatment allocation?
4. Were caregivers blinded to treatment allocation?
5. Were persons measuring the outcomes blinded?
6. Were the groups comparable at baseline?
7. Was complete follow-up available for a sufficient proportion of all included patients? 
(loss-to-follow-up)
8. Were all included patients analyzed in the group to which they were randomized? 
Intention to treat analysis 
9. Other than the intervention, was all care that patients received the same?
intermediate conclusion
10. Are the results of the study valid and relevant?
11. Results. For each primary and secondary outcome, a summary of results for each 
group, and the estimated effect size and its precision (e.g. 95% CI)
- Dichotomous outcomes
- Continuous outcomes
Applicability in healthcare 
12. Is the result found applicable to the situation in the Netherlands?
13. To which echelon(s) can the result be applied?
14. Conclusion
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How to achieve adherence to a ventilation algorithm for critically ill children?
AbstRAct
background
PICUs worldwide use different ventilators with a wide variety of ventilation modes. We 
developed an algorithm, as part of a larger protocol, for choice of ventilation mode at 
time of admission. 
Aims and objectives 
To evaluate to what extent physicians on a paediatric intensive care unit (PICU) adhered 
to a newly implemented ventilation algorithm.
design
This study was performed in a level III PICU of a university children’s hospital and had an 
uncontrolled, pre-post test design with a period before implementation (T0) and two 
periods after implementation (T1 and T2).
Methods 
An invasive ventilation algorithm targeted at two patient groups was implemented in 
October 2008. The algorithm distinguished between lung disease, in which pressure 
control was considered as the preferred mode, and no lung disease, in which pressure-
regulated volume control was preferred. Nurses and physicians were instructed in the 
use of the algorithm before implementation.
Results 
During three test periods, a total of 507 children with a median age of 5 months [in-
terquartile range (IQR) 0–50] on conventional invasive mechanical ventilation were 
included. In patients with lung disease, pre-implementation adherence rate was 79% 
(67/85). At T1 it was 71% (51/72); at T2 84% (46/55). The slight improvement from T1 
to T2 was statistically not significant (p=0.092). In patients with no lung disease, the 
adherence rate rose statistically significantly from 66% at T0 (62/93) to 78% (79/101) at 
T1, and 84% at T2 (85/101) (p=0.015).
conclusion 
Implementation of a new ventilation algorithm increased physicians’ adherence to this 
ventilation algorithm and the effect was sustained over time. This was achieved by edu-
cation, reminders and organizational changes such as admission of postcardiac surgery 
patients with protocolized nursing care including preset ventilator settings. 
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intROductiOn
Pediatric intensive care units (PICUs) worldwide use different ventilators with a wide 
variety of ventilation modes: high frequency oscillation (HFO), pressure control (PC), 
synchronized intermittent mandatory ventilation (SIMV), pressure support (PS), pressure 
regulated volume control (PRVC) and, more recently, neurally adjusted ventilator assist 
(NAVA) [1, 2]. An unambiguous international guideline is lacking; ventilator type and 
ventilation mode are often chosen based on the intensive care physician’s experience 
and preference, financial concerns, or local PICU policy, independent of the underlying 
disease [3-5].
The literature is scarce on the best ventilation mode in critically ill children beyond the 
newborn period [6]. One study found that high-frequency ventilation was associated with 
better oxygenation after 72 hours than was conventional ventilation [7]. However, there 
was no evidence of reduced mortality and duration of ventilation. Furthermore, most trials 
were significantly underpowered as they included small numbers of children [6].
Because of a lack of a ventilation protocol for clinical practice, we developed an algo-
rithm guiding the choice of the most appropriate mode of ventilation upon admission 
of a child to our ICU, either PC or PRVC. A different protocol applies in case of need of 
HFO at admission. HFO is not included in this algorithm because it is not often used.
Separate protocols are in place for HFO and non-invasive ventilation.
This algorithm is based on evidence in the adult literature [8-11] and outcome of 
consensus meetings of all consultants of our unit. However, adherence to protocols and 
guidelines remains a difficult issue and successful implementation is time consuming 
[12-16]. In this study we evaluated to what extent the physicians adhered to the ventila-
tion algorithm.
MEtHOds
design 
The study had an uncontrolled, pre-post test design with a pre-test (T0) from January 
2008 - July 2008, and two post-tests: from May-November 2009 (T1); and from May-
November 2010 (T2). The test periods were chosen to cover seasonal diseases. The T2 
measurement served to evaluate the long-term sustainability of the implementation. 
The Erasmus MC Medical Ethics Review Board approved the study and due to the non-
invasive nature of the study waived the need for informed parental consent.
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setting and patients
The study was performed in the 28-beds ICU of the Erasmus MC - Sophia Children’s 
Hospital, Rotterdam, the Netherlands, a level III referral academic hospital. This ICU con-
sists of four 7-beds units, each with a specific focus: neurology, cardiology, (neonatal) 
surgery and high dependency care. The ICU also serves as one of the two national ECMO 
centers and provides all forms of mechanical cardiac support. It is the only one in the 
Netherlands to provide care to pediatric cardiac transplant recipients. 
The annual number of admissions is around 1800, and 30% of patients are ventilated 
mainly with the Servo-i ventilator of Maquet (Solna, Sweden). Overall, 50% of admitted 
patients are postoperative patients of all surgical subspecialties. The main reasons for 
admission are: respiratory insufficiency (20%), general pediatric surgery (20%), cardiac 
surgery and cardiovascular problems (20%), neurosurgery and neurological problems 
(10%), injuries and intensive care monitoring (20%), and major congenital anomalies, 
gastrointestinal and kidney problems (10%). (data retrieved from the electronic patient 
data management system and the local Quality and Safety Registry)
During the study periods the medical staff included twelve pediatric intensivists, of 
whom one had a basic training in anesthesiology; four fellows in training for pediatric 
intensivist; and six physicians in training (pediatrics (n=4) or anesthesiology (n=2).
development of ventilation algorithm
A multidisciplinary team consisting of a pediatric intensivist-anesthesiologist (R.J.H.) 
and four ventilation practitioners (whose role is similar to that of a respiration therapist) 
developed a ventilation algorithm for the target population aged from 0 to 18 years. 
The algorithm is based on lung protective ventilation strategies which are likely to be 
of benefit to acute lung injury and acute respiratory distress syndrome: open-lung strat-
egy; low tidal volumes (5-8 ml); and a recruitment maneuver in case of increased oxygen 
need [8-11, 17, 18]. Furthermore, permissive hypercapnia will avoid high ventilation 
pressure and thus prevent further lung damage [8, 11, 19]. 
The general purpose of our local ventilation strategy, as far as possible based on evi-
dence, is to achieve the following conditions: 
·	 pH: > 7.30 and < 7.48 
·	 PCO2: 5-8 kPa;
·	 PC above above Positive end expiratory pressure (Peep) ≤ 15cm H2O;
·	 Tidal volume: 6 ml/kg (this was set in PRVC and pursued in PC);
·	 SpO2 > 95%; or a lower saturation in case of a cardiac disease with mixed circulation
·	 Inspiration time: 0.3-0.6 seconds for neonates and I: E ratio 1: 2 for children aged 
above 6 months with an age-dependent frequency.
The algorithm was primarily designed to guide physicians in the choice of ventilation mode 
upon admission of a patient requiring invasive mechanical ventilation. Also, it accounted 
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for conversion of ventilation mode in case a patient’s condition deteriorated. In addition, if 
ventilation with high pressures was needed (ARDS) some of the above-mentioned condi-
tions were to be modified: pH ≥ 7.20 <7.48; pCO2 ≤ 9 kPa; and SpO2 ≥ 85%. 
In specific diseases such as pulmonary hypertension and traumatic brain injury (TBI) 
other target values for pH and PCO2 are applied, described in different protocols (TBI: 
pCO2 values between 4.5 and 5.0 kPa; for pulmonary hypertension initial normocapnia 
is the aim, provided that the needed inspiratory pressure is not too high. Otherwise 
permissive hypercapnia is accepted till values of ≥ pH 7.20). I:E ratio is also modified 
when lung condition deteriorates, dependent on the underlying disease. Extracorporeal 
membrane oxygenation (ECMO) is indicated at oxygenation index around 40.
The algorithm was developed with two patient groups in mind: 1) those with lung 
disease, such as acute respiratory distress syndrome, pneumonia, or bronchiolitis; and 
2) without lung disease but receiving ventilation for epilepsy, postoperative care or 
traumatic brain injury (Figure 1). The PC mode was assumed to be the most appropri-
ate for group 1 because it maintains constant pressure not exceeding 15 cmH2O above 
PEEP. Thus, volutrauma is potentially avoided and a tidal volume of 6 ml/kg is achieved 
[10, 20]. PC is also suited in children at risk of compression atelectasis, in children with 
pulmonary hypertension [9], and to compensate for leakage around the tube. 
The PRVC mode was considered the most appropriate for group 2 because it provides 
the lowest possible pressure at a constant tidal volume and achieves a more stable 
EtCO2 and pCO2. It has a decelerating inspiratory flow pattern with automatic adjust-
ment of the inspiratory pressure for changes in compliance and resistance, resulting in a 
guaranteed constant tidal volume. However, volutrauma may occur when the pressure 
rises in case of deteriorating lungs with different dependent lung regions. Then the aer-
ated lung regions will receive all the volume (higher than 6 ml/kg). There is no evidence 
for the use of PRVC in case of neurotrauma, although CO2 has a direct influence on the 
diameter of the vessels of the brain and the blood volume and therefore influences the 
intracranial pressure. Since ICP and CO2 are inter-related, maintaining a constant CO2 is 
indicated in case of brain injury. ICUs worldwide mostly use Volume Controlled Ventila-
tion for this purpose, but as PRVC provides constant tidal volume, we opted for this 
mode in traumatic brain injury [21].
In the PC mode, ventilation is adjusted to pressure support as soon as the patient 
is breathing spontaneously (triggering in the figure); in the PRVC mode, ventilation is 
adjusted to volume support. Sedation provided at the start of ventilation is reduced 
stepwise on the guidance of scores on the COMFORT behavior scale [22].
A protocol for extubation readiness is not in place at our ICU, and a spontaneous 
breathing trial (SBT) is not used. The following extubation criteria are commonly used: 
cough/swallowing reflex present, respiration indication solved, FiO2 < 0.4, hemody-
namically stable with little inotropic support, sufficient muscle strength, no excessive 
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Ventilation Algorithm 
Lung diseases 
 ARDS, pneumonia,    
      bronchiolitis
 Leakage along the tube
 Stomach problems, fat belly  
with compression atelectasis
 Pulmonal hypertension: with          
or without NO
No lung diseases
 Ventilation because of 
other reasons than lung 
disease
 Traumatic brain 
injury,where PCO2 has to 
be stable
Extubation
Purpose Conventional 
ventilation:
 pH > 7.30 < 7.48
 pCO2 5-8 kPa
 PC above PEEP   15cmH2O
 Vt 6 ml/kg (ideal weight)
 SpO2> 95%
 Ti: 0.3-0.6 sec. neonates
 I:E ratio 1:2 > 6 months
Weaningcriteria 
reached?*
Weaningcriteria 
reached?*
*Weaningcriteria
 Cough/swallowing reflex present
 Respiration indication solved
 PaO2/FiO2 > 200mmHg/26.7kPa
 Hemodynamical stable/ little 
inotropic support
 Sufficient muscle strength
 No excessive mucus
 PEEP < 8 cmH2O
 Proper fluid balance/ no signs of 
edema
 GCS > 8
 No sedative or low dose
 pH > 7.35 < 7.48
 No signs of infection
Pressure Control Pressure Regulated Volume Controlled
Pressure Support Volume Support
figure 1: Ventilation protocol. PC, pressure control; PRVC, pressure-regulated volume control; PS, pressure 
support; VS, volume support; Ti, inspiration time; SpO2, oxygen saturation; Vt, tidal volume; NO, nitric oxy-
gen; pCO2, carbon dioxide partial pressure; ARDS, acute respiratory distress syndrome.
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sputum, PEEP < 8 cmH2O, proper fluid balance, no edema, Glasgow coma score > 8, no 
or low-dose sedatives, pH between 7.35 and 7.45, no signs of infection [23-25]. Separate 
protocols are in place for HFO and non-invasive ventilation.
implementation
To enhance adherence, approval of the ventilation algorithm was sought from all medi-
cal staff before implementation. In July 2008 the ventilation practitioners instructed all 
physicians and critical care nurses how to use it. Newly recruited residents after July 
2008 also received instruction and in addition were familiarized with the theory of 
ventilation and the ventilator software. All information was also made available in print 
and by email. The algorithm was made available on each unit. A laminated version of the 
algorithm was placed at each ICU-bed. 
The algorithm was put into use in October 2008 after the ventilation practitioners had 
presented it to all physicians. Since 2010 all ICU staff are provided with a pocket manual 
that contains all PICU protocols including the ventilation algorithm. Furthermore, in 
2010 the protocol for admission of traumatic brain injury patients was changed to the 
effect that the PRVC mode became the preferred one for these patients. To ensure that 
this policy was adhered to, a sticker reminding of this ventilation mode was placed on a 
crash cart for patients with brain injury. For organizational and logistical reasons, from 
January 2010 cardiac surgery patients were directly admitted to our ICU for postopera-
tive care. The protocol introduced since then prescribed PRVC as the preferred mode for 
these patients, unless they had serious pulmonary edema. Extubation was attempted in 
these patients as soon as possible upon arrival at the ICU, usually within 6-12 hours after 
admission. As such the postoperative cardiac surgery protocol included an algorithm 
for weaning off the ventilator. Before admission of these patients, nurses prepare the 
ventilator settings based on the cardiac weaning procedure described in the ventilation 
algorithm. The nurses are responsible for weaning but need to ask permission from the 
physician in charge for actual extubation.
study procedure
All patients on conventional invasive mechanical ventilation during the three study peri-
ods were included. The initial ventilation mode was chosen by the physicians. In all three 
periods we recorded the initial ventilation mode set for newly admitted patients and re-
corded the reason for ventilation as an indication to what mode this patient should have 
been assigned. Patients on HFO and non-invasive ventilation were excluded. During the 
course of the study times there was no change in ventilation strategy. Patients were not 
excluded due to the their condition. Data were retrieved from the electronic patient 
data management system that prospectively stores data of all physiological parameters, 
laboratory results, medication, procedures, assessments and care plans.
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Outcome measure
Adherence to the ventilation algorithm was measured as: number of patients with cor-
rect ventilation mode according the algorithm divided by the total number of ventilated 
patients during the study period in question.
statistical analysis
Patients’ characteristics, reason for admission, and initial mode of ventilation are sum-
marized by descriptive statistics. Data are presented as percentages: mean (SD) for nor-
mally distributed data; median and IQR (interquartile range) for non-normally distrib-
uted data. Background characteristics for the pre- and posttest groups were compared 
using Chi-Square (categorical variables) and Kruskal-Wallis test for continuous variables. 
In all three test periods, the difference in adherence to the protocol was compared and 
tested for the two groups (lung disease versus no lung disease) with the Chi-square test. 
A p value of 0.05 (two-sided) was considered statistically significant. Data were analyzed 
with IBM SPSS® version 18.
REsults
During the three study periods 615 patients received ventilator support. In total 108 
patients were excluded for analysis (HFO, n=31; non-invasive (home) ventilation, n=87). 
Thus, analysis was based on 507 patients, with a median age of 5 months (IQR 0-50) (T0: 
N=178; T1: N=173; T2: N=156). Age and gender were not significantly different between 
the three periods. However, the reason for ventilation significantly differed between the 
periods, due to the admission of direct postoperative cardiac patients during T2 (Table1).
lung disease 
Before implementation of the ventilation algorithm (T0), 67 of the 85 patients (79%) with 
lung disease were ventilated according to the algorithm (PC). After implementation, this 
held true for 51 of 72 patients (71%) in period T1, and 46 of 55 patients (84%) in period T2 
(p=0.215). Adherence to the algorithm slightly improved from T1 to T2 (p=0.092) (Table 2).
no lung disease
At T0, 62 of the 93 patients (66%) with lung disease or no lung disease were ventilated 
according to the algorithm (PRVC). After implementation this held true for 79 of 101 
patients (78%) in period T1, and 85 of 101 patients (84%) in period T2 (Table 2). This 
means that adherence statistically significantly improved from 66% at T0 to 78% at T1 to 
84% at T2 (p=0.015).
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table 1: Demographic characteristics
T0
n =178
n (%)
T1
n =173
n (%)
T2
n =156
n (%)
p-value
Gender (male/female) 91/87
(51.1/ 48.9%)
94/79
 (54.3/ 45.7%)
86/70
(55.1/ 45.7%)
0.73 (a)
Age 0.66 (a)
0 – 12 months 105 (59%) 97(56.1%) 95(60.9%)
1 – 3 years 33 (18.5%) 27 (15.6%) 19(12.2%)
4- 12 years 26 (14.6%) 32 (18.5%) 25(16%)
> 12 years 14 (7.9%) 17 (9.8%) 17(10.9%)
Median age in months (IQR) 4 (0-211) 8 (0-233) 4.5 (0-218) 0.60 (b)
Reason for ventilation <0.001 
Cardiac 14 9 13
 Cardiac - postoperative surgery 22 31 50
Respiratory failure - acute Pulmonology (e.g. 
bronchiolitis, pneumonia)
36 34 16
Respiratory failure - upper airway 2 8 4
Respiratory failure - others 6 7 0
Neurologic – e.g. trauma injury, epilepsy 16 15 19
Hypo plastic lung 1 2
Shock/sepsis/ECMO/Resuscitation 18 15 18
Trauma 5 7 1
Post operative 23 25 12
Post operative - abdominal 28 20 17
Others (c) 8 1 4
aChi-squared test. bKruskal-Wallis test. cCongenital diseases such as oesophageal atresia, pulmonary hyper-
tension, meconium aspiration, metabolic diseases and neuromuscular diseases.
table 2: Adherence rates 
T0
Jan – July 2008
(n=178)
T1
May – Nov 2009
(n=173)
T2
May - Nov 2010
(n=156)
p-value
Lung disease (PC)
Ventilated according to the algorithm*: 67 (79%) 51 (71%) 46 (84%) p=0.215
No lung disease (PRVC)
Ventilated according to the algorithm**: 62 (66%) 79 (78%) 85 (84%) p=0.015#
* p=0.092 (between T1-T2); ** Between T0 and T1: p = 0.072 and between T0 and T2: p=0.005. #p-value of 
0.05 was considered statistically significant.
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Related factors for (non) adherence
Adherence to the algorithm (correct choice of ventilation mode) was not statistically 
significant associated with patient’s age, shift (day versus evening/night), reason for 
ventilation (lung disease vs. no lung disease) and unit (p=0.52, p=0.16, p=0.84 and 
p=0.06 respectively). In the cardiology unit, however, adherence to the algorithm in-
creased significantly from 74% at T0 to 91% at T2 (p=0.018). Adherence to the algorithm 
in cardiac and postoperative cardiac surgery patients increased significantly from 68% 
at T0 to 90% at T2 (p=0.027). 
Adherence to the algorithm in traumatic brain injury patients seems to have increased. 
In 2010 only one patient was ventilated with PC rather than the prescribed PRVC. This 
also applies to patients with acute respiratory failure during period T2 who were then 
mostly ventilated with the prescribed PC.
discussiOn
Implementation of a ventilation algorithm for PICU patients resulted in higher adher-
ence to the ventilation algorithm in comparison to the pretest periods, especially for 
patients without lung disease. Adherence was not associated with patient factors (e.g. 
age), shift or reason for ventilation (lung disease vs. no lung disease). Adherence to the 
ventilation algorithm tended to be best among post cardiac surgery patients, who re-
ceive protocolized nursing care including pre-set ventilator settings. The improvement 
in adherence regarding patients with lung disease is less marked. Before implementa-
tion adherence was even better (79%) than during the first post-test period (71%). It 
would seem that even after education and approval of the algorithm, physicians need 
time to put personal preferences aside. Still, adherence had increased during the sec-
ond post-test (84%). Regrettably, still too many postoperative patients with abdominal 
problems were not ventilated as the algorithm dictated. This violation is perhaps eas-
ily overlooked; it would be more easy to remember that the first choice of ventilation 
for postoperative patients is PRVC, except for those who have undergone abdominal 
surgery. A reminder sticker on the ventilator, in combination with feedback in case of 
violations, could perhaps optimize adherence for this patient group. The use of cuffed 
tubes vs. uncuffed tubes might have played a role as well. The data do not indicate, 
however, if PC in case of no lung disease was chosen on the grounds of leakage along 
the tube. If so, the choice was right. Any leakage usually occurs later than in the first hour 
of ventilation, and therefore we assume that leakage will not have greatly influenced the 
choice of initial ventilation.
We speculate that the relatively high adherence rates (>80%) in the final post-test pe-
riod can be ascribed to the fact that all newly appointed physicians and residents were 
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well instructed. Furthermore, nurses – provided with a pocket manual of the ventilation 
algorithm – reminded physicians of the correct ventilation mode in cardiac surgery 
patients. We also assume that the use of reminders, such as a sticker on the crash car for 
traumatic brain injury patients, increased adherence to the ventilation algorithm. This is 
consistent with the literature in the ICU and other healthcare settings [26, 27].
Research has shown that consistent use of evidence based guidelines can significantly 
increase the extent to which patients receive recommended therapies [12, 13]. However, 
it is a great challenge to stimulate consistent use of these guidelines and protocols. 
Apart from attempts to change behavior, this requires insight in all influencing factors 
(e.g. human behavioral, organizational, provider characteristics). Therefore, identifying 
potential influencing factors, e.g. with the barrier identification and mitigation tool [13], 
can improve adherence to new protocols. Unfortunately, scarce data are available to 
guide decisions on optimal strategies to implement guidelines and protocols in the 
intensive care unit [12, 14, 28]. On the one hand, it has been suggested that guideline 
implementation strategies tailored to overcome barriers to change might be more ef-
fective than the multifaceted “one size fits all” strategy. On the other hand, multi-faceted 
implementation strategies were considered important enablers of protocol and guide-
line adherence [16, 29]. One example is education tailored to the specific learning needs 
of the ICU team combined with bedside reminders, audit, and visual feedback [15, 29, 
30]. Also, we believe – and previous studies have demonstrated this – that ICU culture 
qualities such as interdisciplinary collaboration, effective communication, and leader-
ship support are associated with better quality of care [31, 32]. This is also confirmed 
in two recent studies about interdisciplinary collaborative decision making regarding 
ventilation and weaning [33, 34]. Enhanced communication and collaboration between 
professionals could probably avoid unnecessary prolonged ventilation and weaning 
[33, 34]. We speculate that manipulating these specific organizational characteristics 
(interdisciplinary collaboration, effective communication, leadership support and 
organizational aspects like nurse-to-patient ratio and ongoing education) may be an 
effective strategy to improve adherence to protocols, which deserves to be explored 
and evaluated in further implementation projects [27]. However, ICU culture qualities on 
our unit also need to be further studied.
Regarding strengths and limitations, a strength of this study is the prospective data 
collection. A limitation is the lack of a control group or randomization. However, it would 
have been difficult to blind physicians or other ICU staff to the study. Second, reasons for 
non-adherence with the algorithm were not documented in the patient data manage-
ment system.
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implications for nurses in the implementation of new algorithms
Care for ICU patients will benefit from interdisciplinary collaboration, also when new 
algorithms or protocols are implemented, related to either nursing care or medical care. 
To improve physicians’ adherence to a medical algorithm, nurses should remind physi-
cians of the steps to take. Nurses are always present at the bedside and as such represent 
the patient. In summary, the following measures may successfully improve adherence:
·	 A well thought-out implementation plan, with attention to potential barriers and 
facilitators is a crucial first step.
·	 Use reminders as pocket manuals and stickers.
·	 Provide repeated education about the algorithm and the results of its use (perfor-
mance feedback).
·	 Provide leadership support at doctor’s and nursing level.
·	 Report non-adherence through safety first reports and feedback when protocol 
violations occur.
cOnclusiOn
Implementation of a new ventilation algorithm increased physicians’ adherence to this 
ventilation algorithm and the effect was sustained over time. This result was achieved 
by education, reminders and organizational changes such as protocolized admission of 
post cardiac surgery patients with protocolized nursing care including pre-set ventilator 
settings. 
Interdisciplinary collaboration between physicians and nurses, effective communica-
tion, leadership support and organizational aspects like nurse-to-patient ratio and 
ongoing education may be effective strategies to improve adherence to protocols.
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AbstRAct
This review will address the different challenges for the use of non-neonatal Extracor-
poreal Membrane Oxygenation (ECMO) will be discussed. It will discuss the available 
evidence for the use of pediatric ECMO in respiratory and circulatory failure, focusing on 
indications and contra-indications and choice of ECMO mode. Furthermore we will try to 
define optimal treatment goals, identify primary outcome parameters and calculate the 
expected need for non-neonatal ECMO per 1.000.000 inhabitants.
In the past 30 years over 46.000 patients have been admitted to dedicated ECMO-
centers; the overall survival rate was 62% (Extracorporeal Life Support Organization 
(ELSO) registry July 2011). Most of these were newborns (30.000) and the number of 
older children amounts to over 11.000; the respective survival rates were 75% and 50%.
One of the striking trends in the last decade is the decreasing need for neonatal ECMO. 
This is partly due to new technologies such as high frequency oscillation with or without 
inhaled nitric oxide, therapeutic modalities for treatment of pulmonary hypertension 
such as Phosphodiesterase inhibitors (Sildenafil) and endothelial receptor blockers 
(such as Bosentan) and gentle ventilation strategies with permissive hypercapnia and 
low tidal volumes More specifically, improvement in perinatal care has also resulted in a 
much lesser need for ECMO in term infants with respiratory failure like meconium aspira-
tion syndrome and GBS sepsis. Moreover, therapies such as surfactant administration 
and surfactant lavage have also contributed to reducing the inflammatory response and 
thus decreasing the need for ECMO in neonates with acute respiratory failure [1].
While indications for neonatal ECMO have been clearly defined, this is not the case for 
non-neonatal ECMO. In many instances, even today, non-neonatal ECMO is considered 
as rescue therapy that brings relief in individual cases. Different concepts on how and 
when to use non-neonatal ECMO have emerged, partly due to the lack of experience 
owing to the relatively few cases in individual centers. Due the variety in etiology and 
recent improvements in the treatment of respiratory failure, it is difficult for the clinician 
to know when to consider ECMO in each individual case. Unlike neonatal indications, 
solid entry criteria are still not available. Each ECMO center has its own set of treatment 
protocol and indication for ECMO. Over the years case series have been reported with 
patients with burns or malignancies and with trauma patients. Therefore when an ECMO 
treatment is considered, each patient must be discussed with the ECMO center, keeping 
in mind that the chance of successful weaning of ECMO is improved when the patient is 
ventilated less than 10 days [2, 3]. Over the past 10 years a steady increase in numbers 
of non-neonatal ECMO cases reported to ELSO have been seen, especially in cardiac 
patients. More and more cardiac surgeons realize that postoperative continuation of 
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cardiopulmonary bypass in the form of ECMO is effective and lifesaving as ECMO de-
creases the workload of the heart and so, supporting recovery of the myocardium [4].
In this review the different challenges for the use of non-neonatal ECMO will be dis-
cussed such as:
1) Indications / contra-indications.
2) Definition of optimal therapy.
3) Primary outcome parameters.
4) Calculated need per 1.000.000 inhabitants.
In all circumstances the application of ECMO for pediatric respiratory and cardiac failure 
should be weighed against the other available treatment modalities, such as small 
tidal volume ventilation, recruitment maneuvers, high frequency oscillation, surfactant 
therapy, inhaled nitric oxide, prone position, kinetic therapy, and corticosteroid admin-
istration [5]. The most difficult decision is when to consider ECMO and when to transfer 
patients to an ECMO center. Performing ECMO in non-neonatal patients requires an 
individualized approach. 
In principle, non-neonatal ECMO is used as adjuvant therapy for which a venovenous 
mode is used. The main differences between the venoarterial mode and the venovenous 
mode are shown in Table 1.
Approximately half of the pediatric respiratory ECMO cases used venovenous (VV)-
ECMO, whereas traditionally venoarterial (VA)-ECMO has been predominant. Improved 
myocardial oxygen delivery, as provided by direct delivery of highly oxygenated coro-
nary blood with VV-ECMO is expected to improve myocardial performance [6].
indications / contra-indications.
Unfortunately the indications to start ECMO in a non-neonatal respiratory and cardiac 
failure differ between institutions and individual physicians. The shortage of random-
ized controlled trials to prove a positive effect of ECMO has hampered the development 
of internationally broadly accepted guidelines.
table 1: Difference between venoarterial- and venovenous ECMO
Venoarterial EcMO Venovenous EcMO
Higher PaO2 is achieved Lower PaO2 is achieved
Lower perfusion rates are needed Higher perfusion rates are needed
Bypasses pulmonary circulation Maintains pulmonary blood flow
Decreases pulmonary artery pressures Elevates mixed venous PO2
Provides cardiac support to assist systemic 
circulation
Does not provide cardiac support to assist systemic 
circulation
Physiologic blood flow nOt maintained Physiologic blood flow maintained
Requires arterial cannulation Requires only venous cannulation
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Following the United Kingdom collaborative trial that showed the positive effect of 
ECMO in neonatal respiratory failure, it took 15 years before the Cesar trial showed a 
positive effect of ECMO in adult respiratory failure [7]. More specifically the Cesar trial 
showed that referral of adult Acute Respiratory Distress Syndrome (ARDS) patients with 
a Murray score of three and a pH below 7.2 (managed with optimal conventional man-
agement) resulted in improved survival rates compared to lung protective ventilation in 
non ECMO centers. 
With death or severe disability six months after randomization as a primary outcome 
measure, allocation to an ECMO center proved beneficial in 63% of patients versus 47% 
of patients treated by conventional therapy. Relative risk: 0.69 in favor of the ECMO 
group (95%-confidance interval: 0.05 – 0.97; P = 0.03). Although the restrictions for 
ECMO (ventilation < 7 days) can be debated as well as the number of patients and the 
duration of the trial (5 years), no other data are available to support the use of ECMO in 
the non-neonatal group. The Cesar trial provides some general guidelines for referral to 
ECMO centers although it remains unclear if these results can be extrapolated to the pe-
diatric population. Ideally the Cesar trial should be repeated in the pediatric age group.
A multicenter trial is warranted because only very few centers perform more than 5 
non-neonatal ECMO-runs a year. Experience in Europe is therefore diluted and widely 
ranging survival rates have been reported. Clear-cut primary endpoints should be de-
fined for such a clinical trial, as well as diagnostic groups and technical modalities such 
as the tubing oxygenators and the ECMO mode: VV-ECMO, VA-ECMO, or other variants. 
Zabrocki et al. clearly showed considerable co-morbidity in pediatric patients on ECMO 
(i.e. in 34% of patients) with a primary diagnosis of acute respiratory failure [5]. Renal 
failure and chronic lung disease were the most common co-morbidities in the ELSO 
registry. One of the main outcome determinants is the pre-ECMO ventilation period. 
Survival was 38% when this was > 14 days versus 56-61% when this was shorter [5]. 
These authors concluded that despite ECMO, the mortality for acute respiratory failure 
due to acute lung injury or ARDS in pediatric patients remains high (18-35%) [5].
Overall survival rates of around 50-60% have been reported for “classic indications” 
such as viral and bacterial pneumonia, aspiration pneumonia, ARDS, and non-ARDS-
related acute respiratory failure. From time to time new diseases emerge such as the 
recent worldwide spread of H1N1 influenza. Physicians in New Zealand and Australia 
predicted a significant need of ECMO for H1N1 related lung disease in the northern 
hemisphere, which forced governments and medical societies to set up systems for 
optimal distribution of ECMO facilities and infrastructure (Italian ECMO network) [8]. 
The Italian ECMO network, established to cope with the predicted increase in ECMO 
patients, treated 153 adult H1N1 ARDS patients in dedicated ECMO centers with an 
overall survival of 68% [9]. Sixty patients (39%) of all patients were treated with ECMO 
support. Noah et al. showed a reduced mortality in patients referred and treated in 
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dedicated ECMO centers in the UK. Using propensity score and Genmatch matching the 
authors compared adults suffering from severe H1N1 influenza related ARDS treated in 
ECMO centers vs. those treated in non-ECMO centers. They found a reduced mortality 
patients treated in ECMO centers. (23.7% vs. 52.5%, RR 0.45 [95% CI, 0.26-0.79]; P = .006) 
[10]. These results are comparable to the Cesar Trial result published by the same group. 
Although the cohort study does not lend itself to identifying individual risk factors, the 
Italian experience clearly showed prolonged mechanical ventilation (e.g. >7 days) was 
associated with higher mortality [9].
In most countries, however, relatively few pediatric patients received ECMO. The num-
ber in our institution was six, of whom four survived. Again it remains unclear whether 
these results can be extrapolated to the pediatric population. However these studies 
suggest that early referral to dedicated ECMO centers may improve overall survival in 
patients with severe respiratory failure.
Another group of patients who might benefit from ECMO are those who need a form 
of mechanical support of the systemic and pulmonary circulation and in which optimal 
use of inotropic drugs as well as mechanical ventilation with or without inhaled nitric 
oxide fails. 
Mclaren et al. showed improved survival using transthoracic cannulation in pediatric 
VA-ECMO for refractory septic shock. Survival significantly increased from 47% to 73% 
in the Children’s Hospital in Melbourne, which has a major cardiac program support-
ing their ECMO facility [11]. Whereas double lumen venous catheters are the preferred 
choice for VV-ECMO, Mclaren et al. showed that for cardiovascular support arterial ac-
cess via the carotid artery may not always be the most beneficial. Whether transthoracic 
access is possible depends on the logistics and available expertise in the local ECMO 
centers. Rapid cannulation may also be achieved using the femoral artery. In adults with 
circulatory failure peripheral cannulation was as effective as transthoracic cannulation 
with significantly reduced bleeding complications compared to open chest ECMO [12]. 
Although this technique seems established in the adult setting but data on efficacy and 
safety are lacking in the pediatric population.
Another patient category that may benefit from early institution of VA-ECMO are 
patients with myocarditis, notably those with enterovirus 71 (EV71) infection) as their 
cardiac failure is considered to be temporary [13]. When patients do not recover within 
a “certain” timeframe, ECMO may serve as a bridge to ventricular assist devices [14-16]. 
Early institution of ECMO is important: a 2010 review of the ELSO data by Rajagopal et al. 
concluded that 61% of patients with myocarditis survived to discharge. However, ECMO 
treatment had been withdrawn after multiple organ failure in an alarmingly high 70% 
of non-survivors [17].
Early identification of patients at threat for therapy resistant cardiac failure is of great 
importance in this particular age group to avoid these complications.
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Apart from infection or cardiac failure, ECMO may also have potential benefits in 
cardiac surgery as a bridge to transplant or as back up in high risk patients for cardiac 
and pulmonary vasculature failure after cardiac surgery. The inability to come off Cardio 
Pulmonary Bypass (CPB) despite inotropic support or nitric oxide to reduce pulmonary 
vascular resistance in the presence of left or right ventricular dysfunction may neces-
sitate ECMO support in the direct postoperative phase. The final outcome of ECMO as a 
form of prolonged CPB is highly dependent on the attitude of the cardiac surgery team 
and the possibility in individual hospitals to provide fast response ECMO around the 
clock. According to European and American recommendations, centers of congenital 
heart surgery should have ECMO available [18]. The conversion from CPB intra-operative 
to an ECMO procedure is relatively simple although significant hemorrhages may occur 
after open chest surgery. Then, ECMO is primarily used as a way to relieve the heart and 
in most instances this will resolve in a successful ECMO-run in 48-72 hours. 
ECMO can be used as a form of “very advanced life support” in resuscitation for cardiac 
arrest. Although many remain guarded about the outcomes for patients who receive 
ECMO in the setting of cardiopulmonary resuscitation (CPR), there are now a number of 
case series describing promising outcomes if emergency car diac life support is initiated 
with sufficient rapid ity [19-21]. 
Rapid deployment of extracorporeal cardiopulmonary resuscitation (ECPR) will most 
likely produce the best results in terms of minimizing the duration as will optimizing 
the technique of conventional CPR [22]. Survival without significant neurologic impair-
ment following a witnessed cardiac arrest is approximately 20-30% in children, and early 
implementation of ECMO can improve the percentage of survivors to 50% [20, 23].
Patients with immune compromised conditions comprise a very special group. A 
relatively recent review of ELSO registry data identified six subgroups: immune defi-
ciency, leukemia lymphoma, other forms of cancer, opportunistic infection, solid organ 
transplant and bone marrow transplant [24, 25]. In each of these subgroups a reduced 
hospital survival was documented varying from 35.6% (solid organ transplant) to 0% 
(bone marrow transplant).
In these particular patients the main determinants of outcome are the attitude of the 
oncology team related to the therapy phase and the possibility to perform ECMO in 
isolation. As a consequence a number of ECMO centers refrained from treating these pa-
tients and the real significance or contribution of ECMO for individual diagnosis should 
be based on ongoing ELSO data acquisition.
Different ECMO indications bring different challenges. Post-operative cardiac ECMO 
support requires strict control of coagulation. “Traditional” neonatal coagulation pro-
tocols may be insufficient in these patients. Alternatives to heparin based coagulation 
strategies may have benefits that need to be explored [26]. The use of smaller, coated 
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ECMO circuits may reduce the need for anticoagulation therapy thereby reducing the 
risk of bleeding complications. 
Cardiovascular drugs will be frequently used in these patients during ECMO. There 
is almost no pharmacokinetic data guiding clinicians in dosing these drugs, whereas 
adequate treatment is essential to wean these patients from mechanical support [27]. 
In prolonged ECMO runs for cardiomyopathy or respiratory failure there is a high risk 
for nosocomial infections [28]. Almost 20% of all non-neonatal respiratory ECMO patients 
have an infection. (ELSO registry 2011 international summary) Pharmacokinetic data for 
most antibacterial, antifungal and antiviral drugs are lacking for the pediatric age group 
[29]. From in vitro studies it is clear that there is a significant loss of lipophilic drugs 
in ECMO systems [30]. There are considerable differences in drug absorption between 
different circuit components which makes it difficult to predict the Pharmacokinetics of 
newer drugs [30]. 
The ability to control or treat complications during ECMO therapy as well as the de-
velopment of clear ECMO criteria may determine whether ECMO remains an individual 
rescue therapy or a standard treatment modality for selected patients.
definition of optimal therapy.
In contrast to neonatal ECMO, for which respiratory parameters such as oxygenation 
index (OI) and alveolar-arterial oxygen tension difference (AaDO2) have been defined, 
there is virtually no generally accepted respiratory parameter to start ECMO in the non-
neonatal group. The standard of care is highly institution–dependent, based on level of 
experience of the (Pediatric) Intensive Care Unit ((P)ICU) teams, logistics around the start 
of ECMO in individual patients, and ethical considerations. From respiratory insufficiency 
mortality statistics in two designated PICUs in the Netherlands over a three-year period 
we calculated that 1 patient per 1.000.000 inhabitants/year would need non-neonatal 
ECMO. This figure can be used as a rough estimate for the institution of a non-neonatal 
ECMO program in any given country. Over the last couple of years this figure fits the 
actual performance of ECMO in our institutions; it has been increasing slowly over the 
past 5 years. 
As failure of optimal therapy is defined as; the best inclusion criteria for non-neonatal 
ECMO, the percentages of patients referred for ECMO and those actually treated with 
ECMO, have been evaluated.. Due to adjustments in the management of the patient in 
the ECMO center or the identification of “hidden” contra-indications upon arrival in the 
ECMO center only 30-40% of all referred pediatric patients were treated with ECMO.
For patients in a cardiac center the calculated need depends on post-operative 
mortality (usually 3-5%) and number of deaths within 24 hours post-surgery. Thus, we 
calculated the potential need for post-cardiac ECMO support at between 2-5 patients/
year (based on 200 CPB yearly). Morris and others advocate a greater use of ECMO, 
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considering improvements of the results in terms of survival [31]. According to Euro-
pean and American recommendations, centers of congenital heart surgery should have 
ECMO available [32].
Taking into account post-cardiac cases, the overall need for non-neonatal ECMO is 
around one patient/1.000.000 inhabitants/year. Non-neonatal ECMO therefore should 
be concentrated in large regional centers rather than performing “occasional” ECMO in 
centers with little experience.
Primary outcome parameters.
Mortality is usually considered as a primary outcome parameter, but data should be 
evaluated very carefully. All reports document a significant discrepancy between a suc-
cessful ECMO run and survival till discharge or transfer. Moreover, a number of patients 
will die even after transfer elsewhere. Post-transfer mortality should also be taken into 
account as to ECMO-related death. Fair reporting including survival after six and twelve 
months is important to identify the real contribution of ECMO to survival rates in certain 
disease states. 
Equally important is careful evaluation of long term outcome, including not only 
somatic aspects but also psychosocial and motor development. Assessed with validated 
scales, in contrast to neonatal ECMO, underlying morbidity or persistent co-morbidity 
determines outcome in many of these children. The risk of neurological damage as a 
result of the ECMO procedure in itself is significantly lower in non-neonatal ECMO 
because the primary ECMO mode is mainly venovenous using either the neck (double 
lumen venovenous) or two sides (neck and groin). Apart from myocarditis and cardiac 
surgery, ECMO is typically used improve CO2 removal and should be considered as an 
adjuvant therapy diminishing the need for ventilatory support (peak pressures, FiO2); in 
other words, really buying time and preventing ongoing damage. 
Previously ECMO was believed to be too complex to be used during patient transport. 
At present, however, numerous patients have been transported worldwide [33, 34]. 
These experiences included both adult and pediatric patients and involved patients 
who require support for pulmonary as well as cardiac failure. Further improvement of 
transport systems can lead to a reduction in the number of ECMO centers, resulting in a 
higher number of patients per individual center, which could benefit outcome.
in conclusion
Non-neonatal ECMO is a high resource demanding treatment modality that should be 
restricted to large regional centers which perform at least one ECMO procedure per 
month and in which the indications for the individual patient are solidly discussed in an 
interdisciplinary team.
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We have to realize that non-neonatal ECMO is not yet supported by properly designed 
randomized controlled trials, so that it should be reluctantly included among the treat-
ment modalities available for pediatric respiratory and cardiac failure. ECMO should be 
performed in specialized centers with an adequate infrastructure. In our opinion this 
includes an interdisciplinary long term follow up which integrates short (survival at 
discharge six months and one year) as well as long term morbidity as outcome measure-
ments. 
The short and long term morbidity figures may shed a light on the value of ECMO in 
the health care system and its costs effectiveness and may support the planning of high 
resource facilities within countries and institutions.
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Part 2
Aspects in the use of Extracorporeal 
Membrane Oxygenation to assist gas 
exchange in children
Learn from yesterday, live for 
today, hope for tomorrow. 
The important thing is not to 
stop questioning 
(Albert Einstein 1879 – 1955)
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AbstRAct
background
Dynamic arterial lactate indices predict mortality more accurately than static arterial 
lactate measurements in children with septic shock or congenital cardiac defects. The 
current study evaluates whether this also applies to children with primary respiratory 
disease requiring extracorporeal membrane oxygenation (ECMO).
Methods
Static arterial lactate levels (LACabs) were prospectively collected before and during 
ECMO support for this single center, observational cohort study. Also, time-weighted 
arterial lactate (LACtw) and lactate change over time (LACdelta) were calculated as dy-
namic indices for, respectively, the duration and the trend over time of lactate derange-
ment. Intensive Care mortality was the primary endpoint. Analyses were performed for 
neonatal and pediatric patients separately.
Results
Fifty-six neonatal and 39 pediatric patients were included. Eighteen (32%) neonatal 
and 12 (31%) pediatric patients died. The evolution of LACabs and LACdelta differed 
between the pediatric survivors and the pediatric non-survivors (p<0.001, p=0.025). The 
hazard ratio was 1.23 (CI95=1.06-1.43, p=0.007) for LACabs and 20.64 (CI95=1.99-214.20, 
p=0.011) for LACdelta, indicating that higher lactate levels increase the risk for mor-
tality. The predictive value for LACabs was 0.75 (CI95=0.57-0.93) and for LACdelta 0.69 
(CI95=0.51-0.87), respectively. There were neither consistent differences for LACtw in the 
pediatric patients, nor for any of the static or dynamic lactate indices in the neonatal 
patients. 
conclusion
Static arterial lactate measurements and, to a lesser extent, dynamic arterial lactate 
indices predict mortality in pediatric, but not neonatal ECMO patients. The magnitude 
and trend over time rather than the duration of lactate derangement are associated with 
mortality.
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intROductiOn
Extracorporeal membrane oxygenation (ECMO) can serve as rescue treatment for 
children with therapy-resistant, primary respiratory failure [1]. From the year 2000 to 
2012, over 10,750 neonatal and 3,800 pediatric patients received ECMO worldwide [2]. 
Mortality rate is high and differs between neonatal (32%) and pediatric patients (44%) 
despite ECMO support [2].
Lactate –an end product of carbohydrate metabolism– is constantly produced during 
glycolysis and, thereafter, metabolized [3]. Unlike pH, pO2, or pCO2, the lactate concen-
tration can increase during both anaerobic and aerobic conditions. The latter include: 
a) liver dysfunction resulting in reduced lactate clearance; b) enhanced glycolysis –e.g. 
in cytokines or due to hyperglycemia; c) increased catecholamine levels affect cellular 
glucose uptake; d) alkalosis causing increased cellular efflux of lactate; e) mitochon-
drial dysfunction; and f ) drug infusion / intoxication –e.g. epinephrine, nucleosidic 
reverse transcriptase inhibitors, methanol–[3, 4]. Lactate concentration correlates to 
both severity of illness and mortality [3-5]. However, lactate concentration can also be 
false negatively low –e.g. sepsis-induced decrease of peripheral perfusion or necrosis-
induced absence of carbohydrate metabolism–[3]. Also, age-related differences in 
lactate production and lactate metabolism have been described between adults and 
children and between newborns and older children[6-11]. Therefore, the value of lactate 
for predicting mortality might dependent on age, disease type, co-morbidity, and dis-
ease severity or –in other words– time [5]. It was demonstrated recently that dynamic 
measures of lactate derangement –i.e. incorporating duration or trend over time next to 
magnitude– are better predictors for survival than static lactate measurements in septic 
children and children with congenital cardiac defects [12-15].
Neonatal and pediatric ECMO candidates are amongst the most critically ill children 
conceivable. Static lactate measurements are established predictors for mortality in 
ECMO children with primary cardiac disease [16-20]. The few studies that focused on 
children with primary respiratory failure included both neonatal and pediatric patients, 
still included some children with primary cardiac disease, recruited patient cohorts from 
before the year 1997, and included patients suffering from prolonged hypoxia [21-24]. 
Today, however, ECMO is generally started early in order to prevent ventilator-induced 
lung injury whilst the ECMO population is has more co-morbidity, amongst other dif-
ferences [25]. Moreover, none of the reports described dynamic lactate indices [21-24]. 
Therefore, this study aimed to evaluate the predictive value of both static and dynamic 
arterial lactate indices obtained before and during ECMO in a general population of 
children with primary respiratory disease. In line with the registry maintained by the 
Extracorporeal Life Support Organization and the majority of scientific literature [26], 
and given that lactate kinetics, patient characteristics, and the crude mortality rate differ 
Arterial lactate for predicting mortality in children requiring extracorporeal membrane oxygenation
5
70
between newborns and older ECMO children, data will be presented for neonatal and 
pediatric patients separately.
MAtERiAls And MEtHOds
study design and setting
This observational cohort study entails data collected prospectively in patients admit-
ted to the intensive care (IC) of a level III university children’s hospital. The local medical 
ethical review board approved the study and waived the need for informed consent.
Patients
Consecutive neonatal –age at admission below 28 days– and pediatric patients –age 
at admission 29 days to 18 years– with primary respiratory disease receiving ECMO be-
tween 2008 and 2011 were included. This inclusion period was chosen for two reasons: 
1) at the end of 2007 a new protocol was implemented for CDH patients – who form 
a major part of the patients in the neonatal ECMO group; and 2) in 2011 our depart-
ment switched to another ECMO system [27, 28]. Both factors were anticipated to lower 
mortality rate, which is the primary endpoint of the current study [29]. 
Patients with primary cardiac disease and patients with less than two lactate measure-
ments were excluded. Only the first ECMO run was included in case patients (n=3) 
received multiple ECMO runs. 
data collection
The primary endpoint was IC mortality, the primary study parameters were static 
arterial lactate (LACabs) and the dynamic arterial lactate indices time-weighted arte-
rial lactate (LACtw) and lactate change over time (LACdelta). LACabs was included as 
it is used in most of the previous studies. The rationale for including dynamic lactate 
indices is threefold: 1) dynamic indices describe duration and trend over time next to 
magnitude and can account disease-severity-induced adjustments over time; 2) results 
are promising in non-ECMO children with septic shock or cardiac defects [12-15]; 3) a 
study in post-cardiac surgery children showed that mortality lowered after introduc-
ing lactate-guided therapy [29]. LACabs levels were determined using an ABL-800 flex 
blood gas analyzer (Radiometer Medical Aps, Copenhagen, Denmark) and stored unit’s 
electronic system. From this system we retrieved all LACabs measurements before and 
during ECMO support. Thereafter LACtw and LACdelta were calculated [30]. LACtw 
–incorporating magnitude and duration of lactate derangement– was determined by 
summing the mean value of LACabs between consecutive time points multiplied by the 
time period in between and then dividing by the total time [30]. For LACdelta –incorpo-
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rating magnitude and trend over time– LASabs values were regressed against time for 
each individual patient, with the regression slope representing the projected change of 
consecutive measurements over time [30].
We also obtained patient demographics and disease severity indices –i.e. pediatric risk 
of mortality II (PRISM II), pediatric index of mortality II (PIM II), pediatric logistic organ 
dysfunction (PELOD), oxygenation index (OI), and the level of vasopressor support (VP-
score) [29-33]. Co-morbidity was registered using definitions described earlier [25, 36]. 
Renal failure was assessed only prior to cannulation because after cannulation all pa-
tients received hemofiltration. Pulmonary hypertension was assumed present in case of 
inhaled nitric oxide therapy combined with either echocardiographic reporting or with 
consistent pre-ductal to post-ductal saturation differences greater than 20%. The mode 
of ECMO support was scored as either venoarterial ECMO (VA-ECMO) or venovenous 
ECMO (VV-ECMO). If the ECMO mode was converted, the ECMO mode with the longest 
duration was scored.
Hospital treatment protocol
After initial stabilization and IC admission, patients were treated according to institu-
tional policy. Respiratory and circulatory management have been described previously, 
as have the ECMO inclusion and exclusion criteria, the sedative and analgesic manage-
ment, the cannulation procedure, and the ECMO weaning procedure [37, 38]. In short, 
the ECMO criteria were: prolonged OI>25 or cardiorespiratory failure for more than 
three hours with pH<7.15 and PaO2<5.3 kPa. VV-ECMO was preferred for patients with 
isolated primary respiratory failure –i.e., good myocardial function as assessed by car-
diac echo and no severe circulatory failure as assessed by conventional hemodynamic 
parameters. VA-ECMO was preferred in patients with congenital diaphragmatic hernia 
(CDH) or isolated septic shock, and in patients with primary respiratory failure that was 
accompanied by poor myocardial function and/or circulatory failure. Both the timing of 
ECMO and type of ECMO modality were decided by the attending intensivist. The ECMO 
membrane and tubing were supplied by Medtronic (Medtronic Inc., Minneapolis, MN, 
USA); the ECMO roller pumps were provided by Stöckert Instrumente GmbH (Stöckert 
Instrumente GmbH, Munchen, Germany). The normal range for arterial lactate was: 0.5 
to 2.0 mmol/L.
statistical analysis
Data are presented and analyzed separately for neonatal and pediatric patients (see in-
troduction). LACabs, LACtw, and LACdelta are expressed as means with 95%-confidence 
interval (CI95). Statistical analysis was done in three steps. Firstly, to assess evolutional 
differences, a repeated measurements analysis was performed using linear mixed ef-
fects models thereby accounting for correlating measurements within each patient. For 
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the linear mixed effects model specification, we used regression splines –i.e. natural 
cubic splines– for both the fixed and the random-effects parts to account for potential 
non-linearity. The models’ assumptions were validated using residuals plots. Secondly, 
as a summary measure of the static and dynamic lactate indices, we calculated per 
patient the area under the longitudinal curve corrected for days of follow-up. Using Cox 
proportional hazards modeling, these were subsequently used to determine the hazard 
ratios (HR) with CI95 and the concordance index (concindex) with CI95, the latter rep-
resenting the predictive value. Finally, the area (AUC) under ROC curve was calculated 
together with the best cut-off value and its sensitivity, specificity, positive predictive 
value, and negative predictive value in case relevant. All other data are described as 
medians (IQR). The correlation between vasopressor score and the respective lactate 
indices was calculated using the spearman rank correlation coefficient. Descriptive 
statistics and non-parametric inferential testing were done using SPSS 17.0 (SPSS Inc., 
Chicago, IL, USA). The advanced statistical testing for the lactate indices was done using 
R2.15.2. A p-value below 0.050 was considered statistically significant.
figure 1: Flowchart for the patients with primary respiratory disease requiring extracorporeal membrane 
oxygenation who were assessed for inclusion in the study.
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REsults
We enrolled 56 neonatal and 39 pediatric patients. Seventeen patients with primary 
cardiac disease were excluded (Figure 1). Of those included, 18 (32%) neonatal and 12 
(31%) pediatric patients died. Table 1 shows the baseline and ECMO-related patient 
characteristics. 
VA-ECMO was used more often in the neonatal non-survivors than in the neonatal 
survivors while fewer non-survivors were transferred from another hospital to the study 
site. The time between admission and ECMO start did not differ. Vasopressor support 
at admission was lower in the non-survivors. The other disease indices differed neither 
before nor or during ECMO. The non-survivors received ECMO support longer than the 
survivors. In one survivor, the ECMO mode was converted from VV-ECMO to VA-ECMO 
because the maximum VV-ECMO blood flow was insufficient to restore cardiorespiratory 
parameters. Eighteen (32%) neonates died. In four patients ECMO could not be weaned 
due to: irreversible primary pathology (n=2; alveolar capillary dysplasia and persistent 
pulmonary hypertension [PPH]), hemorrhagic complication, thromboembolic complica-
tion. The 14 other non-survivors were successfully weaned off of ECMO, but died prior 
to IC discharge –median (IQR) time after ECMO stop: 17 (3-21) days–. Here the causes of 
death were PPH in CDH (n=11), septic shock (n=2), and chronic pneumonitis of infancy.
In the pediatric patients, VA-ECMO was started as often in survivors as in non-survivors. 
In five pediatric patients (four survivors) the ECMO mode was converted from VV-ECMO 
to VA-ECMO while in one pediatric patient VA-ECMO was switched to VV-ECMO. Before 
or during ECMO there were no differences in any of the disease severity indices, apart 
from a clinically irrelevant difference in vasopressor support at admission. Neither the 
time between admission and ECMO start, nor the duration of ECMO support differed 
between the survivors and the non-survivors. In nine (75%) non-survivors, ECMO 
could not be weaned. The causes of death included: pulmonary consolidation (n=2), 
PPH, septic shock, cerebral haemorrhage, ischaemic-hypoxic encephalopathy, cardiac 
tamponade, Waterhouse-Friderichsen syndrome, and auto-immune-induced interstitial 
lung disease. Three pediatric non-survivors were successfully weaned, but died before IC 
discharge –median (IQR) time after ECMO stop: 7 (6-11) days. The causes of death were 
septic shock, idiopathic PPH, and ischaemic-hypoxic encephalopathy.
Arterial lactate before & during EcMO 
Neonatal patients
Fifty-six neonates were included in whom in total 3,430 arterial lactate measurements 
were performed (median [IQR] number per patient: 37 [17-97]). The number of lactate 
measurements on day 1 and day 2 of IC admission was higher in the non-survivors than 
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in the survivors: median (IQR) number= 15 (5-18) vs. 7 (4-13). For the other days, there 
were no differences. 
In the neonatal patients, the mean (CI95) LACabs, LACtw, and LACdelta before and 
during ECMO in relation to outcome are presented in Table 2. The evolution of LACabs, 
LACtw, and LACdelta from admission to ECMO stop is shown in Figure 2. Linear mixed 
effects modeling showed that, based upon the likelihood ratio, the evolution of LACabs 
did not differ between the survivors and the non-survivors (Table 3). Cox regression 
modeling showed that the hazard ratio of LACabs was not significant and that its predic-
tive value, estimated by the concordance index, was poor (Table 3). The evolution of the 
dynamic lactate index LACtw in the non-survivors differed from that of the survivors. 
However, the hazard ratio of LACtw was not significant and its predictive value was poor. 
LACdelta’s hazard ratio was statically different, but the predictive value was poor.
The supplemental table 1 shows the vasopressor score in relation to LACabs, LACtw, 
and LACdelta for the neonatal (and the pediatric) VA-ECMO and VV-ECMO patients.
table 2: The levels of static, absolute arterial lactate level (LACabs), time-weighted arterial lactate (LACtw), 
and lactate change over time (LACdelta) for the neonatal- and pediatric extracorporeal membrane oxygen-
ation patients.
Neonatal patients Pediatric patients 
Survivors
n = 38
Non-survivors
n = 18
Survivors 
n = 38
Non-survivors 
n = 18
Lactate levels
total follow- up
LACabs in mmol.L-1 1.9 
(1.8 to 2.0)
1.8
(1.8 to 1.9)
2.0
(2.0 to 2.1)
2.5
(2.4 to 2.6)
LACtw in mmol.L-1 2.3
(2.2 to 2.4)
1.9
(1.9 to 2.0)
2.2
(2.1 to 2.3)
2.9
(2.8 to 3.0)
LACdelta in mmol.L-1 -0.02
(-0.06 to 0.03)
-0.04
(-0.16 to 0.07)
-0.02
(-0.06 to 0.01)
0.06
(-0.02 to 0.15)
Lactate levels 
pre-ECMO start
LACabs in mmol.L-1 2.4
(2.2 to 2.6)
2.2
(2.1 to 2.4)
2.1
(1.7 to 2.5)
2.8
(2.4 to 3.2)
LACtw in mmol.L-1 2.4
(2.2 to 2.6)
2.2
(2.2 to 2.3)
2.1
(1.7 to 2.4) 
2.5
(2.2 to 2.9) 
LACdelta in mmol.L-1 0.02
(-0.08 to 0.12)
0.07
(-0.02 to 0.15)
-0.03
(-0.19 to 0.13)
0.19
(-0.08 to 0.45)
Lactate levels 
post-ECMO start
LACabs in mmol.L-1 1.7
(1.6 to 1.8)
1.6
(1.5 to 1.7)
2.0
(1.9 to 2.1)
2.4
(2.3 to 2.6)
LACtw in mmol.L-1 2.2
(2.1 to 2.3) 
1.8
(1.8 to 1.8) 
2.2
(2.1 to 2.3)
3.0
(2.8 to 3.1)
LACdelta in mmol.L-1 -0.03
(-0.08 to 0.02)
-0.09
(-0.26 to 0.07)
-0.02
(-0.04 to 0.00)
0.03
(-0.05 to 0.12)
Data are presented in mean (CI95) for the total study period, for the measurements before the start of ex-
tracorporeal membrane oxygenation (ECMO), and for the measurements during the course of ECMO. Inter-
group differences were no assessed. Mmol.L-1 millimoles per liter.
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Pediatric patients
Thirty-nine pediatric were included in whom in total 3,045 arterial lactate measurements 
were performed (median (IQR) number per patient: 57 (29-87)). In the pediatric non-
survivors, the number of lactate measurements was higher only on day 2 of IC admission 
when compared to the survivors: median (IQR) number=6 (9-13) vs. 4 (6-8).
For the pediatric ECMO patients, mean (CI95) LACabs, LACtw, and LACdelta before 
and during ECMO are presented in Table 2 and the evolution is presented in Figure 3. 
The evolution of LACabs and LACdelta differed significantly between the survivors and 
the non-survivors (Table 3). In the pediatric non-survivors, LACabs was constantly higher 
before and during ECMO. Its hazard ratio was 1.23 (CI95= 1.06-1.43, p= 0.007) and the 
predictive value was good (concindex= 0.75, CI95= 0.57-0.93). The overall hazard ratio 
of LACdelta was 20.64 (CI95= 1.99-214.20, p= 0.011) and the predictive value was 0.69 
(CI95= 0.51-0.87). The hazard ratio of LACtw failed to reach statistical significance. Its 
predictive value was 0.63 (CI95= 0.47-0.79).
Figure 3 shows that the most prominent differences for LACabs and LACdelta occurred 
from IC admission up to day 4. These LACabs and LACdelta measurements were used 
subsequently to determine the AUC of the ROC together with the best cut-off value in 
case relevant. For LACabs, the AUC was 0.73 (p-value <0.001) and the best cut-off value 
was 2.5 mmol/L –sensitivity: 62% (CI95:57-67), specificity: 75% (CI95:72-79), positive 
predictive value: 58% (CI95:53-63), and negative predictive value: 79% (CI95:75-82). For 
LACdelta the AUC failed to differ significantly. Hence, a cut-off value was not determined.
table 3: The evolution (expressed by the likelihood ratio), the hazard (expressed by the hazard ratio), and 
the predictive value (expressed by the concordance index) of static, absolute arterial lactate level (LACabs), 
the dynamic measure time-weighted arterial lactate (LACtw), and the dynamic measure lactate change 
over time (LACdelta) in the neonatal and the pediatric patients requiring extracorporeal membrane oxy-
genation.
Longitudinal 
evolution
Hazard Predictive value 
Likelihood 
ratio 
p-value Hazard 
ratio
CI95 p-value Concordance 
index
CI95
Neonatal 
patients
LACabs 6.78 0.237 0.94 0.66 to 1.34 0.716 0.47 0.32 to 0.62
LACtw 12.24 0.032 0.85 0.59 to 1.22 0.381 0.46 0.31 to 0.61
LACdelta 2.52 0.77 0.73 0.56 to 0.97 0.028 0.39 0.24 to 0.54
Pediatric 
patients
LACabs 30.24 < 0.001 1.23 1.06 to 1.43 0.007 0.75 0.57 to 0.93
LACtw 6.54 0.257 1.13 1.00 to 1.27 0.056 0.63 0.47 to 0.79
LACdelta 11.11 0.025 20.64 1.99 to 214.20 0.011 0.69 0.51 to 0.87
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figure 2: The evolution of static, absolute arterial lactate level (LACabs; panel A), time-weighted arterial 
lactate (LACtw; panel B), and lactate change over time (LACdelta; panel C) in relation to mortality in neo-
nates with primary respiratory disease requiring extracorporeal membrane oxygenation. LACtw differed 
between the neonatal survivors and the neonatal non-survivors, in contrast to LACabs and LACdelta. Data 
are presented as mean (lines) with CI95 (gray areas), * p<0.050 vs. survivors using mixed effects models.
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figure 3. The evolution of static, absolute arterial lactate level (LACabs; panel A), time-weighted arterial lac-
tate (LACtw; panel B), and lactate change over time (LACdelta; panel C) in relation to mortality in pediatric 
patients with primary respiratory disease requiring extracorporeal membrane oxygenation. Both LACabs 
and LACdelta, but not LACtw, differed between the pediatric survivors and the pediatric non-survivors. 
Data are presented as mean (lines) with CI95 (gray areas), * p<0.050 vs. survivors using mixed effects models. 
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discussiOn
Our study shows that neither LACabs nor LACdelta or LACtw predicted mortality in 
neonatal ECMO patients. In contrast, LACabs was a good predictor in the pediatric 
ECMO patients. Its hazard ratio indicated that for every one unit increase, the risk for 
non-survival increased by 23%. Moreover, albeit less predictive than LACabs, LACdelta’s 
hazard ratio was very high whilst LACtw did not differ significantly. So, not the duration 
of lactate derangement, but the magnitude and trend over time of lactate derangement 
are in particular associated with mortality in pediatric ECMO patients with respiratory 
disease. 
Multiple studies have reported that static hyperlactatemia is associated with higher 
mortality in ECMO patients with primary cardiac disease [16-20]. For children with pri-
mary respiratory disease, there is one study that focused on a cohort of both neonatal 
and pediatric patients and three studies that focused on neonates exclusively [21-24]. 
The neonatal studies showed that, in contrast to our results, higher static lactate was 
associated with higher mortality [22-24]. The reported mean or median lactate levels 
were, however, markedly higher than ours, as was the oxygenation index and VP-score. 
Catecholaminergic support in itself can increase arterial lactate levels, as has been 
reported previously by others and as can be deduced from some of our results that are 
presented in the Supplemental table 1 [3, 4]. Therefore, the discrepancy in results is most 
likely attributable to differences in treatment, disease severity, and, possibly, to differ-
ences in ECMO population characteristics. 
The question as to why arterial lactate is associated with poor outcome in pediatric 
patients, but not in neonatal patients, is intriguing. In contrast to the neonatal non-
survivors, relatively many pediatric non-survivors were diagnosed septic shock. Sepsis 
is a microcirculatory disease and lactate is more likely to increase. Moreover, when 
compared to the neonates, more pediatric patients were referred to our center and more 
pediatric non-survivors had co-morbidity –most notably liver dysfunction. Additionally, 
less pediatric patients suffered pulmonary hypertension while a higher proportion of 
neonatal survivors was treated with VV-ECMO. Right-to-left shunting through persistent 
fetal pathways and mixing of deoxygenated and oxygenated venous blood in the case 
of VV-ECMO might increase the amount of “venous” blood in the arterial circulation. 
Given that venous blood is associated with higher lactate than arterial blood, both phe-
nomena could act as confounders in the neonatal population. Thus, differences in dis-
ease type, co-morbidity, timing of treatment, and type of treatment might explain why 
lactate predicts outcome only in the pediatric patients [5]. The observed differences are 
unlikely to be of procedural nature as the measurement error of the blood gas analyzers 
was small, the ECMO entry criteria remained unaltered during the study, the cannulation 
procedure was standardized, and the primed ECMO circuit was checked and adjusted to 
Arterial lactate for predicting mortality in children requiring extracorporeal membrane oxygenation
5
81
normal values pre-cannulation. Furthermore, the number of conversions did not differ 
and there were no indications that ECMO support was more often insufficient in the 
pediatric non-survivors. 
This is the first study to focus on the predictive value of static and dynamic lactate mea-
sures in pediatric ECMO patients with primary respiratory disease. Lactate derangement 
has been associated with mortality in various groups of pediatric, critically ill non-ECMO 
patients[3, 13, 39]. Particularly interesting is the report by Rossi et al. that describes a 
marked decrease in mortality in post-cardiac surgery children after implementation of 
lactate-guided therapy[29]. Others observed that dynamic lactate indices predicted 
mortality better in critically ill, pediatric non-ECMO patients[12,13]. We observed the 
reverse: static lactate measurements are a better predictor than dynamic indices. In our 
study, the arterial lactate levels wererelatively low upon admission and after three or 
more days of ECMO support. Likewise, the oxygenation index and the VP-score were 
relatively low. Furthermore, all pediatric patients and approximately 50% of the neona-
tal patients were referred to our center. Therefore, our data are most likely attributable 
to the early referral of patients to our center, which is regarded good practice in our 
country. Moreover, estimating LACdelta and LACtw in only the first few days before and 
after ECMO support will result in other, probably more convincing, differences and in 
higher predictive value. 
Interestingly, relative hyperlactatemia –i.e. higher lactate concentrations within the 
normal reference range–is associated with increased mortality in critically ill adults [40, 
41]. While relative hyperlactatemia is not truly applicable to our study and the topic is 
beyond our scope, it might be interesting for future researchers to investigate whether 
relative hyperlactatemia is also clinically relevant in critically ill children.
The most important limitation of the current study is the modest number of included 
patients. This limited the possibility to correct for hypothetic confounders such as disease 
type at admission, co-morbidity, level of catecholaminergic support, ECMO mode, and 
age during statistical analysis. Results should thus be interpreted with caution. However, 
statistically significant results were still obtained in spite of the small sample and effect 
size. Moreover, in accordance with a review by Allen we do not believe that a single 
biomarker should be used to amend or stop therapy and that, for correct interpretation, 
the cause –i.e. anaerobic or aerobic (co-) morbidity– of lactate increments should ideally 
be identified[3]. The clinical relevance of the current study should be sought in the fact 
that, for pediatric patients, mild lactate derangements that fail to normalize over time 
can serve as warning sign. The high hazard ratio of LACdelta shows that dynamic lactate 
indices –which account for disease-severity-induced adjustments over time– could be 
a valuable addition to clinical practice. Therefore, future prospective studies should 
substantiate the value of absolute and dynamic arterial lactate levels, preferably in ho-
mogeneous ECMO patient groups, and with respect to type, timing, and level of therapy 
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delivered. Ideally, arterial lactate should then be evaluated together with other biomark-
ers such as microcirculatory perfusion [39]. In septic shock children, microcirculatory 
perfusion has been associated with mortality [42]. For neonatal ECMO patients with 
primary respiratory disease, future research should elucidate whether arterial lactate 
monitoring in neonates may be used for other clinically relevant purposes.
cOnclusiOn
Static arterial lactate measurements and, to a lesser extent, dynamic arterial lactate 
indices predict mortality in pediatric ECMO patients with primary respiratory disease. 
The magnitude and trend over time of arterial lactate levels, but not the duration of 
lactate derangement predict mortality. In contrast, the value of arterial lactate for pre-
dicting outcome in neonatal ECMO patients is limited. A prospective multicenter study 
should substantiate the findings presented here in relation to intervention and a panel 
of biomarkers.
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Preoperative ECMO in neonates with 
transposition of the great arteries 
and preoperative cardio-pulmonary 
instability
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AbstRAct 
background
Pulmonary hypertension (PHT) in neonates with transposition of the great arteries 
(d-TGA) can be difficult to treat. Next to the use of prostaglandin E1 and balloon atrial 
septostomy, pharmacological pulmonary vasodilator therapy including inhaled nitric 
oxide cannot prevent preoperative mortality. ECMO support, however, may help reduce 
pulmonary hypoxic vasoconstriction and improve pulmonary vascular resistance (PVR).
design
Retrospective, cohort study.
setting
Single, tertiary-care center PICU
Methods
The local ethics review board approved the retrospective review of all neonatal d-TGA 
patients in our hospital in the period 2002-2012 and those in the ELSO database to 
describe the incidence of PHT and the use of ECMO in these patients. 
Measurements and Main Results
Our hospital admitted 92 d-TGA patients in this period, 17 of whom had preoperative 
PHT receiving conventional treatment (18%). Conservative treatment failed in eight of 
these 17 patients (47%). Six of these eight patients were cannulated for ECMO. All six 
were term neonates and survived to surgery and survived ECMO. As one infant died 
three months after surgery, one-year survival in the ECMO-treated group was 83%. All 
other five patients had favorable neurologic outcome at one year.
conclusion
If conservative treatment of PHT does not sufficiently reduce PVR in d-TGA patients and 
results in profound hypoxia, pre-operative ECMO can safely be used as therapy for PHT 
and to bridge the period to surgery.
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intROductiOn
Patients with a transposition of the great arteries (TGA) account for 5% to 7% of the 
congenital heart defects [1]. When d-transposition (D-TGA) is present and the parallel 
circulations do not mix sufficiently severe hypoxemia can result [2]. 
This is a challenging combination for clinicians especially when the ventricular sep-
tum is intact. The usually effective pre-operative interventions to increase mixing of 
the blood are prostaglandin E1 and balloon atrial septostomy (BAS). However some of 
these patients respond poorly and hypoxemia persists. In addition to mixing problems 
pulmonary hypertension (PH) aggravated by hypoxemia leads to impaired pulmonary 
flow and decreased left sided atrial filling. PH is present in 1-3% of D-TGA patients [3] 
In these persistent hypoxemic cases an immediate primary repair by performing an 
arterial switch operation (ASO) could benefit the patient. However in cases of severe PH 
midterm survival is poor. [4] Another option is to treat PH pharmacologically or to start 
extracorporeal membrane oxygenation (ECMO) [5].
ECMO in the pre-operative TGA setting can be used to improve gas exchange and 
the resulting increase in oxygenation can help to reduce pulmonary vascular resistance 
(PVR) thus stabilizing the patient before corrective surgery. 
Several papers, mainly case reports, show successful treatment with ECMO in the pre-
operative period [6-9]. Despite these reports, there is still a paucity of data on the indica-
tions, choice of ECMO mode and short term effects of preoperative ECMO in these cases. 
In TGA patients the ECMO-mode itself does not influence pulmonary blood flow. Both 
VV ECMO as well as VA ECMO circulate oxygenated blood into the systemic circulation 
either by returning saturated blood in the right atrium or in the aorta which originates 
from the right ventricle. 
It remains uncertain if preoperative ECMO improves mortality and long term outcome 
in these patients. Furthermore it is unclear which ECMO-mode should be preferred. 
We describe the short and long-term outcomes of six patients successfully bridged to 
surgery using ECMO in the pre-operative phase. 
MAtERiAls And MEtHOds
We performed a single-center retrospective observational study in the Erasmus MC-
Sophia Children’s Hospital, Rotterdam, the Netherlands, which serves as a level III referral 
center. It is one of four designated pediatric cardiac surgery centers and one of two 
designated ECMO centers in the Netherlands with on average 30 ECMO runs per year. 
The institutional medical ethics review board approved the study, and waived the need 
for informed consent. All neonates admitted between January 1st 2002 and December 
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31st 2012 with the diagnosis of d-TGA with or without VSD were identified. Clinical medi-
cal records and databases were retrospectively reviewed for details on ECMO support.
Inclusion and exclusion criteria for ECMO support were conform the ELSO criteria for 
neonatal ECMO treatment at that time: Gestational age > 34 weeks, birth weight > 2.0 
kg, mechanical ventilation < 14 days. Contraindications for ECMO were: Lethal chromo-
somal disorder or lethal anomaly, irreversible brain damage, uncontrolled bleeding or 
grade III or greater intraventricular hemorrhage. The in- and exclusion criteria for ECMO 
had not changed over the studied period. 
Prospectively collected physiological parameters were derived from the hospital’s 
computerized patient data management system. The following data were retrieved from 
the medical records: mortality, primary diagnosis, timing of BAS, inotropic support, NO, 
saturation, use of PHT medication, blood lactate, pH, ECMO mode and timing of ECMO. 
Pre-ECMO circulatory inotropic or vasopressor support was expressed as the converted 
to vasoactive inotrope score: Dopamine dose (μg/kg/min) + Dobutamine dose (μg/kg/
min) +100 × epinephrine dose (μg/kg/min) + 10 X Milrinone dose (μg/kg/min) + 100 × 
Norepinephrine dose (μg/kg/min) [10].
The ECMO patients reported in this study participated in a structural follow-up pro-
gram – initiated in 2001 – in which lung function, growth and developmental parameters 
are regularly assessed until 18 years of age [11]. Based on the national consensus on 
neonatal follow-up and the Dutch Ministry of Health’s requirement to provide relevant 
data, the assessment protocol is the standard of care following ECMO treatment in the 
Netherlands. At 12 months after ECMO treatment the Bailey Scales of Infant Develop-
ment – Second Edition – Dutch version (BSID-II-NL) was administered [12]. This standard-
ized instrument assesses motor and mental development of 2 to 30-month-old children. 
REsults
In the period 2002-2012, 92 d-TGA patients, including 19 patients with associated VSD, 
were admitted to the Erasmus MC-Sophia Children’s Hospital. Six of 92 patients were 
cannulated for ECMO (6/92; 6,5%): four within 48 hours after birth due to severe pulmo-
nary hypertension, one after 10 days because of recurrent PHT and suspicion of sepsis, 
and one, three weeks after birth because of low saturations and multi organ failure due 
to closure of the PDA. In all cases the patient was considered too unstable to undergo an 
arterial switch operation (ASO) and the decision to start ECMO was made by a multidis-
ciplinary team including neonatologists, ECMO specialists, pediatric cardiologists and 
pediatric cardiothoracic surgeons. Table 1 shows characteristics and pre ECMO therapies 
of these six patients, as well as the vasoactive inotrope score reflecting pre-ECMO circula-
tory inotropic or vasopressor support. Four patients were supported with VV- ECMO via 
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a 12 or 13 Fr (OriGen Biomedical, 
Austin, TX) double lumen catheter 
inserted in the right jugular vein. 
Two patients were cannulated for 
VA-ECMO using the right jugular 
vein and the right carotid artery. 
Median time on ECMO was 10,5 
days (IQR 1-22). Four patients 
were weaned from ECMO before 
the ASO, one patient was decan-
nulated immediately post-surgery, 
and one patient was decannulated 
96 hours after the operation. Figure 
1 shows the CONSORT patient flow 
diagram.
All six neonates who received 
ECMO support survived to surgery. 
All patients are still alive except for one patient who died in the ICU three months after 
the ASO due to an ongoing sepsis with capillary leakage syndrome, chylothorax and 
recurrent pulmonary hypertension. Thus, one-year survival in the ECMO-treated group 
was 83%. 
table 1: Pre-ECMO data of six consecutive patients with transposition of the great arteries (d-TGA) and 
preoperative cardio-pulmonary instability in the period 2002-2012.
Patient No: 1 2 3 4 5 6
Diagnosis
d-TGA-
IVS
TGA-
VSD-ASD
d-TGA-
IVS
d-TGA-
IVS
d-TGA-
IVS
d-TGA-
IVS
Body weight (gram) 4800 3200 4020 3900 3860 3350
Age at admission (days) 0 0 0 27 0 25
NO (ppm) 20 20 20 20 20 20
Prostaglandin E1 + + + + + +
Vasoactive Inotrope Score 42 70 90 50 98 30
BAS days after admission 0 0 0 0 0 1
Oral sildenafil (mg/kg/day) 3 2 4 0 0 0
Bosentan (mg/kg/day) 0 0 2 0 0 0
Saturation preductal (%) 32 48 37 38 48 52
Saturation postductal (%) 45 65 45 44 76 53
Lactate (mmol/l) 6.3 2 1.6 3.1 5.5 3.9
NO = nitric oxide; BAS balloon atrial septostomy; PH = pulmonary hypertension; IVS = intact ventricular 
septum; ASD = atrial septal defect; VSD ventricular septal defect; ppm = parts per million.
92 d-TGA
17 (18%) PH
8 (47%) of PH
failure
9 (53%) of PH
conventional
6 (35%) of PH
ECMO
2 (12%) of PH
died
figure 1: Consort patient flow diagram.
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All five surviving ECMO patients were included in the structural follow-up program. 
Motor and mental development were tested with the BSID-II-NL at age 12 months. 
Scores were normal or above average, except for patient No. 3 on the motor scale (Table 
2).
discussiOn
To our knowledge the present study reports the largest cohort of d-TGA patients with 
ECMO before ASO. Six percent (6.5%) of all d-TGA patients were supported with ECMO 
prior to surgery with only one patient needing ECMO postoperatively. All 6 survived 
to surgery or discharge from the ICU. Overall one year survival was 83% with all five 
surviving ECMO patients demonstrating favorable neurological outcome at one year.
Despite apparent adequate options for mixture of oxygenated and deoxygenated 
blood patients with TGA sometimes present with persistent hypoxemia. Alone or in 
combination with PH, TGA patients can become extremely difficult to manage preop-
eratively. 
Oxygenation depends on adequate mixture of oxygenated and deoxygenated blood 
across the patent foramen ovale. Decreased pulmonary flow due to a pulmonary 
artery-aortal-right-to-left shunt across the ductus arteriosus in PH will result decreased 
oxygenation and left atrial filling. The resulting right to left shunt over the oval foramen, 
by admixture, will further reduce the saturation of the pulmonary arterial blood. Thus, 
both PVR and pulmonary artery blood pressure are further increased, resulting in even 
table 2: ECMO and post-ECMO data of 6 consecutive d-TGA patients with PHT in the period 2002-2012.
Patient No: 1 2 3 4 5 6
ECMO data
ECMO mode VVDL V-A V-A VVDL VVDL VVDL
ECMO after admission (days) 1 1 10 5 1 1
Start ECMO (days post-partum) 1 1 10 32 1 26
ECMO duration (days) 8 5 7 3 3 5
ASO after start ECMO (days) 10 26 2 3 19 11
Extubation after admission (days) - 28 47 14 16 17
Discharge to home (days post-
partum) - 36 101 37 28 26
ECMO follow-up data
Bayley Scales of Infant Development-II
Mental at 1 year Deceased at Normal Normal Normal Normal Above normal
Motor at 1 year 3 months Normal Below average Normal Normal Normal
ASO = arterial switch operation; VVDL = venovenous double lumen; VA = venoarterial.
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lower pulmonary flow. Although iNO therapy has been shown to improve oxygenation 
in neonates with PHT and has improved survival in TGA patients mortality remains high 
in d-TGA patients with severe pulmonary hypertension [3]. Alternative interventions 
include sildenafil and bosentan, but the role of these drugs in the acute phase remain 
unclear. 
In these unstable patients one option is to go for acute ASO with an option to use 
ECMO in the postoperative setting to stabilize these patients via transthoracic or carotid 
cannulation [5].
However, high overall mortality has been reported in patients needing ECMO directly 
post-surgery in congenital cardiac defects [13]. Conversion from cardiopulmonary by-
pass to ECMO, difficulties in coagulation management and high risk of infection in open 
chest cannulation might all contribute to a high mortality in these patients [14, 15]. 
Overall pre-operative ECMO in pediatric cardiac patients was shown to have a sig-
nificant lower mortality compared to postoperative ECMO in heart surgery [16]. This 
therefore bears the question whether pre-operative ECMO in TGA patients might be 
beneficial compared to a risk of post-operative ECMO. Besides potential easier coagula-
tion management it opens op the opportunity for VV ECMO to improve oxygenation. 
A search in the ELSO-ECMO database identified 217 patients with ECMO in combina-
tion with d-TGA. However pre- and post-ASO patients could not be differentiated due 
to the set-up of the ELSO database. The overall survival to discharge rate for VV-ECMO 
patients was 67% vs. 55% for VA-ECMO patients. PHT (ICD-9 747.83) was recorded as a 
secondary diagnosis for 25 ELSO-ECMO patients and survival to discharge in this sub-
group was 52%. The ELSO data show a predominant use of VA-ECMO, although a clearly 
improved outcome has been demonstrated from the use of VV-ECMO as primary mode 
in the general ECMO population [13, 17]. Even in non-cardiac sepsis patients VV-ECMO 
was associated with a better survival rate [17]. Reasons for this improved outcome are 
unclear but the decreased risk for neurological sequelae has been suggested. VA-ECMO 
compared to VV-ECMO is reported to result in a higher rate of neonatal neurologic com-
plications [18, 19]. In a group of CDH patients with mostly severe PHT, the incidences of 
seizure disorders and infarction were highest in those on VA-ECMO [18].
However in TGA patients VV-ECMO oxygenates the same blood compartment as in 
VA-ECMO due to the unique configuration of TGA. ECMO-related emboli will have the 
same systemic and neurologic effects. VA-ECMO in these patients only differs from 
VV-ECMO in that it requires carotid cannulation, an (artificial) atrial septal defect and 
left atrial venous drainage, which can result in decreased pulmonary blood flow. Other 
factors including reduction of complication risks which are associated with VA ECMO 
post operatively might play an important role [14]. 
We found a 83% survival at one year with only one patient needing extended post-
operative ECMO support. Importantly four out of six of our patients were cannulated 
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using a double lumen catheter and supported with VV ECMO despite high inotropic 
support, whereas post operatively almost all patients would have been supported with 
VA-ECMO. Furthermore four patients could be weaned from ECMO before surgery with 
only one patient on ECMO support after surgery, thereby avoiding potential bleeding 
complications associated with post-operative ECMO [20]. These factors might have 
contributed to the positive results of our study [21].
It is not yet clear whether either pre-operative VV-ECMO or immediate ASO, with post-
operative ECMO as a backup in case of postoperative LV failure – with the inherent risks 
of postoperative bleeding and arterial cannulation – is the best option for TGA patients 
with severe PHT. Still both our short and long term one-year outcome data on the use of 
ECMO in the pre-operative setting in this small sample are promising. The search in the 
ELSO registry for d-TGA in combination with ECMO and PHT resulted in too few results 
to make definite conclusions, but closer evaluation of ECMO in TGA might be warranted.
Based on our findings and the ELSO database, we feel that preoperative ECMO is a 
viable option in neonates with severe therapy resistant hypoxemia not responsive to 
BAL, iNO and inotropic support. Furthermore VV-ECMO could be considered the first 
choice of ECMO mode in pre-operative TGA patients. 
Timing of decannulation or surgery depends on reversibility of PPHN. Daily echo-
graphic estimates of pulmonary artery pressure can be made while the patient is on 
ECMO, in order to prevent left ventricular deconditioning and to guide timing of ASO. 
The presence of unidirectional left-to-right ductal shunting could indicate optimal AOS 
timing [8].
liMitAtiOns
This is a retrospective case series of pre-operative ECMO use in d-TGA patients. With 6,5 
% need of ECMO support there seem to be a high number of patients who do not re-
spond to conventional therapies. Several authors have shown that a postnatal diagnosis 
of cardiac defects instead of an antenatal diagnosis may adversely influence outcome 
[22, 23]. Delaying therapies in situations with severe hypoxemia may only aggravate 
the situation resulting in therapy resistant PPHN in these patients. In our study all but 
one of the ECMO patients were not diagnosed antenatally which might have resulted in 
delayed therapy and ultimately therapy failure. Table 2 shows all patients were severely 
hypoxic with all but one having lactate acidosis showing signs of severe hypoxemia ne-
cessitating ECMO support. Whether these patients would have required post-operative 
ECMO if they were operated early remains uncertain but with a 83% survival at one year 
with favorable outcome it is at least a viable alternative to acute ASO in these patients.
Preoperative ECMO in neonates with transposition of the great arteries and preoperative cardio-pulmonary instability
6
95
As PHT in d-TGA patients is relatively rare, randomized controlled trials are unavail-
able and international data reports are sparse on both pre-operative mortality, utility of 
ECMO pre or postoperatively and effects of conventional therapies. Case series as well 
as large cohort data from registries such as the ELSO registry can therefore be of great 
value when adapted or expanded to include extra data for specific patient categories. 
Furthermore, long-term follow-up programs are essential to guide decisions concerning 
which short-term solutions are the best for future outcome. 
cOnclusiOn
When in d-TGA patients conservative treatment of PHT does not sufficiently reduce PVR 
and results in profound hypoxia, VV-ECMO can be considered as a bridge to surgery.
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AbstRAct
introduction
Extracorporeal membrane oxygenation (ECMO) is a means of gas exchange in cases of 
acute severe but temporary cardiorespiratory failure. We determined the frequency of 
pediatric ECMO treatment for longer than 20 days in our tertiary referral center as well 
as related interventions. 
Method 
We searched our institutional database for neonatal and pediatric patients on ECMO for 
21 days of longer and evaluated overall survival, possible causes of death and ECMO-
related complications and subsequent management. 
Results
Three cardiac and nine respiratory failure patients in the period 2009 till August 2015 
received ECMO for 21 days or longer. The median age was 3.3 (IQR 0.3-13.4) years; the 
median duration of ECMO support 25.2 (22.6-35.2) days. The overall survival was 33%; 
survival in the patients with primary respiratory disease was 44% (4/9). For most non-
survivors continuation of ECMO therapy was considered futile. Switching the ECMO sys-
tem was needed at least once in all patients. Bronchoscopy (N=35 in total) was the most 
frequent diagnostic procedure, without major sequelae. A thoracotomy was performed 
in two patients during ECMO without significant bleeding complications. Seven patients 
underwent diagnostic CT scans to assess the potential reversibility of pulmonary dam-
age/underlying pathology at a median of 19 days of ECMO therapy. 
conclusion
Prolonged ECMO is feasible in view of the 44% survival to discharge in respiratory pa-
tients. Still many diagnostic and intensive therapeutic interventions were needed. These 
data can help to formulate clear guidelines on management and maximum duration of 
prolonged ECMO, which are currently lacking. 
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intROductiOn
Extracorporeal membrane oxygenation (ECMO) is a technique to support cardiac and 
pulmonary functions in patients with severe reversible cardiopulmonary failure. It 
enables gas exchange or oxygen delivery if conventional treatment modalities fail. In 
the first decades after its introduction in the late 1980s ECMO was primarily used to 
support acute respiratory failure in newborns with persistent pulmonary hypertension 
for no longer than two weeks. This period was rather arbitrarily set internationally as a 
cut-off period and prolongation was long considered futile. Runs longer than two to 
three weeks were found to carry a high risk of complications and were associated with 
high mortality [1, 2]. Since then, however, indications for ECMO support have broadened 
to include primary cardiac failure, post cardiac surgery patients and primary respiratory 
failure in older patients. Especially since the 2009 influenza H1N1 pandemic, ECMO is be-
ing applied more and more in the older pediatric and adult populations with conditions 
that may require longer ECMO runs as a bridge to either recovery or transplantation [3].
Apart from the introduction of alternative ECMO-modes, smaller systems and cen-
trifugal pumps combined with changes in the overall management of patients have 
increased the feasibility of prolonged ECMO runs. Recently a 265-days ECMO run in an 
adult with cryptogenic organizing pneumonia proceeded without major problems [4]. 
Even longer ECMO runs are imaginable if complications such as bleeding, thrombosis 
and infections can be prevented. The question remains how to achieve this. Other ques-
tions concern the issue of when to decide that treatment is futile or that normal organ 
function can be regained [5].
To provide more data on both outcome and management of patients on prolonged 
ECMO we evaluated data of all patients supported with either venovenous or venoar-
terial ECMO in our institution for more than 20 days with special focus on respiratory 
management and complications. 
MEtHOds
setting
We performed a single-center retrospective observational study in the Erasmus MC-
Sophia Children’s Hospital, Rotterdam, the Netherlands, which serves as a level III referral 
center. It is one of two designated ECMO centers in the Netherlands with on average 30 
ECMO runs per year. The Erasmus MC institutional medical ethics review board approved 
the study, and waived the need for informed consent. 
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Patients
We searched records and databases for patients treated with ECMO in our institution 
between January 1990 and August 2015 and retrieved data of those patients who had 
been on ECMO for ≥ 21 days. This cutoff period was based on previous reports on pro-
longed ECMO [1, 6]. If a patient had received more than one course of ECMO ≥ 21, only 
data on the longest course were included. 
EcMO procedure
Decisions to start or stop ECMO treatment were made by the attending pediatric ECMO-
intensivist and regarding cardiac patients in collaboration with the pediatric cardiologist 
and cardiothoracic surgeon. Cardiac patients who were eligible for cardiac transplanta-
tion were switched from ECMO to a Berlin Heart ventricular assist device.
Open or semi-percutaneous cannulation was performed by a pediatric surgeons in 
the right jugular vein and if needed the carotid artery in children ≤ 15 kg or the femoral 
vessels in children >15 kg. The preferred mode of venovenous (VV-) ECMO was by double 
lumen cannula, with either an Origen TM (VR13, OriGen Biomedical, Austin, TX) or Avalon 
elite TM (Maquet, Rastatt, Germany) cannula. 
Up to 2011 we used a roller pump (Stockert-Shiley SIII) with a Medtronic silicone mem-
brane ECMO oxygenator (Medtronic, Minneapolis, MN, USA) in all cases, which was then 
replaced with the Novalung iLA active system centrifugal system (iLA active®, Novalung, 
Germany) with an appropriately sized polymethylpentene diffusion membrane oxygen-
ator. Hemofiltration, incorporated into the ECMO circuit, can be started by the attending 
ECMO physician if the child has a low urine output or kidney failure. 
data collection
We collected patient characteristics and data on diagnostics and interventions to 
improve lung function, including the frequency and timing of extubation, chest CT, 
bronchoscopy, high dose corticosteroid administration and surgical interventions. In 
addition we collected data on ECMO-related complications. The data were retrieved 
from medical records and from our patient data management system, i.e. prospectively 
collected physiological data, and data on medication use and support modalities. Ad-
ditionally, the institutional part of the Extracorporeal Life Support Organization registry 
(ELSO) (Ann Arbor, MI) registry was accessed to retrieve data on reported complications 
during the individual prolonged ECMO runs. 
statistical analysis
Data are presented as median values and interquartile range. When applicable a chi-
square test was used to test for significance.
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REsults
Between 1990 and August 2015, 618 patients had been treated with ECMO. The first 
ECMO run longer than 20 days (38 days) was in 2009. Between 2009 and 2015, 196 
patients had been treated with ECMO, of whom 12 (6%) for ≥ 21 days, i.e. three car-
diac patients and nine respiratory failure patients. The median age of all 196 patients 
was 2.2 (interquartile range (IQR)0.1-48.5) months versus 3.3 (0.3-13.4) years for the 
group receiving prolonged treatment. The median duration of ECMO support was 5.9 
(3.1-11.1) days and 25.2 (22.6-35.2) days, respectively. The median number of days of 
ventilation before prolonged ECMO initiation was 5.5 (IQR 1.8-8.0). The survivors had 
been ventilated for a median of 45 (IQR 34.5 50.3) days after cessation of ECMO. Seven 
of the patients receiving prolonged treatment were boys (58%). All 12 were sedated 
and received pressure controlled ventilation or pressure support. Eight were supported 
using any form of VV-ECMO (7 respiratory, 1 cardiac). Four patients (Nos 1, 2, 9, 10) were 
supported on venoarterial (VA)-ECMO. Two of the three cardiac patients and three of the 
nine respiratory patients were initially supported with VA-ECMO mode (see table 1). A 
switch from VV-ECMO to VA-ECMO was needed in two patients with cardiac failure.
Two patients were paralyzed for more than 48 hours to reduce respiratory drive and 
to improve oxygenation. Attempts to extubate and mobilize were successful in two 
patients only. Further demographics are presented in Table 1.
survival 
Overall survival to decannulation and discharge from the ICU was 33% (4/12). None of 
the three cardiac patients survived; they were taken off ECMO because continuation of 
treatment was considered futile. All three patients had contra-indications for cardiac 
transplantation unrelated to any ECMO complications. Four out of the nine patients 
(44%) with respiratory failure survived to discharge home (Figure 1). 
Two respiratory failure patients (Nos 1 and 2) had died due to septic shock and mul-
tiple organ dysfunction. Treatment of one of them (No. 2) had been stopped on parental 
request. One other patient (No. 7) had died due to persistent inoperable pericardial 
tamponade. ECMO treatment was withdrawn in the case of two other patients whose 
lung function was not expected to recover at that time. These two patients had not been 
perceived as candidates for lung transplantation and died. Interestingly, the survivors 
represented the most recent cases. Figure 2 shows the increase in survival over time. 
All five patients receiving VA-ECMO as initial mode died and one (No. 7) of the two 
patients (Nos 3 and 7) who had been switched from VV-double lumen to venoarterial-
venous ECMO to treat hemodynamic instability died. 
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EcMO related complications
A median of 7 complications during the ECMO run had been reported for the survivors 
versus a median of 4.5 for the non-survivors. Table 2 shows the type and number of 
complications reported. There was no significant difference in the complications rate 
between survivors and non-survivors (table 3). ECMO system switches were done at a 
median of 13, 17, 22 and 32 days in 11, 5, 4, 2 patients, respectively. 
Airway-related problems
During ECMO treatment, flexible or rigid bronchoscopy (N=35) was performed for diag-
nostic purposes in the nine respiratory failure patients and one cardiac patient (table 2). 
Indications for bronchoscopy were a sudden reduction of tidal volume or a persistent 
white out of the lungs. Median day for first bronchoscopy was after 6 (IQR 4.3-18) days on 
196 
ECMO
12
Prolonged 
ECMO
9
Respiratory
3
Cardiac
4
Survived
5
Died
3
Died
figure 1: The Consort diagram showing the flow of patients
table 3: Types and numbers of complications.
complication Nonsurvivors (n=8) Survivors (n=4) Combined (n=12)
Pulmonary 1 6 7
Mechanical 17 12 29
Hemorrhagic 3 6 9
Cardiovascular 10 3 13
Infectious 2 4 6
Renal 5 3 8
Metabolic 1 0 1
Total 39 34 73
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ECMO. Three out of the 10 patients had severe bronchial obstruction. One patient (No. 
7) had severe thick mucoid secretions and two patients had extensive trachea-bronchial 
obstruction with clots either due to bleeding following tracheotomy (patient No. 6) or 
lesions following duodenal feeding tube placement (patient No. 8).
One patient (No. 11) suff ered from bronchoscopy-related bleeding, which had been 
treated with a topical vasoconstrictor. All other bronchoscopies were not associated 
with signifi cant bleeding or other complications. The anticoagulation management 
complied with the standard departmental ECMO protocol and was not adjusted in 
preparation for bronchoscopy.
diagnostic procedures
A total of nine chest CTs were made during prolonged ECMO, i.e. in 7 patients (6 with 
respiratory failure). In fi ve patients a chest CT was also made prior to ECMO initiation 
(table 2). No major incidents were reported during transfer to the CT room and back. 
Timing of CT scans during ECMO varied widely with a median of 19 (IQR 9-20) days after 
initiation. The primary reason for a CT-scan was evaluation of reversibility of pulmonary 
damage. The details of utility and consequences of chest CT-scans are shown in table 2. 
In six respiratory patients, VV-ECMO provided only marginal suffi  cient oxygenation due 
to limitations of ECMO fl ow. These patients received a β blocker to reduce cardiac output 
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figure 2: Cumulative survival in patients on prolonged ECMO.
The shaded bars represent the cumulative number of patients surviving ECMO (≥21 days). The open bars 
represent the non-survivors. The dotted line shows the cumulative survival.
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and in all patients oxygenation improved sufficiently so that additional interventions 
were not necessary.
surgical procedures
Patient No. 2 underwent left thoracotomies on days 5 and 11 of ECMO for persistent 
blood loss and clots after placement of a chest drain for pneumothorax.
One patient (No. 8) underwent a Video-assisted thoracic surgery procedure, a phased 
bilateral thoracotomy for pleural empyema removal and for the resection of restrictive 
sub pleural thickening, and removal of organizing pleural exudates. All three operations 
were performed without any complications. 
discussiOn
We show that prolonged ECMO in 12 pediatric patients is feasible and was associated 
with an overall survival of 33% and a 44% survival in patients with primary respiratory 
disease. Cessation of therapy was the major cause of death. 
A survey of the ELSO registry learned that none of the neonates with acute respiratory 
failure on ECMO support for >43 days survived [1]. 
In a review of respiratory disease patients in the ELSO registry, the overall survival of 
these patients receiving prolonged ECMO was 38%. In this review, the highest survival 
(41%) was found in the patient group one month to one year of age [6]. Both our and 
previously published data indicate that prolonged ECMO treatment for respiratory fail-
ure patients is associated with acceptable survival. Still little is known neither about the 
time to recovery for specific diagnoses nor the moment to decide that further treatment 
is futile. Although useful and important for benchmarking, large data bases such as the 
ELSO registry unfortunately lack sufficient details to develop treatment guidelines.
A single center study on 22 pediatric patients supported with VA-ECMO for 28 days or 
more reported that ten (45%) patients were successfully decannulated. In 15 out of all 22 
patients the primary indication for ECMO was cardiac failure, either post-operative low 
cardiac output syndrome (n=8) or cardiomyopathy/myocarditis (n=7) [5]. For six of them 
ECMO served as a bridge to transplantation and for one as a bridge to recovery. 
In the above-mentioned study only four patients (19%) survived to discharge. It is 
a disturbing thought that none of the patients with respiratory failure survived. The 
authors suggest that ”prolonged ECMO while waiting for healing of potentially recover-
able lesions may lead to life-threatening complications and may even increase the risk 
of death” [5].
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Management during prolonged EcMO
Attempts to extubate and mobilize patients were successful in only two patients. This 
issue is often raised at ECMO congresses, but the pediatric literature on this subject is 
still scarce [7, 8]. Deciding on extubation or allowing for spontaneous breathing during 
prolonged ECMO can be difficult if the patient shows rapid breathing and apparent 
dyspnea despite adequate gas exchange. We speculate that the Hering-Breuer reflex 
could play an important role in the disturbed breathing and success of extubation. Un-
successful attempts at extubation could be due to near total collapsed lungs either as a 
result of infections or interstitial lung disease [9, 10]. Tracheostomy has been suggested 
to reduce duration of sedation on ECMO, but little is known about indications and the 
optimal timing of tracheostomy in pediatric ECMO patients [11, 12].
testing the recruitability
Little data is available on the time to recovery in prolonged ECMO. To test the recruit-
ability of the lungs after the first signs of improvement on plain chest films we instilled 
surfactant by bronchoscopy or perfluorocarbon via the tracheal instillation of in com-
bination with recruitment maneuvers on the ventilator to open up the lung. The use 
of surfactant therapy during ECMO was recently described to be safe and to improve 
the respiratory system compliance [19]. Our standard ventilator resting settings during 
ECMO therapy are: peak 20 cm H2O and PEEP 10 cm H2O. After successful recruitment 
of the lungs PEEP was increased on the guidance of the attending intensivist. We do not 
know if this strategy will reduce days on ECMO and further studies on this procedure are 
warranted.
Deterioration of oxygenation due to increased cardiac output can be treated with 
beta-blockers [13, 14]. We used beta-blockers to prevent critical hypoxemia during 
prolonged VV-ECMO. Our policy is to start with esmolol to test the patient’s response. To 
achieve prolonged β blockade we then switch to enterally administered propranolol to 
avoid propylene glycol related toxicity [15]. We try this strategy first before embarking 
on more invasive, potentially higher risk procedures like multiple cannulations or VA-
ECMO. 
diagnostic and therapeutic interventions
Bronchoscopy
Diagnostic tests to determine the likelihood of native lung recovery are not yet available 
[16]. To confirm the diagnosis or to diagnose concurrent disease in our study population 
we made use of flexible and rigid bronchoscopies. A low threshold for bronchoscopy 
helped to diagnose the buildup of clots, which had gone unnoticed after tracheotomy 
in one patient and continuing nasopharyngeal bleeding after feeding tube placement 
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in another patient. Due to the absence of tidal volume in severe respiratory failure the 
ventilator volumes were not changed and clots could accumulate over time. Multiple 
prolonged bronchoscopy sessions, in combination with endotracheal administration 
of alteplase to induce thrombolysis of the clots, were necessary to clear the airways. 
With only one bleeding due to bronchoscopy the rate of complications was low and 
comparable to a case series on flexible bronchoscopy on ECMO [17].
CT scanning
In case of complete opacity of the plain film chest exam in patients with severe respira-
tory failure, chest CT can help to identify complications or underlying pathology. In a 
separate study, a chest CT was performed in 4.2% of the ECMO patients with respiratory 
disease, at a median 18 days after initiation of ECMO [18]. 
In our study, chest CTs helped in the decision to start surgical interventions (video 
assisted thoracic surgery or thoracotomy) or guided the application of regional surfac-
tant instillation to assess the recruitability of the collapsed lung. Some scans had to be 
delayed due to instability of the patient, especially when ECMO flow was at maximal 
capacity due to the size of the cannulas and oxygenation was only marginal. If contrast 
CT scanning was performed, the ECMO flow was temporally minimized and contrast 
dose was optimized for adequate dose [18]. 
This is a retrospective case series covering a 7-year period during which several 
changes in ECMO management had been implemented that make it difficult to general-
ize the results. For example, we switched from roller pumps with silicone membranes to 
centrifugal pumps with PMP membranes. In respiratory failure patients we now prefer-
ably start with VV-ECMO and try to minimize the amount of additional cannulas. Still, 
this case series describes several steps in a single high volume pediatric ECMO center 
that might influence outcome in these patients. 
cOnclusiOns
Although guidelines on prolonged ECMO treatment are lacking and no clear-cut points 
of futility have been published, combinations of interventions and to the application of 
prolonged ECMO may improve outcomes of these patients over time. This may espe-
cially be true for respiratory patients, for whom we showed a 44% survival to discharge. 
No single item will dramatically improve outcome, but sharing of experiences and 
centralization of prolonged ECMO cases will potentially improve quality.
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AbstRAct
background 
Open lung biopsy can help differentiate between reversible and irreversible lung dis-
ease and may guide therapy. To assess the risk-benefit ratio of this procedure in pediatric 
extracorporeal membrane oxygenation (ECMO) patients we reviewed all open lung 
biopsies performed in the Netherlands in the period 1990-2014.
Results 
In nineteen neonatal and six pediatric patients (0-15 years), twenty-five open lung bi-
opsies were performed during the study period. In 13 patients (52%) a classifying diag-
nosis of underlying lung disease could be made. In another nine patients (36%) specific 
pathological abnormalities were described. In three patients (12%) only non-specific 
abnormalities were described. The histological results led to withdrawal of ECMO treat-
ment in 6 neonates with alveolar capillary dysplasia/misalignment of pulmonary veins 
(24%) and in another 6 patients corticosteroids were started (24%) All patients survived 
the biopsy procedure. Hemorrhagic complications were rare.
conclusion
An open lung biopsy during an ECMO run in neonates and children is a safe procedure 
with a minimum risk for blood loss and biopsy-related death. It can be very useful in 
diagnosing the underlying pathology and can guide cessation of ECMO treatment and 
thereby avoid continuation of futile treatment, especially in neonatal patients.
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bAcKgROund
In cases of severe respiratory failure in neonates and children, clinicians may be facing 
uncertainty about the underlying diagnosis, different forms of interstitial lung disease 
and thoracic X-rays not explaining underlying disease. An open lung biopsy procedure 
is potentially helpful to determine the cause of respiratory failure [1]. When on clinical 
grounds a diagnosis incompatible with life is expected, this procedure ideally should 
be performed before ECMO is initiated. Still, these patients’ clinical condition seldom 
allows postponing the initiation of ECMO. Histological findings following an open lung 
biopsy may help clarify the underlying disease and deciding between continuation and 
withdrawal of ECMO or help in changing other aspects of the treatment. This important 
role in decision-making justifies performing the procedure during ECMO despite its 
potential drawbacks, such as bleeding and infection [2-4]. 
Surgical interventions during ECMO, such as repair of congenital diaphragmatic 
hernia, laparotomy and thoracotomy are possible without a high incidence of major 
complications [5, 6]. A few reports have already shown the usefulness and safety of an 
open lung biopsy in neonatal and pediatric ECMO patients, although study populations 
were small, ranging from 1-9 patients [3, 5, 7, 8]. Many questions pertaining to indica-
tions, timing and implications of biopsies remain. We reviewed data of all patients who 
underwent an open lung biopsy during ECMO in one of the two pediatric ECMO centers 
in a nationwide study in the Netherlands. The aim of the study was to describe the re-
sults of the biopsies and to evaluate the effect on the patient’s treatment. Furthermore 
to describe complications (i.e. safety) of this surgical procedure performed on ECMO.
MEtHOds
The Erasmus MC institutional medical ethics review board approved the study, and 
waived the need for informed consent as only data from our patient data management 
system, i.e. prospectively collected physiological data and information on medication 
and support modalities, were used. Data of pediatric patients requiring ECMO in the 
period 1990-2014 were reviewed retrospectively. These patients have been treated ei-
ther in the Erasmus MC-Sophia Children’s Hospital Rotterdam (EMC) or the Radboudumc 
Amalia Children’s Hospital Nijmegen (RAD). All patients <18 years undergoing an open 
lung biopsy during ECMO were included. Patients undergoing a biopsy before or after 
ECMO or post-mortem were excluded. Information was obtained about age at admis-
sion, gender, days of ECMO treatment when biopsy was taken, heparin administration, 
anticoagulation parameters, and blood loss in the first 24 hours after biopsy, histological 
findings and possible change in treatment. 
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We studied the effect of timing of the biopsy on treatment change by comparing data. 
Furthermore we studied the effect of heparin dosage, activated clotting time (ACT) and 
patient’s age on the amount of blood loss (Pearson correlation). P-values <0.05 were 
considered statistically significant.
coagulation management
Anticoagulation was adjusted according to the hospital protocols. All patients received 
unfractionated heparin as anticoagulation. One hour prior to a surgical intervention a 
loading dose (4 mg/kg) tranexamic acid was administered followed by a continuous in-
fusion of 1 mg.kg-1.h-1 during 24 hours postoperatively. Heparin infusion was adjusted to 
decrease actual ACT levels by 20 s. Platelet level was maintained greater than 100,000/
mm3; fibrinogen level was corrected when fibrinogen was < 1 g/l. These values were 
maintained for 24 hours and controlled directly postoperatively and at 6-8 hour intervals.
surgery
Open lung biopsy was performed at the hospital’s intensive care unit. Under general an-
esthesia, preferably a left lateral or ventral thoracotomy was performed. When a solitary 
right-sided lesion was present, the procedure was performed on the right side. A chest 
tube was placed at the discretion of the surgeon.
REsults
Between 1990 and 2014, 1008 pediatric patients were treated with ECMO (EMC n=602, 
RAD n=406). The majority of these patients were neonates (EMC n=440, RAD n=353). In 
total 25 patients (2.5%) underwent open lung biopsies during ECMO and were included 
in this study (EMC n=16, RAD n=9), of whom 11 were boys (44.0%) and 14 were girls 
(56%). None of these patients were diagnosed with congenital diaphragmatic hernia. 
Details of this group are shown in table 1. Nineteen of them were neonates (76%). Three 
patients had been born preterm (<37 weeks of gestational age); four with a low birth 
weight (<2500 grams). The lowest bodyweight at initiation of ECMO was 2200 grams. 
Other parameters of these preterm and low birth weight patients did not differ from 
those of the other patients who underwent lung biopsy. In all patients the indication for 
the biopsy was unexplained pulmonary hypertension and/or respiratory failure. 
biopsies and their relevance
A classifying diagnosis was provided by the biopsy in thirteen (52%) patients. Six 
patients were diagnosed with alveolar capillary dysplasia/misalignment of pulmonary 
veins (ACD/MPV), three with meconium aspiration syndrome (MAS), two with pulmo-
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nary interstitial glycogenosis (PIG), one with chronic pneumonitis of infancy (CPI) and 
one with miliary tuberculosis (table 1). 
Regarding the patients without a definite diagnosis, inflammation with or without 
fibrosis was reported for three of them and pulmonary hypertensive vascular changes 
for six - in two cases together with sepsis. Specific abnormalities were not reported for 
the remaining three patients.
table 1: Individual patient data.
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5 1 16 9 32.5 11.6  Non-specific+ no Survived -
6 1 14 11 42.5 6.3 ACD/MPV# Stopped* Died 3
7 2 13 8 20 5.3 ACD/MPV# Stopped* Died 5
8 2 9 8 40 no drain ACD/MPV# Stopped* Died 1
9 3 7 4 30 15.3 Undefined+ No Survived -
10 5 7 3 28.7 2.6 MAS# No Survived -
11 6 17 11 22.2 1.7 MAS# No Survived -
12 7 7 1 2.8 12.3 PH with sepsis No Died 6
13 7 9 8 52.5 4.4 ACD/MPV# Stopped* Died 1
14 9 15 6 20.6 14.5 MAS# No Died 37
15 10 15 3 18.5 1.5 PIG# Cortico-steroids* Died 86
16 10 11 10 32.5 4.6 PIG# Cortico-steroids* Died 1
17 13 8 1 37.5 0.5 CPI# Cortico-steroids* Survived -
18 21 13 2 51 1.9 Idiopathic PH No Died 14
19 21 11 6 63.6 34.1 Idiopathic PH No Died 9
20 190 15 6 40 120 PH with sepsis No Died 9
21 196 14 7 44.6 no drain Idiopathic PH No Died 19
22 480 18 8 40 0.6 Fibrosis and inflammation$ Cortico-steroids* Died 15
23 1207 24 11 15 47.3 Miliary tuberculosis# No Died 64
24 1839 17 9 30 13.7 Fibrosis and inflammation$ Cortico-steroids* Survived -
25 5649 38 13 15 3.4 Inflammatory pneumonia$ Cortico-steroids* Died 25
PH = pulmonary hypertension, MAS = meconium aspiration syndrome, ACD/MPV = alveolar capillary dysplasia 
with misalignment of pulmonary veins, PIG = pulmonary interstitial glycogenosis, CPI = chronic pneumonitis of 
infancy. * = Biopsy result with consequences for treatment, # = classifying diagnosis, $= Descriptive diagnosis 
with consequences for treatment, + = Descriptive diagnosis without consequences for treatment.
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A post mortem examination was performed in four patients. In one patient the biopsy 
during ECMO showed minor alveolar damage without clear evidence for ACD/MPV. 
ECMO was withdrawn because of lack of clinical improvement and the patient subse-
quently died. In this patient suspicion of ACD/MPV remained high and therefore post 
mortem examination was performed and showed ACD/MPV. In one patient the post 
mortem examination confirmed the diagnosis ACD/MPV, in one the diagnosis fibrosis 
and inflammation was reported as “end stage fibrosis”, and in one patient pulmonary 
interstitial glycogenosis in the biopsy was revised to pulmonary capillary hemangioma-
tosis post mortem.
In twelve patients (48.0%) the result of the biopsy had an effect on the therapy. In 
six of these patients (24.0%), all diagnosed with ACD/MPV, the results of the biopsy led 
to cessation of treatment and six other patients (24.0%) were given corticosteroids. In 
thirteen patients (52.0%) the treatment did not change.
Eight patients survived to discharge (32.0%) and 17 died (68%). Death was caused 
by the lethal disease ACD/MPV in six cases (35.3%). The other deaths could not be at-
tributed to a fatal prognosis. The pathology contributing to death in this group was 
pulmonary hypertension (PH) in five, PIG in two and MAS in one patient. Three patients 
(all non-neonates) died of pneumonia or tuberculosis. The reason to perform an open 
biopsy in the three patients with a clinical diagnosis of MAS was uncertainty whether 
other underlying pathology was also present.
timing of biopsy
The median length of the ECMO run was 13 (IQR 85 to 16) days. In the neonatal patients 
biopsy was performed at a median of 6 (IQR 3-8) days on ECMO and in the non-neonatal 
patients at a median of 8 (IQR 7 – 10) days. In all non-neonatal patients ECMO treatment 
was continued for at least a week after the biopsy. 
In total, fourteen patients (56.0%) were on ECMO for less than a week when the biopsy 
was performed. In three neonates suspected of ACD/MPV the procedure was performed 
within two days after initiation of ECMO. Four neonates were taken off ECMO within 
two days after the biopsy. Three of them were diagnosed with ACD/MPV; the other was 
respiratory stable enough to be weaned from ECMO and survived. 
Regarding the eleven patients (44.0%) in whom the biopsy was performed one week 
or later after initiation of ECMO, treatment was not changed in three, treatment was 
stopped in four (all diagnosed with ACD/MPV) and four were given corticosteroids. In 
the group of patients who were biopsied after a week of ECMO, the percentage of pa-
tients without a change of treatment was less compared to the early biopsy group (72% 
vs 28%), while the percentage of patients who were given corticosteroids was higher 
(14% vs. 36%) (table 2).
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safety of the procedure
The heparin dosage during the start of the lung biopsy varied from 2.8 to 63.6 IU/kg/h 
(mean 30.0); the ACT at time of biopsy varied from 154 to 247 seconds (mean 198). 
Median blood loss in the fi rst 24 hours was 5.2 ml/kg (range 0.6-244.8). In fi ve patients 
(20.0%) the blood loss was more than 15 ml/kg in the fi rst 24 hours. When no drain was 
placed (n=3), we assumed that the blood loss would have been minimal. 
There was no signifi cant correlation between the heparin dosage or ACT and the 
amount of blood loss. Patient age did not correlate signifi cantly with the total amount of 
blood loss or the blood loss per kilogram body weight (data not shown). Unfortunately 
in one patient biopsy was complicated by a sampling error showing thymus tissue, 
whereupon another open lung biopsy was performed the next day.
discussiOn
We found that an open lung biopsy had been performed in 25 of all 1008 ECMO patients 
(2.5%) in the two pediatric ECMO centers in the Netherlands. In 22 cases (88.0%) the 
biopsy contributed to understanding of the pulmonary pathology, i.e. either a classify-
ing diagnosis or specifi c pathological fi ndings. In almost half of the cases the biopsy 
table 2: Treatment policy after open lung biopsy performed either in the fi rst week of ECMO or later
Biopsy in fi rst week of ECMO (n=14) Biopsy after fi rst week of ECMO (n=11)
No change in treatment 10 (72%) 3 (28%)
Stop treatment 2 (14%) 4 (36%)
Give corticosteroids 2 (14%) 4 (36%)
25 biopsies
14 biopsies after  7 
days of ECMO
11 biopsies after >7 
days of ECMO
Treatment stopped
ACD/MPV n=2
Corticosteroids 
given
PIG n=1, CPI n=1
No change in 
treatment
others n=10
2/2 died 1/2 died
Treatment stopped
ACD/MPV n=4
Corticosteroids 
given
PIG n=1, pneumonia 
n=2, other n=1
No change in 
treatment
others n=3
4/4 died 2/4 died6/10 died 1/3 died
figure 1: Consort of lung biopsies
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result led to a change in therapy or cessation of ECMO. Biopsy within the first week 
resulted in a therapy change in four (28.6%) patients; a later biopsy resulted in a therapy 
change in eight (72.7%) patients. No significant complications of the procedure were 
reported. In the literature most reports deal with the issue of a solid pathology diagnosis 
to determine whether treatment should be continued or considered futile [5, 7]. 
As the majority of the biopsies were performed in neonates with therapy-resistant 
atypical PH, the subsequent requests to the pathologist involved primarily ACD/MPV. 
The longest reported survival in ACD/MPV is about 8 months with severe morbidity [9, 
10]. The definitive diagnosis of ACD/MPV in our population resulted in withdrawal of 
life support therapy in all patients diagnosed as such. In rare cases ACD/MPV can also 
present beyond the neonatal age [11]. If ACD/MPV is considered, an open lung biopsy 
should ideally be performed before ECMO is initiated, thereby preventing possibly futile 
ECMO therapy [5, 12]. In this regard, a clinical algorithm has been proposed for infants 
with atypical PH who are suspected of ACD/MPV, defined as a near term born infant 
with a normal Apgar score, severe respiratory/circulatory failure ≤48 hours or a positive 
family history and having associated anomalies [12]. If ECMO has been started already, 
biopsy is recommended when no clinical improvement is seen after 7-10 days. Some 
patients can still be taken of ECMO successfully but then a biopsy is recommended in 
case of cardiopulmonary deterioration [12].
Our neonatal ECMO patients were found not clinically stable enough to undergo an 
open lung biopsy before ECMO initiation. In this situation when ACD/MPV or another 
lethal congenital pulmonary abnormality was highly suspected, the procedure was 
performed within the first seven days of the ECMO-run.
 In eight of the twelve cases biopsied in the first seven days of ECMO, treatment had not 
been adjusted. In two of these patients life support was withdrawn after ACD/MPV was 
confirmed. One patient was diagnosed with CPI, for which corticosteroids were given 
and ECMO could be successfully stopped after eight days of ECMO. One patient with 
PIG was successfully decannulated before the results of the biopsy were known because 
respiratory support was hardly needed. However he died due to severe rebound PPHN 
shortly after decannulation. 
The biopsy results were often clinically helpful, although a definite classifying diag-
nosis could be made in only 13 of the 25 cases. This is in line with prior findings [2, 3]. In 
twelve of the cases (48%) the biopsy result lead to a goal directed change of treatment. 
Of the patients without a change of treatment 7 of 13 (54%) died. On the other hand, in 
six patients the biopsy led to the diagnosis ACD/MPV. Consequently ECMO was stopped 
and therefore prolongation of futile treatment was avoided.
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safety of the procedure 
Given our results, open lung biopsy during ECMO can be considered a safe procedure 
with no biopsy-related mortality and minimal morbidity. 
Several studies reported about biopsies during ECMO [3, 5, 12]. None reported severe 
complications including biopsy-related deaths. Biopsy-related hemorrhagic complica-
tions occurred in respectively 2/5 and 1/9 patients [5, 12]. Jaklitsch et al. specifically 
reported about four patients who developed sepsis syndrome post-operatively, all of 
whom had an underlying infectious lung disease [3]. In our patient group we did not see 
any infectious complications.
cOnclusiOns
An open lung biopsy during an ECMO run can be very useful in diagnosing the underly-
ing reason for PH, especially in neonatal patients. In case of a fatal prognosis, ECMO can 
be stopped to avoid futile treatment. The histological diagnosis can lead to the pre-
scription of corticosteroids, whereby treatment can be started earlier. In older patients, 
the chance of a fatal prognosis is minimal, but biopsy can guide therapy or diagnostic 
workup. Biopsy is recommended after seven days of ECMO, except when ACD/MPV 
or another lethal congenital pulmonary abnormality is highly suspected. In that case 
biopsy is recommended within the first week of ECMO. Performing an open lung biopsy 
during an ECMO run is a safe procedure with a minimum risk for blood loss and biopsy-
related death.
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AbstRAct
background:
Congenital diaphragmatic hernia (CDH) can be repaired on or off ECMO (extracorporeal 
membrane oxygenation). In many centers, operating off ECMO is advocated to prevent 
bleeding complications. We aimed to compare surgery-related bleeding complications 
between repair on or off ECMO.
Methods
All patients with CDH repair and ECMO treatment between January 1st 1995 and May 
31st 2008 were retrospectively reviewed. Tranexamic acid was routinely given to all pa-
tients repaired on ECMO for 24 hours peri-operatively after 2003. Extra fluid expansion, 
transfusion or relaparotomy due to post-operative bleeding were scored as surgery-
related bleeding complications and were related to the Extracorporeal Life Support 
Organization (ELSO) registry. We used Chi square test and t-test for statistics.
Results
Demographic data and surgery-related bleeding complications in the on ECMO group 
were not significantly different compared to the off ECMO group (p= 0.331) in our insti-
tute. In contrast, more surgery-related bleeding complications were reported by ELSO in 
their on ECMO group (p<0.0001).
conclusion
In contrast to data from the ELSO registry, we did not observe significantly more surgery-
related bleeding complications after CDH repair on ECMO. Using a specific peri-operative 
hemostatic treatment enabled us to perform CDH repair on ECMO with a low frequency 
of bleeding complications, thereby taking advantage of having the physiologic benefits 
of ECMO available peri-operatively.
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intROductiOn
Congenital Diaphragmatic Hernia (CDH) is a developmental defect in the diaphragm 
resulting in herniation of the abdominal viscera into the thorax. The incidence of CDH 
is approximately 1 in 2200 live births. The primary determinants of mortality in CDH 
patients are the amount of associated pulmonary hypoplasia (PH) and persistent pul-
monary hypertension (PPH) (reviewed in Sluiter et al.) [1]. The treatment of CDH consists 
of preoperative stabilization directed towards optimal management of PH and PPH, fol-
lowed by surgical repair of the diaphragmatic defect either with a patch or primarily [2].
Treatment of CDH remains a challenge for both pediatric surgeons and pediatric in-
tensive care specialists. Survival of these children has improved substantially during the 
past decades. Better antenatal diagnosis and improvement of neonatal intensive care 
following the introduction of gentle ventilation strategies are responsible for this [3].
One of the treatment modalities for CDH in the neonatal intensive care is extracor-
poreal membrane oxygenation (ECMO). ECMO provides a temporary cardiopulmonary 
bypass system to overcome reversible lung failure. This respiratory failure can be attrib-
uted to the PPH and/or PH that are associated with CDH. [3,4,5]. Survival rates for CDH 
patients undergoing ECMO treatment currently range from 44-86% [6]. ECMO has been 
available in our institution since 1993. Indication for ECMO treatment of CDH babies in 
our institution is failure of maximal conventional therapy together with the fulfillment 
of strict ECMO criteria predicting an 80% mortality as published before by us [7]. Dif-
ferent criteria exist between institutions with respect to the moment to initiate ECMO 
treatment [8,9]. 
In 2002, the CDH study group reported that 54 % of CDH infants placed on ECMO 
underwent repair of the diaphragmatic defect while on ECMO [8]. Timing of CDH repair 
in patients requiring ECMO remains controversial and is dependent on local protocols 
[6]. One of the reasons to operate subsequent to ECMO treatment is the concern of 
surgery related bleeding complications. Hemorrhage in general is a major complication 
in neonates on ECMO [8]. 
The aim of our study was to determine the number of surgery-related bleeding com-
plications in patients undergoing CDH repair on ECMO and to compare this number 
to those undergoing CDH repair off ECMO in our institution. We were able to perform 
this study because we started CDH repair after ECMO treatment, but switched to CDH 
repair while on ECMO after the institution of a new protocol to prevent bleeding com-
plications in 2003. We observed no significant differences in surgery-related bleeding 
complications between the on ECMO and off ECMO CDH repair group in our institution. 
Subsequently we related these results to the results of the Extracorporeal Life Support 
Organization registry (ELSO registry) and found that there were a significantly higher 
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number of surgery-related bleeding complications in the on ECMO CDH repair group in 
the ELSO registry. 
MAtERiAls And MEtHOds
Eligibility criteria
We retrospectively reviewed all charts of patients undergoing open abdominal CDH 
repair while on ECMO or after ECMO treatment in our institution between January 1st 
1995 and May 31st 2008.
surgery
During this study all patients were operated using an open CDH repair and all surgeons 
used a subcostal incision. Diaphragmatic defects were closed using either non-ab-
sorbable interrupted sutures or a Goretex® patch, upon the discretion of the attending 
surgeon. All patients undergoing repair on ECMO were operated in the ICU, whereas 
patients repaired off ECMO were operated in the operating room.
EcMO protocol in our institute
During the study period the same circuit, type of tubing and roller pump was used in all 
patients. Hemolysis was evaluated on a daily basis as discussed below in more detail. All 
patients in our institute are treated with tranexamic acid (Cyklokapron, Pfizer, The Neth-
erlands) peri-operatively until 24 hours postoperatively since 2003. In detail, a loading 
dose (4 mg/kg) is given 1 hour prior to surgery and continued for 24 hours postoperative 
as a drip at 1 mg/kg/hr. Platelets are kept higher than 100.000, fibrinogen levels above 1 
and ACT (activated clotting times) levels are decreased by 20% (normal 200-230 sec) for 
24 hours. Clotting analysis following surgery includes platelets, hemoglobin, fibrinogen, 
APTT (activated partial tromboplastin time) and factor V Leiden and levels are corrected 
if necessary. In case fibrinogen levels are lower than 1, fibrinogen (Haemocomplettan, 
CSL Behring, The Netherlands) is given in doses of 0.5-1 g as a drip for 30 minutes.
Variables
The following demographic data were collected for all patients treated in our institution: 
gender, gestational age in weeks, birth weight in kilograms, APGAR score at 1 minute, 
side of the diaphragmatic defect (left/right), type of CDH repair (primary or patch), 
ECMO mode (venous-arterial or veno-venous) and age at repair in days. 
The group of patients undergoing CDH repair on ECMO was compared to the group 
undergoing repair following ECMO. The primary outcome measure was the occurrence 
of surgery-related bleeding complications. Surgical site bleeding was scored positive if 
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extra fluid expansion, transfusion or relaparotomy due to postoperative bleeding were 
reported in the charts and data derived from our data management system (PDMS). This 
is a computer based prospective collection of all physiological parameters including 
amount of fluid, ventilation settings and eventually ECMO settings. Due to the change 
in timing of CDH repair over time in our institution, analysis was performed in 3 sub-
groups, indicative of three different time periods, to try to eliminate other confounding 
treatment factors that might influence the primary outcome. The entire population was 
thus subdivided into three groups to indicate the number of patients operated on or off 
ECMO. During the study period the entry criteria for ECMO in CDH did not change.
Secondary outcome measures were length of stay in ICU in days, duration of 
mechanical ventilation in days, ECMO runtime in days, and duration of CDH repair in 
minutes. 
comparison to the ElsO registry
Data derived from the ELSO registry were used to correlate our data to a large interna-
tional patient cohort. All patients in this registry from 1984 until 2008 that had ECMO 
treatment together with CDH repair were included and surgery-related bleeding com-
plications were compared to those in our institution. Surgical site bleeding was scored 
positive according to the supplied data from the ELSO registry database.
statistics
Three investigators collected data from patient charts and existing databases in an 
Excel-spreadsheet. Subsequently, all data were exported to SPSS for statistical analysis. 
Normally distributed continuous variables were compared using a Student’s t-test, while 
non-normally distributed variables were analyzed using the Mann-Whitney-U non-
parametric test. To compare categorical variables a Chi square test and Fisher’s exact 
test were performed. A p-value < 0.05 was considered statistically significant.
The Institutional Review Board of ErasmusMC-Sophia, Rotterdam, The Netherlands, 
approved the study.
REsults
Results ErasmusMc-sophia
Between January 1995 and May 2008, 195 CDH patients were admitted to our institu-
tion. Of this group, 129 (66,2%) underwent repair of the diaphragmatic defect. Initially, 
survival was 50% and has increased over the years to 85% during the last three years 
[10]. Of all the patients undergoing CDH repair, 51 (39.5%) required ECMO treatment. 
Three patients underwent CDH repair and required ECMO treatment afterwards; these 
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patients were excluded from this study. All patients underwent venous-arterial ECMO. 
Demographic data are summarized in Table 1. Sex, mean gestational age at birth, mean 
birth weight, side of the hernia and median APGAR score after 1 minute were not sig-
nificantly different. 
In our institution, surgery-related bleeding complications following CDH repair on 
ECMO (4 out of 32 patients (12.5%)) were higher, but not significantly different from 
surgery-related bleeding complications following repair off ECMO (1 out of 16 patients 
(6.25%)) (p=0.652, see Table 2). Changes in management over time could result in po-
tential bias and therefore a subgroup analysis was performed for three different time 
periods: 1995-1999, 2000-2004 and 2005-2008. 
Since 2005, CDH repair in patients requiring ECMO was only performed on ECMO (Fig-
ure 1). In contrast, during the first study period when ECMO was instituted (1995-1999), 
half of the patients had CDH repair off ECMO.
Results surgical site bleeding ElsO registry
The group of patients undergoing CDH repair on ECMO was bigger than that off ECMO 
in the ELSO registry during all periods. The ELSO registry registered surgical site bleed-
ing in their database for all patients that had repair of their CDH. Table 2.2 demonstrates 
that 616 out of 2230 patients (27.6%) undergoing CDH repair on ECMO were reported 
to have surgical site bleeding, compared to 34 out of 1109 patients (3.07%) undergoing 
CDH repair off ECMO in the ELSO registry between 1984 and 2008 (p<0.0001).
secondary outcome measures ErasmusMc-sophia
Surgical data
Surgical data are summarized in Table 3. The number of patients undergoing CDH repair 
using a patch was 42 (87.5%) and was not significantly different in both groups. In the 
repair on ECMO group, 6.6 % (2 out of 30) had a primary repair compared to 12.5% (2 
out of 16) in the repair off ECMO group (p= 0.602). For two patients it was not known 
table 1: Demographic data ErasmusMC-Sophia
Repair on ECMO Repair off ECMO p-value
n 32 16
Birth weight in kilograms (mean±SD ) 3,04 ( ±0,65) 3,21 ( ±0,43) 0,714a
Gestational age in weeks (mean ±SD) 38,63 (± 1,76) 39,0 ( ±1,15) 0,121a
Gender (M/F) (number) 21/11 8/8 0,297b
Side Hernia (left/right) 15/1 29/3 0,348 b
Median APGAR score at 1 minute (IQR) 5 (2) 7(4) 0,124c
a: T-test, b: Chi square, c: Mann- Whitney-U non parametric test 
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whether repair was done by using a patch or by primary closure of the diaphragmatic 
defect. Operating time between the two groups was also not different. Median operat-
ing time was 2.0 hours in the repair on ECMO group compared to 1.9 hours in the repair 
off ECMO group (p=0.188). Patients undergoing CDH repair on ECMO were significantly 
younger compared to those repaired off ECMO. Median age at repair in the repair on 
ECMO group was 5.0 days (IQR 5) compared to 20.5 days (IQR 23) in the repair off ECMO 
group (p< 0.0001) 
ECMO / ventilation data
There was no difference in days of admission to the ICU and duration of mechanical 
ventilation between the two groups (Table 4). Patients undergoing repair on ECMO had 
a median ICU stay of 37 days (IQR 59) compared to 57 days (IQR 62) in the group that had 
repair after ECMO (p=0.404). The median number of days requiring mechanical ventila-
tion was 21 days (IQR 28) in patients undergoing repair on ECMO compared to 28 days 
(IQR 34) in those undergoing repair off ECMO. However, ECMO runtime was significantly 
less in the repair off ECMO group. Median ECMO runtime in the group that had repair 
on ECMO was 9.77 days (IQR 8) compared to 7.11 days (IQR 5) in the off ECMO group 
(p=0.041).
table 2: Bleeding complications ErasmusMC-Sophia versus ELSO registry
2.1: ErasmusMC-Sophia 
Surgery related bleeding complications ErasmusMC-Sophia Total
Yes No
On ECMO 4 28 32
Off ECMO 1 15 16
2.2 ELSO registry
Surgery related bleeding complications ELSO registry Total
Yes No
On ECMO 616 1614 2230
Off ECMO 34 1075 1109
table 3: Surgical data
Repair on ECMO Repair off ECMO P -value
Primary/patch closure* 2/28 2/14 0,602a
Median time of repair in hours (IQR) 2,00 (0,65) 1,9 (1,07) 0,188b
Median age at repair in days (IQR) 5,0 (5,0) 20,5 (22,50) 0,000b
*: missing values: for two patients information on whether a patch was used for the repair could not be 
retrieved, a: chi square, b: Mann-Whitney U non-parametric test
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table 4: ECMO/ventilation data
Repair on ECMO Repair off ECMO p-value
Median ECMO runtime in days (IQR) 9,77 (8) 7,11 (5) 0,041a
Median time on mechanical ventilator in 
days (IQR) 
21 (28) 27,67 (33,63) 0,552a
Median time on ICU in days (IQR) 37 (59,23) 57 (62) 0,404a
figure 1: The number of patients operated on or off ECMO during three different time periods. After 2005 
all patients were operated on ECMO
figure 2: The number of patients operated on or off ECMO during four different time periods, as registered 
in the ELSO registry database
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discussiOn
To our knowledge this is the first study to demonstrate the feasibility of neonatal CDH 
repair on ECMO using a specific anticoagulant protocol. Although we found a higher 
bleeding complication rate in the group repaired on ECMO, this percentage was not 
statistically significant and lower than the number reported in the ELSO registry. This 
is despite the fact that the definition of surgery-related bleeding complications was 
less well defined in the ELSO registry as compared to our group. This corroborates 
with previous reports, which observed more surgery-related bleeding complications 
when repair was done on ECMO [11,12, 13]. In addition, we observed a trend towards a 
shorter length of stay in the ICU in the repair-on ECMO group as well as a trend towards 
a shorter duration of mechanical ventilation in the repair-on–ECMO-group compared to 
the repair off ECMO group. However, changes in management over time have certainly 
contributed [10, 14]. 
Results from the ELSO registry indicate that nowadays more CDH patients treated with 
ECMO are operated on ECMO than off ECMO internationally. Van der Staak et al. reported 
already in 1997 that repair on ECMO may increase the risk of bleeding complications 
and that these complications can be a hallmark of poor outcome. The administration 
of Tranexamic acid (TEA) is effective in reducing hemorrhagic complications, but might 
increase the risk of thrombotic complications [11]. However, after introducing our 
specific peri-operative bleeding prevention protocol, we did not observe more clotting 
problems in the ECMO circuit and/or oxygenator. Since the institution of a protocol to 
prevent complications from bleeding in 2003 we used TEA during all our repairs on 
ECMO, and data from the ELSO registry database did not indicate the use of TEA. In 
addition to the importance of antifibrinolytic agents in a specific peri-operative bleed-
ing prevention protocol like ours, the importance of a delicate and meticulous surgical 
technique should not be underestimated.
Vasques and Cheu report that surgery-related site bleeding complications as well as 
overall hemorrhagic complications were significantly higher in patients undergoing 
CDH repair on ECMO. These data included also data from the ELSO registry and were 
derived from 88 ECMO centers during the period of January 1989 until December 1991. 
In addition, they report that patients repaired on ECMO are more prone to have acidosis 
and hypoxia compared to those that had repair off ECMO [12]. However, both acidosis 
and hypoxia were associated with hemorrhage and the authors did not report signifi-
cant differences in these parameters between both groups. Another retrospective study 
performed by Sigalet et al. in 1995 demonstrated that in a group of 60 CDH patients, the 
9 patients that had repair on ECMO required a significantly higher transfusion volume 
and they advice against repair of CDH on ECMO [13]. 
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One of the limitations of our study is the small number of patients (N=48). The low 
observed frequencies of bleeding complications in both groups of our series makes it 
difficult to draw firm conclusions about significant differences. However, a more relevant 
finding from our study is that we observed only 12.5% bleeding complications in the 
group repaired on ECMO, despite the fact that we used a broader definition of bleeding 
complications than the ELSO registry.
Another limitation is the retrospective character of our study. At ErasmusMC-Sophia 
surgery-related bleeding complications were scored positive if extra fluid expansion, 
transfusion or relaparotomy due to post-operative bleeding were specifically reported 
in our prospective computerized patient data management system (PDMS). Although 
till 2003 information was retrieved from the patient charts, our data were very reliable 
from that time point onwards as patients were operated in the ICU and therefore all data 
including extra fluids are integrated prospectively in PDMS. 
The data from the ELSO registry was lacking any demographic data and potentially 
very different among centers. Moreover, the ECMO and anti-coagulant protocol used in 
these patients was not reported. Differences in anti-coagulant protocols could therefore 
result in substantial bias in this analysis, because this was found to be a major determi-
nant of hemorrhagic complications in our series at ErasmusMC-Sophia. Surgery-related 
site bleeding complications reported in the ELSO registry were not well defined, and 
data in this registry originate from different hospitals, so correcting for these data was 
not possible. Because we used a broader definition of surgery-related site bleeding 
complications, our bleeding complications are probably overestimated as compared to 
the norm of the ELSO registry. At a glance, our bleeding complications in the on-ECMO 
group were lower than reported in the ELSO registry: 12.5% versus 27.6%. We choose 
not to compare our numbers statistically to the numbers of the ELSO registry due to a 
lack of a clear definition of surgery-related bleeding complications in the latter group.
Days on ICU together with duration of mechanical ventilation were reviewed as 
secondary outcome measures in our series. We observed a trend towards a shorter ICU 
stay and a shorter period of mechanical ventilation in the patients repaired while on 
ECMO. This trend was not statistically significant and is probably more related to mod-
ernized ICU management than to the actual repair on ECMO. Due to the small sample 
size, matching of patients was not possible. These parameters were not measured in the 
population from the ELSO registry.
Although this is a retrospective study which has its limitations as stated above, conclu-
sion remains that in a single center in a 13 years experience period no major surgery 
related bleeding complications are seen in our institution while performing repair of 
CDH on ECMO. In addition, we see a trend towards shorter ICU stay and a shorter period 
of requiring mechanical ventilation. In the past 5 years all patients requiring ECMO were 
operated on ECMO for their CDH in our institute, without major bleeding complications. 
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In conclusion, CDH repair on ECMO is feasible and using a specific anticoagulation pro-
tocol with tranexamic acid resulted in a low complication rate. A large prospective study 
should be performed to evaluate whether there are indeed differences in surgery-related 
bleeding complications and which coagulant protocol should be used to perform repair 
on ECMO as safely as possible.
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AbstRAct
ECMO support is an established lifesaving therapy for potentially reversible respiratory 
and/or cardiac failure. Improvement of outcome depends on effective treatment of the 
primary diagnosis and complications. Adequate drug therapy is important in reach-
ing these goals. Pharmacokinetic and pharmacodynamic data in neonates and older 
children on ECMO are sparse. Most studies show altered volume of distribution and 
clearance for the drugs studied. This article gives an overview of the available PK and PD 
studies in neonates and children on ECMO, suggests possible mechanisms of altered PK 
and PD and identifies areas of interest for further research.
Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO)
10
143
intROductiOn
Pharmacological data in the pediatric population is sparse, especially within the pediatric ICU 
[1]. Dosing of frequently used drugs in the intensive care unit such as sedatives, analgesics, 
antibiotics and inotropes are partly based on non ICU pediatric or adult patients. A special 
category of patients are those receiving prolonged cardiopulmonary support where pul-
monary and/or cardiac functions are mechanically supported using extracorporeal circuits.
Extracorporeal life support or extra corporeal membrane oxygenation (ECMO) is a 
technique for providing life support in severe but potentially reversible cardio-respira-
tory failure in patients with an expected mortality greater than 80% [2]. 
First pioneered in cardiopulmonary bypass during cardiac surgery, extracorporeal life 
support has been used as prolonged cardiopulmonary support in neonates since 1976 
[3] with a proven survival benefit in neonates and adults [4, 5]. New diseases, such as 
the recent H1N1 influenza pandemic, results in an increased need for ECMO support in 
young adults as well as children with severe pulmonary failure [6].
ECMO provides extracorporeal gas exchange and circulatory support by pumping 
blood from the patient through an artificial circuit comprising of tubing, a pump, an 
oxygenator and a heater. The oxygenator is used to oxygenate the blood and extract 
carbon dioxide. Blood is drawn from a venous access site, preferably a central catheter 
positioned in the right atrium, and returned either into the right atrium via a double 
lumen catheter (venovenous ECMO) for respiratory support, or via the carotid artery 
(venoarterial ECMO) for cardiopulmonary support. Alternatively venous or arterial ac-
cess can be achieved via the femoral vein or artery.
ECMO support is used in a variety of diagnoses. Neonatal indications include congenital 
diaphragmatic hernia, meconium aspiration syndrome, persistent pulmonary hyperten-
sion of the newborn, congenital heart defects and sepsis. Pediatric and adult diagnoses 
include cardiomyopathy, cardiomyositis, sepsis, viral and bacterial pneumonia and acute 
respiratory distress syndrome. ECMO support can also be used as a bridge to recovery or 
organ transplant. Although it may be life-saving in critically ill patients, ECMO treatment 
is associated with several complications and co-morbidity. Up until July 2011 ECMO sup-
port has been initiated in a total of 46.509 patients worldwide, including 29.839 neonates, 
11.779 pediatric patients and 4891 adult patients, with an overall survival of 62 %. (Extra-
corporeal Life Support Organization (ELSO) registry report July 2011)
Overall survival after ECMO support is 62%, and mortality is primarily associated with 
the underlying disease and complications on ECMO such as bleeding, renal failure and 
infections. [7-11] Prolonged ECMO support (eg > 10 days) is associated with increased 
complications (such as nosocomial infections [12-21]) and poor outcome [11, 22].
Surgical and pharmacological treatment of the underlying disease and occurring com-
plications remains pivotal in the overall management of ECMO patients. Effectiveness and 
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complications of these treatment modalities are main determinants of outcome, apart from 
the ECMO procedure itself. ECMO indications may be expanded to include new diseases that 
necessitate specific medication. The H1N1 pandemic emphasized the lack of knowledge of 
pharmacokinetic (PK) and pharmacodynamic (PD) properties of antiviral drugs in these pa-
tients. It was unclear if therapeutic levels could be achieved and if so if any dose adjustment 
was necessary. The same holds true for a myriad of other regularly used drugs.
This article gives an overview of the available PK and PD studies in neonates and 
children on ECMO, suggests possible mechanisms of altered PK and PD and identifies 
areas of interest for further research.
PHARMAcOKinEtic studiEs in nEOnAtAl And PEdiAtRic EcMO
Patients on ECMO generally receive more than ten different drugs per day [23]. These pa-
tients are heparinized to prevent clotting of the ECMO circuit, most often receive seda-
tives and analgesics to alleviate pain and discomfort, diuretics to manage fluid overload 
and antibiotics or antiviral medication to treat infections [23]. PK and PD data of widely 
used drugs on ECMO are sparse; concentration versus time profiles and concentration 
effect relationships have not systematically been evaluated. 
There are several factors that may influence PK and PD. By connecting patients to an 
extracorporeal life support system the circulating volume of the patient is increased 
due to the added blood volume necessary to fill the circuit. There are different ECMO 
circuit components available with varying materials, priming volumes and total surface 
area. The total volume of an ECMO circuit may increase the total circulating volume of 
a patient by between 5 and 100%, which influences blood composition, coagulation, 
circulation and pharmacokinetics. ECMO may influence organ perfusion and organ 
function, with a potential influence on drug absorption, distribution, metabolism and 
elimination. Patients on ECMO are critically ill, which in itself changes PK and PD [24-26]. 
Whether ECMO patients differ from critically ill non ECMO patients in this regard remains 
to be determined. Profound changes in drug metabolizing enzymes, organ function 
and body composition take place in early infancy. This results in age and drug specific 
PK changes [27, 28]. These changes should be taken into account when evaluating PK 
changes during ECMO treatment. 
Since the use of extracorporeal life support there have been reports showing altered 
pharmacokinetics for a variety of drugs. Most available studies have demonstrated al-
tered pharmacokinetics with changes in volume of distribution as well as clearance [29-
43]. These studies have been summarized in a review article in 2003 [23]. The number of 
drugs studied has increased since then, shedding more light on possible mechanisms 
underlying PK changes in ECMO patients. Table 1 gives an overview of all the PK studies 
Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO)
10
145
in children on ECMO. Antibiotics, especially gentamicin and vancomycin, and sedatives 
and analgesics are the most studied drugs and will be discussed in the next section.
table 1: PK and PD studies in ECMO patients
Drugs No. studies Effect on PK-PD
amiodarone 1/n [117] Yes
bumetanide 11/n [43] Yes
caspofungin 2/a [74] No
caspofungin 1/a [73] Yes
cefotaxime 37n/i [65] Yes
esmolol 1/i [118] Yes
fentanyl 12/i [83] Yes
furosemide 7/n [105] No
gentamicin 29/n [32] Yes
gentamicin 18/i [33] Yes
gentamicin 17n/i [34] Yes
gentamicin 15/n [35] Yes
gentamicin 10/n [36] Yes
midazolam 20/n [29, 82] Yes
midazolam 20/n [57, 85] Yes
morphine 11n/i [31] No
morphine 7/n/i [47] Yes
morphine 14/n [30, 101] Yes
nesiritide [119] Yes
nicardipine [120, 121] No
oseltamivir 3/ch [71] No
phenobarbital 1/n [111] Yes
prostaglandin E1 [122] Yes
ranitidine 13/n [41] Yes
ribavirin 1/n [75] yes
sildenafil 23/n [110] Yes
theophyline 75n/ch [42] Yes
ticarcillin-clavulanic acid 2/ch [76] No
vancomycin 12/i [39] Yes
vancomycin 15/n [37] No
vancomycin 45n/i/ch [38] Yes
voriconazole 2/a [74] Yes
voriconazole 1/ch [72] Yes
voriconazole 1/a [83] Yes
No= number of patients included in study /n neonates, i=infants, ch=child >2years, a=adult
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in Vitro studies
Absorption of drugs to the material of the ECMO systems may contribute to the reported 
altered pharmacokinetics. Absorption rates have been tested for several drugs [29, 44-
47]. In vitro tests show significant absorption, especially of lipophilic drugs, to different 
ECMO circuits. Dagan et al. described significant drug loss in two blood primed closed 
looped systems [48]. Later studies confirmed significant drug loss in ECMO systems [45, 
49, 50].
Our own group demonstrated that absorption was correlated with lipophilicity, where 
higher Log P values resulted in increased drug loss [49].
Several authors tried to identify the major absorption point of drugs within the ECMO 
circuit. Midazolam and fentanyl seem to be mostly absorbed in the membrane, especially 
silicone based membranes [50, 51]. Silicone membranes have been shown to highly 
increase drug loss of these drugs compared to the newer microporous polypropylene 
membranes [49, 52]. Intriguingly Preston et al. found significant fentanyl absorption in 
the PVC tubing of an ECMO circuit, with only a 6% increase in drug loss after addition 
of a microporous polypropylene membrane [53]. There is also evidence that different 
coatings may influence absorption rates and therefore PK of certain drugs [54], although 
others report no clear effect on drug absorption [55]. 
There are ma.ked differences in drug absorption between the different in vitro studies. 
(Table 2) Some studies show a rapid decrease of drugs within minutes of injection [48, 
49, 56], whereas others find a slowed decrease over time [45, 50].
Study design differs significantly between studies from single component testing to 
full blood primed ECMO circuits. All set-ups have their advantages and disadvantages. 
Single component testing gives us information concerning saturation of binding sites 
and enables calculation of a theoretical maximum drug loss for an ECMO circuit, whereas 
blood primed circuits reflect daily clinical practice and enable comparison of new and 
used ECMO circuits. 
There are some conflicting data concerning saturation effects of binding sites in 
used ECMO systems. There is a clear saturation effect of binding sites of PVC tubing 
and silicone membranes when tested separately [50]. Furthermore Dagan et al. showed 
decreased drug loss in clinically used ECMO circuits compared to newly primed circuits. 
[48] This could however not be confirmed by others [44, 49]..
Translating in vitro results to clinical practice remains difficult. There is a large dis-
crepancy between drug absorption observed in in-vitro tests and the increased volume 
of distribution observed in the pharmacokinetic studies in neonates on ECMO [57]. 
Whether this is due to rapid distribution in body fat tissues or whether continuous infu-
sion rates are higher than absorption rates in ECMO circuits remains uncertain.
In conclusion, ECMO circuits affect drug availability by absorption to components of 
the ECMO circuit. Circuit material, size and priming fluid composition could affect the 
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increase in volume of distribution upon cannulation [50, 56, 58-60]. Silicone membranes 
have a higher capacity for drug absorption compared to the newer microporous mem-
branes. Given that most pk studies used silicone based membranes, extrapolation of 
these data to the newer circuits and oxygenators should be done with caution. The in vi-
tro results with rapid absorption within minutes after injection indicate that highly lipo-
philic drugs should not be administered via the ECMO circuit. The relationship between 
log P values and absorption will enable clinicians to predict the extent of absorption 
of different drugs, based on their chemical properties. Future studies need to address 
maximum absorption rates and need to try to incorporate in vitro data into pharmacoki-
netic models. The development of new ECMO circuits or ECMO circuit components may 
influence PK and drug absorption should be evaluated for these components.
Antimicrobial drugs
Infections remain a significant problem in neonates and children on ECMO, with 37% of 
patients with a proven infection prior to, or during ECMO support. Nosocomial blood 
stream infection (BSI) rates in ECMO patients range from 14% or 23 BSI/1000 ECMO 
table 2b: In vitro studies performed with ECMO circuits
Study No. 1a 1b 1c 1d 2a 2b 3a 3b 4a 4b 5
Drugs* * * * * * * * * * * *
Ampicillin         72% 15%          
Cefazolin         21%          
Cefotaxime 16% 2% 51% 22%              
Dopamine         30%          
Diazepam                     50%
Epinephrine         97%          
Fentanyl 100% 66% 100% 99% 87% 100%          
Fosphenytoin         18% 31% 43% 0%      
Gentamicin             10% 0%      
Heparin         33% 53%          
Lorazepam                 30% 50% 25%
Meropenem 17% 11% 42% 27%              
Midazolam 99% 36% 99% 0             75%
Morphine 76% 68% 69% 70% 18% 36% 16% 20% 40%  
Paracetamol 66% 56% 55% 53%              
phenobarbital             17% 6%      
Propofol                     100%
Vancomycin 32% 33% 46% 46%     36% 11%      
Voriconazole           71%          
* percentage of drug loss
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days to 9% or 13 BSI/1000 ECMO days depending on definitions [12]. Even using Center 
of Disease Control (CDC) criteria for nosocomial BSI, infection rates are still 5-10 times 
higher than the central line related BSI in non ECMO critically ill children [14, 61]. Noso-
comial infections are associated with higher mortality, although most patients die due 
to the underlying disease [62].
Besides the use of preventive measurements there is an urgent need for PK data on 
antibiotics.
Efficacy of antibiotics whose effectiveness depends on peak concentrations (such 
as aminoglycosides) may be reduced by increased volume of distribution. At the same 
time, the risk of adverse events related to trough levels may be increased due to reduced 
clearance. Antibiotics whose effectiveness depends on time above minimal inhibitory 
concentration (such as cefalosporins and vancomycin) may be affected by differences in 
drug clearance as well as volume of distribution. Both undertreatment and toxicity need 
to be considered when dosing antibiotics on ECMO. To guide antibiotic dosing regimens 
in ECMO patients, PK models that take into account ECMO-related PK-changes need to 
be developed.
Gentamicin
Several studies describe gentamicin PK in neonates and infants on ECMO. The five studies 
published so far show an increased volume of distribution ranging from 0.51 L/kg [36] to 
0.748 L/kg [32-35] compared to 0.45 L/kg in post ECMO patients and critically non ECMO 
patients. [34, 35] Clearance on ECMO was decreased compared to the clearance in the 
post ECMO period: +/- 45 ml/kg/hour vs. of +/- 60 ml/kg/hour [34, 35]. Choosing suitable 
control patients may be difficult since gentamicin PK varies, especially in the new-born 
period. Compared to term septic neonates gentamicin clearance on ECMO seems to be 
comparable or slightly increased [32-36, 63]. All studies showed an increased elimina-
tion half-life of 10h compared to 5-6 hours in non ECMO patients. 
Dosing regimens from literature do not reflect current insights into aminoglycoside 
dosing in neonates and infants [64]. The altered PK with decreased volume of distri-
bution and increased elimination half-life make aminoglycoside dosing a challenge in 
ECMO patients.
Vancomycin
In 1990 Hoie and colleagues were the first to describe vancomycin PK in six neonates on 
ECMO. They found a volume of distribution of 0.68 l/kg and a clearance of 1.1 ml/kg/min, 
resulting in an elimination half-life of 7.71 h [40]. All patients had a normal creatinine 
level. Amaker et al. used a two compartment model to describe the data of 12 neonates 
on ECMO with a volume of distribution of 1.1 l/kg and a mean vancomycin clearance 
of 0.78 ml/ kg/ min, resulting in an elimination half-life of 16.9 hour. They found that 
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vancomycin clearance was strongly correlated with renal function [39]. These findings 
were confirmed by Mulla et al. who improved model fit by modelling clearance as a 
nonlinear function of serum creatinine. [38] They developed a dosing regime based on 
age and renal clearance as described by serum creatinine. 
A retrospective study of 15 neonates on ECMO found a prolonged elimination half-life 
in the ECMO group compared to non ECMO controls (8.3h vs. 6.5h). However volume 
of distribution and clearance alone did not show significant differences [37]. Based on 
the available literature vancomycin dosing intervals should be based on age and renal 
function. Drug monitoring should be used to adjust dosing.
Cefotaxime
Cephalosporins are widely used in pediatric patients including those on ECMO. Us-
ing NONMEM and sparse sampling, our group was able to describe cefotaxime PK in 
neonates and young children. [65] The cefotaxime clearance estimate found in ECMO 
patients (0.36 L/h) was similar to those for non-ECMO treated full-term neonates, which 
vary from 0.20-0.55 L/h. [66-68] The distribution volume however was larger than in 
non-ECMO patients (1.82 L vs. 0.68-1.14 L) [67, 68]. These differences could be caused by 
hemodilution due to the additional blood volume or capillary leakage of protein-bound 
drug into the extravascular compartment, especially in the early phase of ECMO (24h-36 
h after cannulation).
Despite the increased distribution volume, the percentage of time above the minimal 
inhibition concentration was at an effective level for all patients. Dose adjustments 
therefore do not seem to be necessary in ECMO patients. There was considerable vari-
ability in plasma concentrations of both cefotaxime and the metabolite. The altered PK 
found in patients on ECMO as well as the inter-patient variability did not influence dose 
requirements; probably due to the large therapeutic window of cefotaxime, which has 
allowed relatively high dosing in non-ECMO patients without adverse effects. The only 
covariates with a statistically significant correlation were body weight and time after 
decannulation (cefotaxime clearance post ECMO), and hemofiltration flow and time 
after decannulation (desacetylcefotaxime clearance post ECMO). [65] Although the 
article identified several variables with a statistically significant effect on cefotaxime and 
desacetylcefotaxime PK, the percentage of variability explained is max. 8.1%.
Oseltamivir
In the recent H1N1 influenza pandemic ECMO support was successfully instigated in 
children and adults with survival rates of 70% [6, 69, 70]. Oseltamivir is the drug of 
choice in H1N1 new influenza, where alternatives such as inhaled zanamivir or intrave-
nous zanamivir have not been evaluated in critically ill children. A case report describing 
three patients with H1N1 new influenza supported with ECMO showed that adequate 
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plasma levels were achieved in two out of three patients. More specifically a two fold 
dose increase of 4mg/kg/d (vs. 2mg/kg/d) resulted in a two fold increase in plasma lev-
els. The influence of the ECMO circuit seems to be limited in this small case series. One 
patient with profuse gastric retentions and hematemesis failed to achieve adequate 
plasma concentrations of oseltamivir and oseltamivir carboxylate probably reflecting 
insufficient oral absorption of the parent drug [71].
Voriconazole
There is one case report of voriconazole PK in a 5 year old pediatric patient on ECMO. 
Using therapeutic drug monitoring the authors increased the voriconazole dosing two 
fold to achieve adequate plasma levels. They found a decreased clearance compared to 
non ECMO pediatric patients [72]. Similar findings are reported in the adult population 
[73, 74].
Caspofungin
There are no pediatric data concerning caspofungin in pediatric ECMO patients. Spriet et 
al. report no altered PK in two adult ECMO patients, whereas Ruiz et al. found inadequate 
or undetectable caspofungin levels in one patient [73, 74].
Ribavirin 
Ribavirin PK may be altered during ECMO treatment. In a 21 day old neonate treated 
with ribavirin intravenously volume of distribution was markedly increased compared 
to non ECMO children although neonatal data in non ECMO patients is lacking. Clear-
ance during hemofitration seemed to be unaltered. The authors concluded that no dose 
adjustments are necessary [75].
Ticarcillin-clavunate acid 
A case series of reporting the use of ticarcillin-clavunate acid in three children includ-
ing two patients on ECMO and hemofiltration showed no clear effect on volume of 
distribution or clearance due to ECMO. Both volume of distribution and clearance varied 
widely between the three subjects. Based on these data dose adjustment do not seem 
necessary [76].
Fluoroquinolones
Fluoroquinolones are broad spectrum antibiotics. Although PK and PD data in neonates 
and children is limited both ciprofloxacin and levofloxacin have been used in se-
verely ill neonates and children [77, 78]. There are case reports mentioning the use of 
fluoroquinolones in pediatric ECMO patients [79]. However there is no data available on 
fluoroquinolones PK during ECMO. In adults during cardiopulmonary bypass Volume of 
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Distribution does not seem to be affected, whereas clearance decreases during surgery 
[80] Concerns of toxicity as well as increased risk of multiresistent pathogens with these 
drugs necessitate evaluation of PK parameters during ECMO in all age groups essential.
Sedatives and analgesic drugs
Children on ECMO receive multiple sedative and analgesic drugs to provide comfort 
and pain relief. A survey among different ECMO centers in the United States showed a 
wide variety of sedatives and analgesics used in children on ECMO, with a preference for 
fentanyl and midazolam. [81] Reported sedation goals differ from no motor movement 
and deep sedation, to spontaneous movement and conscious sedation [81].
Data on sedation and analgesia in ECMO patients are only available from newborn 
studies. Higher sedative needs have been reported for these patients [47, 82, 83, 84.]. 
In an unpublished cohort study including 78 neonates, infants and older children we 
found that 50% of all ECMO patients required three or more drugs to achieve adequate 
sedation evaluated by COMFORT-B and Numerical Rating Scale (NRS) pain scores. Medi-
cation included morphine, midazolam, fentanyl, clonidine, ketamine-S and continuous 
pentobarbital infusions. Furthermore 65% of all patients received morphine despite low 
NRS pain scores. This suggests that morphine was predominantly used as a sedative in 
the study population, not as an analgesic. Since cannulation for ECMO is considered 
a minor surgical procedure non-opioid analgesics such as paracetamol might suffice 
to achieve adequate pain relief. This approach may reduce opioid use and its related 
adverse events [85].
Prolonged and high cumulative dosages of opioids and benzodiazepines in neonates 
and children are associated with serious adverse effects such as tolerance, physical de-
pendency and subsequent withdrawal syndrome in neonates and children [86-93]. This 
may necessitate strict weaning protocols in individual patients, even up to six months 
after hospital discharge. [94].
Developing standardized PD parameters and endpoints is invaluable in interpreting 
PK data. A myriad of co-variables influence PK and PD in ECMO patients. Difference in 
desired levels of sedation, the use of multiple drugs and poor correlation between seda-
tion scores and plasma concentrations make it difficult to use PK data to create dosing 
guidelines for sedatives and analgesics. 
In a cohort study of 20 neonates on ECMO, our group evaluated the safety and ef-
ficacy of sedation interruption in this population [85]. Interruption of all sedatives and 
analgesics was feasible and safe in these patients and resulted in a median (interquartile 
range) time without any sedatives of 10.3 hours (5.0-24.1 h). Median plasma levels of 
midazolam were significantly lower compared to the plasma levels reported by Mulla 
et al.: median (interquartile range) 107ng/ml (48-184 ng/ml) vs. 1400-2600ng/ml. In 
previous studies the correlation between plasma concentrations of midazolam and 
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level of sedation has been poor, with large inter and intra-patient variability [95-98]. The 
study outcomes support the hypothesis that daily sedation interruption may result in 
reduced cumulative dose requirements of sedatives and analgesics for ECMO patients. 
Furthermore they show that, PK data alone are not enough to come to evidence based 
dosing regimens. To our knowledge only morphine, midazolam and fentanyl PK have 
been studied in neonatal and pediatric ECMO patients.
Midazolam
There are two PK studies evaluating midazolam in neonates on ECMO. Mulla et al. 
described a one-compartment model with time-dependent change in volume of dis-
tribution. The volume of distribution expanded monoexponentially from the onset of 
ECMO from 0.8 L/kg to a maximum value of 4.1 L/kg. Consequently, plasma half-life was 
substantially prolonged: 33.3 h. Total body clearance was constant at 1.4 +/- 0.15 ml/
kg/min. Due to a prolonged elimination half-life there was accumulation of midazolam 
after 48 hours on ECMO. Adequate sedation levels were achieved with plasma levels of 
1400-2600 ng/ml [46].
Furthermore they showed that patients receiving midazolam via the circuit required 
higher doses within the first 24h compared to those who were given midazolam via an 
indwelling venous line [29]. In a similar cohort of neonates Ahsman et al. reported a 
comparable threefold increase of volume of distribution immediately after cannulation 
[57]. Contrary to the report by Mulla et al. there was an increase of midazolam clear-
ance over time on ECMO from 2.6ml/kg/min to 7.6 ml/kg/min. Interpatient variability 
estimates of midazolam and the two metabolites for clearance and volume of distribu-
tion between 87% and 129%. The clearance of hydroxymidazolamgluruonide seems 
to lag behind midazolam clearance [57]. This could lead to active concentrations even 
after just a couple of days on ECMO, causing prolonged sedation [99]. Most variability 
remains unexplained, which exemplifies our limited understanding of physiology, organ 
function and their effects on pediatric PK during critical illness and ECMO. 
The only apparent differences between the two datasets are the type of ECMO applied 
(venovenous vs. venoarterial), and possibly the composition of circuits and membranes. 
Midazolam drug loss reported by Mulla et al. in an in vitro study were lower compared to 
the absorption rates in the ECMO circuit used by Ahsman et al. [49, 50].
In conclusion, volume of distribution and clearance of midazolam are higher during 
ECMO, adsorptive drug loss could be a cause of higher dose requirements. Although 
PK data suggests a dose increase following cannulation, alterations in PD and sedation 
goals may instead allow the physician to decrease or stop sedation following cannula-
tion and titrate sedation based on validated sedation scores. Future studies need to 
focus on both PK and PD data using validated scores such as COMFORT-B and NRS-pain 
scores as PD outcome measures [85].
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Fentanyl
Koren et al. reported drug sequestration of fentanyl in extracorporeal circuits [51] with a 
subsequent need for high fentanyl infusion rates. High fentanyl infusion rates have been 
reported by others as well indicating altered PK or PD in these patients [83, 100].
Morphine
Morphine is widely used in neonatal intensive care as an analgesic and as a sedative dur-
ing mechanical ventilation and ECMO. In 1994 Dagan et al. reported decreased morphine 
clearance in neonates on ECMO of 0.574 L/kg/h during ECMO with a concomitant two 
fold increase following decannulation. [47] Geiduschek et al. found a similar clearance of 
morphine in eleven newborns on ECMO. Almost half of the patients showed increased 
clearance over time possibly reflecting age related maturation of drug metabolizing 
enzyme activity. Furthermore they found no significant decrease of morphine levels 
directly following cannulation. They concluded therefore that PK of morphine was not 
significantly altered during ECMO [31].
In 2006 Peters et al. reported a two fold increase of volume of distribution for 
morphine in neonates on ECMO compared to postoperative non ECMO patients. Fur-
thermore clearance was decreased at start of ECMO but increased over time, equalling 
age normalized clearance by day 14. The clearance of morphine-3-glucoronide and 
morphine-6-glucoronide is related to creatinine clearance [30, 101].
Krekels et al. developed a new model for morphine PK in neonates, infants and chil-
dren resulting in an alternative dosing advice for neonates and children below the age 
of two years. In validating this model in different data sets they found that it was also 
predictive for neonates on ECMO, indicating no significant difference in PK. There was 
however an underestimation of metabolites in neonates without hemofiltration sup-
port indicating diminished renal clearance in these patients, which was corrected by 
introducing hemofiltration [102].
All studies reported high interpatient variability. Although morphine PK is altered 
in neonates on ECMO clear dose adjustments cannot be made based on the available 
literature and should be based on effect using validated scores. The data suggests that 
morphine PK is less affected than fentanyl and should be the preferred choice of opioids 
in ECMO patients. 
Although there are limited pharmacokinetic data on morphine and midazolam in 
neonates on ECMO, no data are available in older children on ECMO. Also there are no 
pharmacokinetic data on clonidine or ketamine-S in ECMO patients of any age. Dos-
ing of these drugs is titrated to effect, but the therapeutic window in ECMO patients is 
unknown.
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Cardiovascular drugs
There are case reports describing the PD of amiodarone, esmolol, prostaglandin E1, ne-
siritide, and nicardipine in pediatric ECMO patients. These studies have been evaluated 
in a recent review by Watt et al., in which they conclude that there is either no effect 
(nicardipine) or increased dose requirements (amiodarone, esmolol, prostaglandin E1, 
nesiritide) [103]. Although helpful these reports do not provide combined PK and PD 
data necessary to develop an evidence based dosing regimen. A case series of 23 neo-
nates treated with hydralazine did not show any clinical benefit on cardiac performance 
during ECMO. Whether this is caused by altered PK, with subtherapeutic drug concentra-
tions, remains unclear since PK data is lacking [104].
Furosemide
There are two studies on furosemide use in ECMO patients. Van der Vorst et al. showed 
that continuous furosemide administration is well tolerated in ECMO patients and leads 
to stable and adequate diuresis. In a follow up study continuous infusions furosemide of 
4mg/kg/d resulted in plasma concentrations below toxic levels [105] [106].
Bumetanide
Bumetanide PK was evaluated in eleven neonates treated with ECMO. Wells et al. found 
an increased volume of distribution and elimination half-life for bumetanide with high 
non renal bumetanide clearance. Although effective diuresis was achieved, the effects 
were less than expected due to possible sequestration of drug within the ECMO circuit 
[43].
Sildenafil
Sildenafil has been used off-label to treat pulmonary hypertension in the neonatal and 
pediatric setting, with dose regimens based on titration and a few case reports [107, 
108]. Mukherjee et al. showed in their PK analysis of intravenously administered silde-
nafil that sildenafil clearance increases over time from 0.7 L/h at a postnatal age of 1 
day up to 3.3 L/h at 10 days, which suggests a clearance maturation that may require 
dose adjustments over time [109]. Our group examined sildenafil PK after nasogastric 
administration of extemporaneously prepared capsules during ECMO and in the post-
ECMO period [110]. There was a gradual non-linear increase of sildenafil PK parameters 
over the course of an ECMO-run, with a return to pre-ECMO levels upon decannulation. 
For a 6 day-ECMO run, sildenafil clearance increased from 1.0 to 6.7 L/h, The distribution 
volume also increased: from 50 to 116 L. Simulations showed that a dose of 3 - 5 mg/
kg/24h leads to a combined sildenafil and desmethylsildenafil exposure equivalent to 
that of an adult treated with 3 dd 20 mg p.o. During ECMO, a dose of between 5 and 7 
mg/kg/24h provides the same exposure. As a result of the return of PK parameters to 
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non-ECMO values, the total exposure would increases at decannulation, unless the dose 
is reduced by approximately 50%.Clinicians should therefore be aware of a potential 
increase in efficacy or side effects after the end of ECMO therapy [110].
Miscellaneous
Ranitidine
Wells et al. described both PK and PD of ranitidine in term neonates on ECMO. A single 
intravenous dose of ranitidine resulted in an intragastric pH to rise above 5 in all pa-
tients. Volume of distribution (1.8L/kg) is slightly higher and clearance (0.25L/kg/h) is 
slightly lower compared to non ECMO neonates, but this difference does not seem to 
be clinically relevant [41]. The authors advised that dose adjustments should be made 
based on intragastric pH measurements.
Theophylline
In 2003 Mulla et al. described a one-compartment model with first order elimination for 
theophylline in 75 neonates on ECMO. Bodyweight and age were predictors for volume 
of distribution and clearance respectively. The results showed the familiar pattern of 
an increased volume of distribution and decreased clearance compared to non ECMO 
patients. Again the authors reported large unexplained interpatient variability [42].
Phenobarbital
Phenobarbital PK data is limited to a single case report. A slightly higher volume of 
distribution (1.2L/kg) with normal elimination half-life (92hours) resulted in low but 
therapeutic serum concentrations. Dose recommendations cannot be made based on 
this single case reports, but clinicians should be aware that higher loading doses may 
be required [111].
Heparin
Green et al. described heparin PK in 5 patients on ECMO. Heparin clearance was markedly 
influenced by the ECMO circuit, accounting for approximately 50% of total Clearance 
[112]. Reported heparin doses range between 20 and 70E/kg/h in ECMO patients [113]. 
Higher than normal heparin requirements on ECMO may be expected.
futuRE PERsPEctiVEs
Evidence based dose regimens are still lacking for many regularly used drugs in neonates 
and older children on ECMO. PK-PD studies could help us construct dose regimens, but 
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they require sufficiently large datasets with clinical records, dose information, plasma 
concentrations and relevant clinical outcome parameters. extracorporeal circulation can 
help our understanding of the behavior of individual drugs. Several recent pharmacoki-
netic studies NONMEM population modeling. This enables the construction of PK mod-
els with limited and random patient samples. Using these techniques routine collection 
of blood samples in combination with registration of clinical and dose information in 
a patient data management system (PDMS) would improve the availability of data for 
these analyses. By analyzing samples in such a biobank, it might be possible to get 
enough samples to model these drugs and their metabolites as well, so that proper dose 
regimens can be constructed [114]. Perhaps the number of samples might be increased 
in future by using leftover material from routine clinical chemistry measurements using 
LC-MS. Finally the PK models need to be validated in a prospective study. Combining PK 
sparse sampling with randomized controlled trials including clear PD outcome measure-
ments will help us to construct evidence based dosing guidelines, evaluate toxicity and 
establish efficacy of drugs. Rayyan et al. suggested a similar strategy. They also empha-
sized the need for randomized controlled trials and well defined PD outcome [115].
The power of PK studies in these patients could be enhanced by incorporating data 
from critically ill and relatively healthy non-ECMO patients, but only for drugs that are 
used in different patient categories. For drugs like midazolam (for which the influence of 
illness and maturation are being studied by combining different datasets in non-ECMO 
patients [116] the ECMO data might be included in the model. Studies into the mecha-
nisms of PK changes due to maturation, disease progression or the extracorporeal circu-
lation can help our understanding of the behavior of individual drugs. To help identify 
factors that underlie PK changes, studies into fluid dynamics, organ perfusion, organ 
function, capillary function and microcirculation might be useful, but it is still a long 
way before they might be used in (mechanistic) population PK analyses. Developing 
accurate mechanistic population models will enable us to predict PK and possibly PD 
for new drugs used in these patients, thereby avoiding toxicity and increase efficacy of 
drugs.
cOnclusiOn
PK for several drugs is altered in neonates and children on ECMO. Our understanding 
of ECMO-induced PK-altering mechanisms is insufficient to prepare a predictive model, 
reflected by the large interpatient variability found in almost all studies. This variability 
as well as the lack of clear PD endpoints makes it difficult to construct ECMO specific 
dosing regimens for most drugs. Changes in PK are drug and circuit dependent with 
more dramatic changes found in lipophilic drugs and silicone oxygenators. Differences 
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in ECMO circuits, patient populations and diseases may influence PK and PD further. 
The combination of routine sparse sampling, drug assay via LC-MS and a PK analysis 
using NONMEM in combination with validated PD endpoints such as the COMFORT-B 
will allow the study of drug behaviour in these vulnerable patients without harm to the 
individual subject. Combining data sets and a biobank may enable researchers to fine-
tune PK models and hopefully this, in combination with a good cooperation between 
pediatricians, pharmacists and clinical pharmacologists, leads to more evidence-based 
dose regimens for neonatal and pediatric ECMO patients. Finally PK models need to be 
validated in prospective randomized controlled trials to proof efficacy and accuracy.
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AbstRAct
Objective
Mechanical circulatory support for heart and/or lung failure has become routine in 
specialized pediatric centers. We report on the first multicenter results with a new min-
iaturized third generation diagonal centrifugal pump.
Methods and Results
241 neonates and older children, age median 2.2 (range 0-201) months, from 7 centers 
were treated with the pump system (16 ml priming volume), able to generate a flow of 
below 0.5 up to 8 liters. A fully preconnected set and quick pump-driven priming allows 
transportation.
Veno-arterial ECMO was used in 163 and veno-venous ECMO in 70 patients. In 8 the 
pump was used as ventricular assist device. Supporting time was median 5.5 (range 
0.2-69) days. 116 infants presented with primary cardiac and 125 with pulmonary indica-
tions, including 8 oncologic patients. In 24 children veno-arterial ECMO was installed 
under ongoing cardiopulmonary resuscitation.
All 8 oncologic patients died of pulmonary failure after a median support time of 15 
days. The overall weaning rate from bypass of the 233 other patients was 72.5% with a 
discharge home rate of 59%. 127 (55 %) children were without severe complications. 
Bleeding occurred in 75 and technical failure in 5 patients. Three children suffered a fatal 
cerebral event. Renal replacement therapy was performed in 28% and pump exchange 
in 24%. Multivariable analysis identified pump exchange (OR 1.94), kidney failure (OR 
3.43) and complications on support (OR 2.56) as risk factors for dismal outcome. 
conclusion
The pump’s use proved to be feasible, efficient, and was associated with a low complica-
tion rate. It is multifunctional, useful in different kinds of support and can be initiated 
outside an intensive care unit or operating room.
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intROductiOn
After the first report in 1974 on its use in children, extracorporeal membrane oxygen-
ation (ECMO) became a lifesaving tool for patients with pulmonary failure and children 
suffering from cardiac failure [1, 2]. The goal of veno-venous (VV) and veno-arterial (VA) 
ECMO is to serve as a bridge to recovery or transplantation, or to medical- , intervention-
al- or surgical therapies once a diagnosis is made [3-5]. Cannulation sites now include 
the neck, groin, direct intracardiac access, or a combination thereof. Since the circuits 
have become smaller, rapidly employed, and easier to handle, VA-ECMO-supported 
cardiopulmonary resuscitation (E-CPR) is being increasingly administered in specialized 
pediatric centers [6].
The past decade has seen a shift from roller pumps towards miniaturized centrifugal 
pump technology [6-8]. Nevertheless, ECMO runs worldwide are still often carried out 
with first generation centrifugal pumps or even traditional roller pumps, a decade-old 
technology [5].
With this multicenter study we aimed to evaluate the feasibility, efficacy, complica-
tion-, and survival rate associated with a new miniaturized third generation diagonal 
centrifugal pump used in Europe in 241 consecutive neonatal and pediatric patients.
PAtiEnts And MEtHOds
After having obtained institutional Review Board approval from all seven centers, we 
enrolled 241 consecutive neonates, infants and children (53% male) supported with this 
new pump between 1st January 2012 until 31 March 2015 in this retrospective study. 
All centers included their consecutive patients treated with a Xenios Deltastream® 
DP-3 diagonal pump without exception, with number per center ranging from 12 to 94 
(median 32). Patients’ demographics and supporting times are shown in table 1. Forty of 
the patients have previously been reported in a study focusing on different aspects [9].
The indication of almost half of the patients (n = 116) was of cardiac origin, e.g., 
weaning failure from cardiopulmonary bypass or later circulatory collapse after cardiac 
surgery; chronic cardiac disease like cardiomyopathy or myocarditis; and sudden cardiac 
arrest with E-CPR. In the other 125), the indication was of primary pulmonary origin like 
ARDS, pneumonia, lung hypoplasia in congenital diaphragmatic hernia, or meconium 
aspiration syndrome (Table 2).
Weaning success was defined as survival longer than 24 hours without mechanical 
support.
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MAtERiAls
The Deltastream® DP-3 (Xenios, Deltastream, Aachen, Germany) is a rotational pump 
(Fig 1). This diagonal pump system unifies the advantages of a radial pump with high 
hydraulic capacity and low inertia and the small size of an axial pump system. The DP-3 
pump system with 16 ml priming volume can generate a flow of up to 8 liters per minute 
and a pressure up to 600 mmHg. Maximum rotational speed is 10,000 revolutions per 
table 1: Patient demographics and supporting time
All patients, n=241
Median
Quartiles
Range
Oncology pt, n=8
Median
Quartiles
Range
NOP, n=233 
Median
Quartiles
Range
Age (months) 2.2 57.5 1.9
0.1/28.8 6.1/85.2 0.1/24.9 
0-201 5.1-128 0.1-201 
Bodyweight (kg BW) 4.1 10.7 4.1
3.1/11.8 6.1/17.5 3.0/11 
1.7-72 3.6-33 1.7-72 
Days on support (d) 5.5 15.0 5.5
3.1/10.6 4.0/17 3.1/10 
0.2-69 2.0-26 0.2-69 
table 2: Diagnosis of the DP3-patients
indication (all) n = 241 (%)
cardiac indication n = 116 (48.1%)
Cardiac arrest, ECLS under CPR 24 (10%)
Post-cardiac surgery # 73 (30.2%)
Cardiac disease, chronic * 19 (7.9%)
Pulmonary failure n = 125 (51.9%)
PPHN 4 (1.7%)
CDH 35 (14.5%)
MAS 15 (6.2%)
Pneumonia/sepsis 25 (10.4%)
ARDS 45 (18.7%)
Chronic lung failure 1 (0.4%)
*myocarditis n=4; cardiomyopathy n=11; others n=4
#weaning failure n=51, LCOS at ICU n=5, CPR n=14, unknown n=3
ARDS, acute respiratory distress syndrome; CDH, congenital diaphragmatic hernia;
 CPR, cardiopulmonary resuscitation; ECLS, extracorporeal life support; MAS, meconium aspiration syn-
drome; LCOS, low cardiac output state
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minute. The flow can be adjusted even at ranges under 0.5 l/min, essential for its use in 
babies. Thus the system is applicable in a broad age range from neonates up to adults. 
The entire pump circuit has obtained its seven days CE Mark and is composed of a single-
use diagonal blood pump, motor, driving console, and flow probe. Safety functions are 
ensured by several control systems: cannula aspiration is prevented by preload control; 
brief interruption of the flow can be managed with the zero-flow mode without risking 
back- flow. The pump can be driven in pulsatile mode by varying the pump speed under 
different frequencies [10]. The system is multifunctional and applicable in all kinds of 
mechanical cardiac support (MCS) like ECMO, ECLS or as a ventricular assist device (VAD) 
for the right (RVAD) or left (LVAD) ventricle, and as uni- or biventricular support.
stAtisticAl AnAlysis
Patient and procedure characteristics were analyzed descriptively. Categorical data 
are presented as absolute and relative frequencies. Continuous data are presented as 
median, quartiles, and range. The incidences of successful weaning, death on device, 
and change to other device over time were estimated with cumulative incidence rates.
The effects of patient and procedure characteristics on the outcome parameter death 
on device and death before discharge were analyzed using logistic regression models. 
Effects were estimated as odds ratios (OR) with 95%-confidence intervals (CI) and tested 
at a two-sided significance level of 0.05. First, all variables were analyzed in univariate 
models. In a second step, variables with p<0.05 in the univariate analysis were simulta-
neously analyzed in a multivariate model.
Since the statistical analyses were not planned prospectively in a confirmative man-
ner, all p-values have to be interpreted in a descriptive sense.
figure 1: DP-3 diagonal centrifugal pump.
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REsults
1. the total group (n = 241)
Cannulation
Mechanical circulatory support implantation was performed in the NICU/PICU in 59.0%, 
in the OR in 33.2%, within the hospital but outside an OR/ICU in 3.5%, and at an external 
clinic followed by transport under ongoing MCS in 4.4%. (Fig. 2). Intracardiac access by 
open chest was made in 85 patients (77 VA-ECMO and 8 VAD), and 75 patients underwent 
VA-ECMO with cervical cannulation. Of the 85 patients with intracardiac cannulation, 77 
were supported with VA-ECMO and 8 with VAD without an oxygenator. Details on can-
nulation are given in table 3. Cannulation access had no significant influence on wean-
ing rate (p = 0.24) or discharge home rate (p = 0.81). 69% of the femorally-cannulated 
patients were weaned successfully and 54% were discharged home. The corresponding 
figures for the cervically-cannulated patients are 73% 60%, respectively and for the 
patients with intracardiac cannulation 83% and 57%, respectively.
figure 2: DP-3 system for interhospital ECMO transport.
Multicenter experience with mechanical extracorporeal assist using a new diagonal pump in 241 pediatric patients
11
173
VV- vs. VA-ECMO
The DP-3 was used in 70 children as VV-ECMO, in 163 as VA-ECMO; and as a VAD without 
oxygenator in eight patients with cardiac failure and restored lung function solely for 
left- or right or univentricular heart support (Table 3).
Survival
Weaning was successful in 169 (70.1%) patients, 63 (26.1%) patients died while on the 
device or failed to survive 24 hours after weaning, nine (3.7%) were switched to another 
device, and 137 (56.9%) patients were ultimately discharged home (Table 4).
Bridging to another device
Nine children needing long-term cardiac support were switched to other devices after a 
median DP-3 pumping time of 10.0 days (range 2 – 40 days). Six were older than one year 
of age, five had a bodyweight of > 10 kg. Eight out of nine underwent VA-ECMO because 
of a cardiac indication, four because of weaning failure after cardiac surgery, three with 
acute decompensation of chronic cardiac disease, and one after sudden cardiac arrest 
and e-CPR. Five were discharged home.
table 3: Cannulation details
n Cannulation site n Comments
VA-ECMO 163 Intra-cardiac 77 9 with LA vent
Cervical 62 1 with septostomy, 1 LA vent 
Femoral 11 2 with septostomy 
Cervical + femoral 13 
VV-ECMO 70 Cervical, dual lumen 52
 Cervical, single lumen 9  
 Femoral 2  
 Cervical + femoral 7  
VAD 8 LVAD (LV-Ao) 2
 RVAD (RA-PA) 2  
 Univentricular VAD (V-Ao) 4  
Abbrev.: Ao, aorta ascendens; LA, left atrium; RA, right atrium; PA, pulmonary artery; VAD, ventricular assist 
device;
table 4: Total outcome:
n=241 %
Weaning successful 169 70.1
Death on device 63 26.1
Switched to another device 9 3.7
Discharged home 137 56.9
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Complication rates
Overall complication rate was 45%; the most frequent complication was bleeding in 
32%, followed by thromboembolism in10 % and blood culture-positive sepsis in 9% 
(Table 5). Of the five patients (2.1%) with technical failure, two were successfully weaned 
and three died on support. 55 % of the patients were without major complications. 
Renal replacement therapy (RRT) was reported in 67 children (28.4 %, in five patients 
data on RRT were missing). Hemolysis was reported in 22 patients (12%).
2. children with oncologic disease and pulmonary failure (n = 8)
A total of 8 children on long-term immunosuppression due to malignant disease were 
treated with ECMO in three centers (Table 1, fig. 3). The mean age of these children was 
higher than that of the other children (57.5 vs. 1.9 months) and their ECMO support 
lasted longer (median 15.0 vs. 5.5 days). Indications in this patient group were: pulmo-
nary failure due to ARDS (n = 6), pneumonia/sepsis (n = 1) and chronic lung disease (n = 
1). Seven children underwent ECMO implantation in a PICU, 1 in the operating room. VV-
ECMO was performed in 5 with double lumen cervical cannulation, two had VV single 
lumen ECMO, and in one case VA-ECMO was implanted. No technical device failure was 
reported; nevertheless all patients died without successful weaning. The complications 
were: bleeding in 2 (one cerebral); new blood culture positive sepsis in 1; kidney failure 
requiring dialysis in 3; signs of hemolysis in 2. 
3. non-oncology patients
Characteristics of the 233 non-oncology patients are given in Table 1. The overall success-
ful weaning rate was 72.5 %, and 58.8 % survived until discharge home. The discharge 
home rate was 62% in the pulmonary indication group as compared to 55% in the cardiac 
group. Best reported results were in the subgroup of 15 MAS patients, of whom 14 (93%) 
table 5: Complications
n %
None 127 54.5
Bleeding 75 32.2
Thromboembolism 23 9.9
Seizures 3 1.3
Sepsis (blood culture Positive) 21 9.0
Others 10 4.3
Technical failure 5 2.1
Missing 8, multiple answers possible
-severe cerebral events in 3 children: 2 cerebral bleeding and 1 thromboembolism
-renal replacement therapy in 67 patients (28.4%), 5 missing
-hemolysis in 22 patients (11.6%), 52 missing
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survived to discharge home. Further details are given in table 6. During hospital stay 37 
children died although weaning was successful. Time interval between weaning and 
death was a median 12.0 days (quartiles 3.3 – 27.3 days). Twenty-four of these patients 
had a cardiac indication as compared to 13 patients with a pulmonary indication; 81% 
were in their fi rst year of life. Most of these children received VA-ECMO (92%).
The rate of change of pump head, oxygenator or the entire system ranged from 0 - 85% 
of the patients per center. At least one change was applied to 61 (26%) of all systems 
had. There was no diff erence in this regard between pulmonary or cardiac indication 
or between VV- and VA-ECMO. In 8 VAD patients whose system had no oxygenator, the 
change rate was 50%.
N = 241
All patients
N = 233
Non-oncologic 
patients
N = 8
Oncologic patients
N = 63
VV-ECMO
N = 162
VA-ECMO
N = 8
VAD
N = 7
VV-ECMO
N = 1
VA-ECMO
figure 3: Flowchart of the patients
table 6: Indication for DP-3 implantation and outcome of all non-oncologic patients (NOP)
Indication (NOP) n (%) Weaning successful Discharge home
All non-oncologic patients 233 (100%) 169 (72.5%) 137 (58.8%)
cardiac indication 116 (49.8%) 83 (71.6%) 64 (55.2%)
Cardiac arrest, E-CPR 24 (10.3%) 13 (54.2%) 9 (37.5%)
Post-cardiac surgery # 73 (31.3%) 57 (78.1%) 43 (58.9%)
Cardiac disease, chronic* 19 (8.2%) 13 (68.4%) 12 (63.2%)
Pulmonary failure 117 (50.2%) 86 (73.5%) 73 (62.4%)
PPHN 4 (1.7%) 3 (75.0%) 1 (25.0%)
CDH 35 (15.0%) 28 (80.0%) 21 (60.0)
MAS 15 (6.4%) 14 (93.3%) 14 (93.3%)
Pneumonia/sepsis 24 (10.3%) 18 (75.0%) 15 (62.5%)
ARDS 39 (16.7%) 23 (59.0%) 22 (56.4%)
*myocarditis n=4; cardiomyopathy n=11; others n=4
# weaning failure n=51, LCOS at ICU n=5, CPR n=14, unknown n=3
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table 7: Univariate analysis of effects of patient and procedure characteristics on death on device or before 
discharge home. 
All patients
(non-oncology)
n = 233 n
Weaning failure
death on device
death 
before discharge home
n (%) OR (95% ci) p n (%) OR (95% ci) p
Male 122 28 (23) 1.00 0.84 44 (36) 1.00 0.12
Female 108 26 (24) 1.06 (0.58 – 1.96) 50 (46) 1.53 (0.90 – 2.59) 
Age ≥ 1 year 76 21 (28) 1.00 0.32 30 (39) 1.00 0.71
Age < 1 year 157 34 (22) 0.72 (0.39 - 1.36) 66 (42) 1.11 (0.64 – 1.94) 
Bodyweight ≥ 10 kg 62 16 (26) 1.00 0.63 24 (39) 1.00 0.64
Bodyweight < 10 kg 171 39 (23) 0.85 (0.43 – 1.66) 72 (42) 1.15 (0.64 – 2.09) 
Indication
Pulmonary 117 30 (26) 1.00 0.073 44 (38) 1.00 0.17 
Cardiac with surgery 73 12 (16) 0.57 (0.27 – 1.20) 30 (41) 1.16 (0.64 – 2.10) 
Cardiac without surgery 19 3 (16) 0.54 (0.15 – 2.00) 7 (37) 0.97 (0.35 – 2.64) 
E-CPR 24 10 (42) 2.07 (0.83 – 5.15) 15 (63) 2.77 (1.12 – 6.85) 
Previous CPR
No 171 37 (22) 1.00 0.24 64 (37) 1.00 0.053 
Yes 62 18 (29) 1.48 (0.77 – 2.86)  32 (52) 1.78 (0.99 – 3.21)  
1 – 15 min 11 4 (36)   5 (45)   
16 – 30 min 16 3 (19)   9 (56)   
31 – 45 min 14 5 (36)   9 (64)   
>45 min 19 6 (32)   9 (47)   
Cannulation 
Intra-cardiac 81 14 (17) 1.00 0.24 35 (43) 1.00 0.81 
Cervical 134 36 (27) 1.76 (0.88 – 3.51)  53 (40) 0.86 (0.49 – 1.51)  
Femoral 13 4 (31) 2.13 (0.57 – 7.89)  6 (46) 1.13 (0.35 – 3.65)  
VA-ECMO 165 36 (22) 1.00 0.21 73 (44) 1.00 0.18
VV-ECMO 64 19 (30) 1.51 (0.79 – 2.90)  22 (34) 0.66 (0.36 – 1.20)  
Pump exchange
No 172 38 (22) 1.00 0.36 62 (36) 1.00 0.008 
Yes 61 17 (31) 1.36 (0.70 – 2.65)  34 (35) 1.94 (1.00 – 3.72)  
Complications
No 123 18 (15) 1.00 0.0005 37 (30) 1.00  
Any 103 35 (34) 3.13 (1.65 – 5.97)  56 (54) 2.77 (1.60 – 4.78) 0.0003 
No bleeding 153 28 (18) 1.00 0.005 54 (35) 1.00 0.010
Bleeding 72 26 (36) 2.47 (1.32 – 4.64)  39 (53) 2.00 (1.13 – 3.52)  
No Thrombosis 203 46 (23) 1.00 0.20 80 (39) 1.00 0.12
Thrombosis 23 8 (35) 1.82 (0.73 – 4.56) 13 (57) 2.00 (0.84 – 4.78)  
No technical failure 226 53 (23) 1.00 0.082 91 (40) 1.00 0.11
Technical failure 5 3 (60) 5.02 (0.82 – 30.8) 4 (80) 5.93 (0.65 – 54.0)  
No renal support 164 30 (18) 1.00 0.003 51 (31) 1.00 < 0.0001
Renal support 64 24 (38) 2.68 (1.41 – 5.10) 42 (66) 4.23 (2.29 – 7.81)  
OR = Odd ratio; CI = 95%-confidence interval.
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A pump change had no effect on the complication rate (48.3% of patients with pump 
change versus 44.6% of patients without pump change). On the other hand, kidney 
failure occurred more often in the former group (43% vs. 23%), and also the death rate 
before discharge home rate was higher in in patients with pump change (56% vs. 36%, 
see tables 7 and 8).
Cardiopulmonary resuscitation occurred in 62 of these 233 non-oncology patients but 
this had no effect on later outcome even in the group resuscitated longest (> 45 min) 
(Table 7).
E-CPR involving emergency cannulation under ongoing chest massage was performed 
in 24 patients (10%) with a successful weaning rate of 54% and survival to discharge rate 
of 38%.
Pump change, complications, and renal support were related with outcomes (death 
on device and death before discharge home) in univariate and multivariate analyses (for 
details see tables 7 and 8). Patients with pump exchange had a death before discharge 
rate of 56% as compared to 36% for patients without pump exchange (odds ratio (OR) 
with 95%-confidence interval from multivariate analysis 1.94 (1.00-3.75), p=0.049). Pa-
tients with complications had a death before discharge rate of 54% as compared to 30% 
in patients without complications (OR=2.56, 95%-CI (1.43-4.60), p=0.002). Patients with 
renal support had a death before discharge rate of 66% as compared to 31% in patients 
with- out renal support (OR=3.43, 95%-CI (1.80-6.53), p=0.0002.
table 8: Multivariate analyses of effects of patient and procedure characteristics on death on device or 
before discharge home) in non-oncologic patients
Weaning failure
death on device
death
before discharge home
OR (95% ci) p OR (95% ci) p
Pump exchange 0.64 0 049
No 1.00  1.00  
Yes 1.19 (0.58 – 2.45)  1.94 (1.00 – 3.75)  
Complications 0.002 0 002
No 1.00  1.00  
Yes 2.91 (1.50 – 5.68)  2.65 (1.43 – 4.60)  
Renal support 0.024 0.0002
No 1.00  1.00  
Yes 2.20 (1.11 – 4.36)  3.43 (1.80 – 6.53)  
OR = Odd ratio; CI = 95%-confidence interval.
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discussiOn
In this multicenter study of 241 children with life threatening organ failure, treatment 
with the new miniaturized third generation diagonal centrifugal pump (DP-3) proved 
to be feasible, efficacious and was associated with a low complication rate and with 
70% a quite good weaning rate. The DP-3 proved suitable not only for VV- or VA-ECMO 
in case of pulmonary or combined cardiopulmonary support in children but also as a 
ventricular assist device, without oxygenator, in patients with cardiac failure only.
In our main data analysis we excluded the severely immunodeficient oncologic pa-
tients. Although in all cases technical failure was not encountered and the time courses 
were even much longer (median 5 times longer, 15 vs. 3 days) compared to the non- 
oncologic group, all eight died on the system without any weaning chance or even a 
short glance on the ECMO horizon. In many centers children with severe chemotherapy-
induced cytopenia and respiratory failure combined with bacterial or fungal infections 
are excluded from ECMO programs. Although they have a poor prognosis, there are 
some case reports of successful support [11]. Our retrospective analysis suggests a 
restraint decision making process is needed for this population.
Indications for ECMO play a significant role in predicting the outcome. The Kids’ 
Inpatient Database found congenital heart disease to be an independent predictor of 
increased mortality, followed by respiratory distress syndrome and persistent pulmo-
nary hypertension of the newborn (PPHN) [12]. In our patients the type of indication 
had no effect on the weaning rate. Nevertheless we confirm poor outcome in oncologic 
patients, followed by PPHN, whereas the discharge home rate of children with ECMO 
due to meconium aspiration syndrome was 93 %.
The ELSO registry documents a neonatal / pediatric survival-to-discharge-or- trans-
fer rate of 74% / 58% in pulmonary indications and 41% / 51 % in cardiac indications, 
which compares well with our discharge home rate of non-oncologic patients of 59 % 
(62 % pulmonary and 55% cardiac indications). A comparative analysis of the results 
is not effective since the ELSO data are mixed data without detailed knowledge of the 
devices used or the reporting quality of the centers. (ECLS Registry Report, International 
Summary, January 2016). Moreover our study was not set up as a comparative analysis 
between different devices using a randomized trial design because the individual cen-
ters have not yet passed their learning curves and aspects such as the anticoagulant 
strategy, ventilator management etc. have not yet been harmonized.
Since the pumps have become smaller and smaller and more mobile, E-CPR has become 
focus of attention [13, 14]. Ten percent of our patients were temporarily rescued with E-
CPR and otherwise would have died. The successful weaning rate of these patients was 
54 %. Survival to discharge was reduced to 35.5 %, however, mainly because of cerebral 
dysfunction. In the ELSO registry 2.6% of all cases were cannulated under E-CPR with a 
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discharge rate of 38% [15]. In this group the indication and length of cardiac arrest and 
quality of previous CPR determines the result. Nevertheless, in contrast to roller pumps, 
this diagonal pump with its small size, the fully preconnected set, short tubings and the 
high speed of pump priming makes this pump eligible for e-CPR either in the OR, the 
ICU or other wards in the hospital and allows stable transport under ongoing support.
Zamora et al. [16] using data from the ELSO registry concluded that single-vessel dou-
ble lumen cannulation has become the preferred modality for ECMO therapy in younger 
children with respiratory failure. In our study, 74 % of all VV-ECMO runs were performed 
with the double lumen cannula and this had no effect on outcome. It is advantageous to 
implant the double lumen catheter in Seldinger technique through the internal jugular 
vein in infants, where femoral access is limited due to the small vessel dimensions [17].
The thromboembolism rate of 9.9% that we found is lower than that of the ELSO 
registry, that is a 12% stroke rate while receiving ECMO for cardiac indication, and those 
with stroke had greater in-hospital mortality (72% versus 51%) [18].
Regarding eight cardiac patients after the rescue application of ECLS for short-term 
support, we used the given „time-to-decision“ to communicate with the care givers. For 
ethical reasons it is important to prove neurology before switching to a suitable long 
term device such as the HeartWare device (HeartWare Systems, Framingham, MA) or for 
smaller children the Berlin Heart EXCOR (Berlin Heart, Berlin, Germany) as a bridge to 
recovery or to wait for a suitable donor 19. The BerlinHeart US trial showed that ECMO 
before implantation of the BerlinHeart for longer term support was not associated with 
mortality [19].
Since the pumps have become smaller and smaller and more mobile, E-CPR has become 
focus of attention [13, 14]. Ten percent of our patients were temporarily rescued with E-
CPR and otherwise would have died. The successful weaning rate of these patients was 
54 %. Survival to discharge was reduced to 35.5 %, however, mainly because of cerebral 
dysfunction. In the ELSO registry 2.6% of all cases were cannulated under E-CPR with a 
discharge rate of 38% [15]. In this group the indication and length of cardiac arrest and 
quality of previous CPR determines the result. Nevertheless, in contrast to roller pumps, 
this diagonal pump with its small size, the fully preconnected set, short tubings and the 
high speed of pump priming makes this pump eligible for e-CPR either in the OR, the 
ICU or other wards in the hospital and allows stable transport under ongoing support.
Zamora et al. [16] using data from the ELSO registry concluded that single-vessel dou-
ble lumen cannulation has become the preferred modality for ECMO therapy in younger 
children with respiratory failure. In our study, 74 % of all VV-ECMO runs were performed 
with the double lumen cannula and this had no effect on outcome. It is advantageous to 
implant the double lumen catheter in Seldinger technique through the internal jugular 
vein in infants, where femoral access is limited due to the small vessel dimensions [17].
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The thromboembolism rate of 9.9% that we found is lower than that of the ELSO 
registry, that is a 12% stroke rate while receiving ECMO for cardiac indication, and those 
with stroke had greater in-hospital mortality (72% versus 51%) [18].
Regarding eight cardiac patients after the rescue application of ECLS for short-term 
support, we used the given „time-to-decision“ to communicate with the care givers. 
For ethical reasons it is important to prove abcence of neurological impairment before 
switching to a suitable long term device such as the HeartWare device (HeartWare 
Systems, Framingham, MA) or for smaller children the Berlin Heart EXCOR (Berlin Heart, 
Berlin, Germany) as a bridge to recovery or to wait for a suitable donor 19. The Berlin-
Heart US trial showed that ECMO before implantation of the BerlinHeart for longer term 
support was not associated with mortality [19].
liMitAtiOns
One of the main limitations of this study is its retrospective character, with a trend of 
underestimating minor complication events. On the other hand, all centers reported 
their cases serially, without exception, and thus there is no selective reporting. Centre 
practice variability, which is expressed in the different diagnosis, in the practice of pump 
exchange, anticoagulation, use of renal support, length of DP-3 support etc. makes it 
difficult to compare the cases, but on the other hand testifies to the wide spectrum of 
the DP-3 application. Another limitation is the lack of mid- or long-term follow-up and 
resilient neuro-imaging like CCT or CMRI.
cOnclusiOn
The new miniaturized third generation diagonal centrifugal pump DP-3 proved to be 
feasible, efficacious and was associated with a low complication rate, and thus makes 
e-CPR and transport und ongoing support feasible.
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In congenital diaphragmatic hernia (CDH), lung hypoplasia and pulmonary hyperten-
sion are the main causes of neonatal mortality [1]. Mortality significantly decreased over 
the last 10 years, after the introduction of the gentle ventilation strategy and the de-
velopment of international standards for postnatal therapy [2]. Still, ventilator induced 
lung injury is largely responsible for the development of chronic lung disease in children 
with CDH [3]. 
In this issue of Pediatric Critical Care Medicine, Herber-Jonat and colleagues present the 
results of a well performed laboratory study in rabbits with induced CDH [4]. CDH was 
induced by fetal surgery and five days later perfluorooctylbromide (PFOB), a perfluoro-
carbon, was instilled into the lungs of randomly selected fetal rabbits; other fetal rabbits 
received saline. A third group were non-operated fetuses who served as controls. Fetal 
instillation of PFOB was associated with improvement of lung to body weight ratio, total 
lung capacity and lung compliance as compared to fetal instillation of saline. Secondly, 
at mRNA level only, expression of genes involved in extracellular matrix formation and 
remodeling in the hypoplastic lung was increased. However, surfactant protein expres-
sion, distal airway size, mean linear intercept and airspace and tissue fractions were 
similar between the two groups and also similar to fetuses who were not operated upon. 
The authors concluded that fetal PFOB treatment resulted in improved lung growth, 
lung mechanics and extracellular matrix remodeling. Extra-pulmonary effects of PFOB, 
such as effects on neuronal cell alteration and effects in the brain should be determined 
in future studies before this therapy can be studied in human prenatal studies. 
A ventilation technique known as liquid ventilation stems from the year 1929, when 
Von Neergard incidentally found that filling the lungs with saline solution dramati-
cally improved the static pulmonary compliance in cats [5]. After further investigation 
of different types of liquids, Clark and Gollan received fame for their experiments of 
liquid ventilation by using perfluorocarbon in mice for the first time [6]. In 1989, liquid 
ventilation showed its potential in a first trial in prematurely born neonates [7]. In CDH 
Hirschl and colleagues conducted a randomized trial in sheep [8] and concluded that 
partial liquid ventilation (PLV) during extracorporeal membrane oxygenation may have 
beneficial effects on pulmonary function and gas exchange. Pranikoff and coworkers 
applied partial liquid ventilation with the use of perflubron in four CDH patients who 
required extracorporeal life support postnatally [9]. They concluded that this therapy 
was possibly associated with improvement in gas exchange and lung compliance. 
Later on Hirschl and colleagues conducted a randomized trial in 13 CDH infants who 
were randomized to either PLV perfluorocarbon-induced lung growth or conventional 
mechanical ventilation [10]. They found that perfluorocarbon-induced lung growth can 
be performed safely. However, when this trial was still ongoing, in 2001 the FDA decided 
that all clinical trials with perflubron had to be discontinued until safely data were avail-
able. That decision was based on findings that adults with acute respiratory distress 
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syndrome randomized to PLV had no improved outcome and experienced more adverse 
events such as more pneumothoraces, hypoxic episodes and hypotensive episodes [11]. 
Nevertheless in China adults with acute respiratory distress syndrome are currently re-
cruited in a randomized controlled trial of perfluorocarbon instillation (NCT01391481).
In normal fetal lung development, the lungs are liquid-filled and fluid secretion and 
fetal breathing movements are necessary for lung maturation [12]. In abnormal situa-
tions such as in prematurely born neonates in which transition from liquid-breathing 
to an air-breathing situation takes place prematurely, and in fetuses with an amniotic 
fluid-deficient environment, lung development is likely to be immature resulting in lung 
related problems postnatally. Instillation of PFOB in the trachea approximately to 
functional residual capacity can simulate the antenatal situation of liquid-filled airway 
branches. Thereafter, gas tidal volumes are delivered by using a mechanical conventional 
ventilator. This is called partial liquid ventilation. In total liquid ventilation the lungs are 
completely filled with a liquid whereas in partial liquid ventilation the lungs are filled 
until functional residual capacity. Perfluorocarbons have a high solubility for respiratory 
gases [6]. By eliminating the air-liquid interface, lung compliance can be improved [13]. 
Due to their dense characteristics, PFOB gravitate to dependent part of the lungs, and 
collapsed regions can be re-opened and ventilation/ perfusion ratio may improve [13]. 
Next to these advantages, pulmonary inflammation and injury may be reduced as a 
result of decreased cytokine production. Moreover, in pigs receiving PLV a redistribution 
of pulmonary blood flow away from the dependent region of the lung was found, as well 
as increased vascular resistance and pulmonary artery pressure [14].
In line with the experiments of the article from Herber-Jonat and colleagues, we know 
that a complete obstruction of the fetal airways results in massive lung distension and a 
poly-alveolar lung the so called congenital high airway obstruction syndrome (CHAOS)
[15]. Taking this concept, the TOTAL trial (NCT01240057) is an ongoing trial of tracheal 
occlusion to accelerate lung growth in prenatally diagnosed high-risk CDH infants strati-
fied according to observed to expected lung-to-head ratio. Another study is planning to 
include patients for early tracheal occlusion (NCT01731509). Moreover, a trial known as 
the VICI-trial (NTR 1310) was performed in nine European centers to identify the optimal 
ventilation strategy in antenatally diagnosed CDH infants. These studies might solve 
some of the challenges that stand in the way of further improvement in the treatment 
of CDH infants. Herber-Jonat and colleagues conducted a randomized laboratory study 
in animals with a unique study design. Instead of only obstructing the fetal airway, they 
antenatally filled the lungs with PFOB, thus simulating the situation in normal lung 
development. However, the authors focused on mRNA expression and protein analyses 
were not performed which should be a serious limitation for the interpretation of the 
results. Secondly, in this study diaphragmatic hernia was induced by fetal surgery of 
normal programmed lungs which makes the pathophysiology of developing CDH 
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potentially different as compared to humans. Moreover, in rabbits term birth occurs in 
the early saccular stage of lung development whereas in humans the alveolarization 
process has taken place already during gestation. Therefore a different respons on PFOB 
may be found in humans. 
Although the prognosis of CDH has improved over the last years, it is still a life-
threatening disease and ventilator induced lung injury remains a significant problem. 
Conclusive findings from randomized clinical trials may enable us to further improve 
the outcome of CDH. Once adverse long term effects of PLV have been excluded, setting 
up a randomized clinical trial of antenatal or postnatal instillation of PFOB in carefully 
selected patients might be a promising tool to further investigate alternative ways of 
supporting the vulnerable lungs in high risk newborns with CDH. 
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Artificial ventilation of the lungs has been used to provide gas exchange both in healthy 
lungs and in diseased lungs due to a variety of congenital and acquired abnormalities. 
During the course of time the mode of ventilation has varied from negative pressure 
ventilation to positive pressure ventilation either in low or high frequency. The best way 
to ventilate children with acute respiratory failure has not yet been defined however. 
One of the problems is that these children have different underlying pathology and 
that we also have to take into account age-related factors such as lung growth and 
responses from the innate and adaptive immune systems [1]. In chapter 2 we system-
atically reviewed randomized controlled trials comparing different ventilation modes 
used in critically ill children (term born up to 18 years of age) to find evidence for the 
best mode of ventilation. It is obvious that a “one size fits all” approach would be an 
overt oversimplification of the underlying problem as there is no standard method for 
measuring the effect of the mode of ventilation. In this regard, Randolph et al., sug-
gested that long-term morbidity would be a more sensitive indicator than mortality or 
duration of ventilation [2, 3]. As long-term morbidity data were not available we pooled 
the results of five randomized clinical trials assessing the following outcomes: length 
of ventilation, oxygenation, chronic lung disease (CLD), mortality and weaning. Still we 
failed to find sufficient evidence for the best ventilation mode in critically ill children 
beyond the newborn period.
Therefore future clinical studies should be designed in such a way that modes of ven-
tilation can be related to outcome [4, 5]. This strong recommendation from the pediatric 
acute lung injury consensus conference for mechanical ventilation of pediatric patients 
with acute respiratory distress syndrome is in line with our conclusions as formulated 
in chapter 2 [1]. The Pediatric Acute Lung Injury Ventilation (PALIVE) study concluded 
that a robust study with reduction in mortality as an endpoint would take four years 
and 60 PICUs to enroll 800 patients, which is only possible by international collabora-
tion [6]. If nevertheless a mode of ventilation could be selected for a certain group of 
patients, target ventilator settings with concomitant adjustment of ventilation need to 
be determined. 
In chapter 3 we described the implementation of such an algorithm for use in our 
PICU. Implementation of the algorithm improved physician adherence and this was 
sustained over time. However the maximum adherence was only 84% and was mainly 
achieved in the so-called “no-lung-disease” group. This result was obtained by intensive 
education and training indicating that implementation strategies tailored to specific cir-
cumstances are needed to increase adherence to protocols and guidelines. In healthcare 
in general and in particular in the intensive care setting it is still a challenge, however, to 
successfully implement evidence based strategies or therapies into daily clinical practice 
[7-10]. Apart from attempts to change healthcare professionals’ behavior, organizational 
and structural (non-behavioral) implementation strategies need to be combined with 
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education and training. Therefore, getting insight in all influencing factors (e.g. human 
behavior, organization, provider characteristics) is a crucial first step to a tailored and 
multifaceted implementation strategy which could be more effective than the earlier 
mentioned “one size fits all” strategy. I agree with the authors [4], that international 
collaboration is imperative to design and perform large multicenter studies. chapter 
3 also illustrates that protocols guiding daily care are a prerequisite for collaborative 
studies. Scientific societies like the European Society of Pediatric and Neonatal intensive 
Care (ESPNIC) or the Society of Critical Care Medicine (SCCM) should take the lead in 
organizing these studies.
Protective ventilation of the lungs
Despite optimal ventilator settings, gas exchange nay still be insufficient. Researchers 
have therefore explored alternative ways to recruit lung volume to participate in gas 
exchange. In 1992 an editorial by Burkhard Lachmann entitled “Open up the lung and 
keep the lung open” introduced the concept of recruiting atelectatic lung volume and 
ventilating the lung in the least harmful way [11]. This basic concept is still valid and 
just recently Amato nicely described the importance of the second part of the concept: 
Ventilate the lung in the least harmful way [12]. The focus on reducing tidal volume, 
initiated by the ARDS Network trial, means a shift away from Lachmann’s original ideas 
[13]. Amato clearly demonstrated in adults that decreases in pressure amplitudes were 
significantly associated with increased survival [12]. Although the same physiological 
paradigms underlying the low tidal volume approach seem to apply to children, there 
are currently no pediatric studies showing any changes in outcome. Several reasons 
could be suggested. First of all the incidence, prevalence and mortality of pediatric ARDS 
are much lower than those of adult ARDS, so that mortality seems an inappropriate 
endpoint for prospective studies [14-16]. As stated earlier, long term morbidity might a 
better outcome parameter but clear definitions and data are lacking. Secondly, both the 
etiology of pediatric ARDS and the associated comorbidity might be different from adult 
ARDS. Lastly, recoverability of the lung might be different between adults and children, 
with inherent differences in the long term outcome of mechanical ventilation. Future 
research will need to focus on alternative outcome parameters including long term 
changes of lung function. Currently only adult data and animal data support the use of 
low tidal volume strategies in children on mechanical ventilation. 
Several therapeutic strategies to increase recruitment of the lung and to improve gas 
exchange without increasing plateau pressures have been studied. Prone positioning is 
a method to recruit lung tissue; the patient is turned from supine to prone position thus 
allowing gravity to achieve changes in ventilation and perfusion of the lung. After sev-
eral failed studies Gattinoni et al. finally showed improved survival in prone positioned 
patients, supporting the idea of “opening” up the lung [17].
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Endotracheal application of surfactant is another of these therapies, and this has 
proven to be of benefit to premature neonates, both in randomized controlled trials 
as well as in meta-analyses and Cochrane reviews [18, 19]. The use of surfactant in the 
pediatric population beyond the neonatal period has shown mixed results in trials. It 
usually improved the oxygenation but without a beneficial effect on outcome and venti-
lator free days [20, 21]. Therefore the routine use of surfactant cannot be recommended 
[22]. In selected cases it may be feasible however, and we used surfactant as diagnostic/
therapeutic tool (chapter 7) to test recruitability in individual patients during prolonged 
(i.e. 21 days or longer) extracorporeal membrane oxygenation (ECMO). 
Another therapeutic approach to improve gas exchange is the use of perfluorocar-
bons (PFCs). Despite promising pre-clinical studies [23, 24] and initial enthusiasm in 
early clinical trials [25, 26] a larger randomized study showed no difference in mortality 
and patients ventilated with PFCs had fewer ventilator-free days [27]. Those patients 
also experienced more adverse events such as pneumothorax and hypoxic- and hypo-
tensive episodes. These negative effects meant the end of the pharmaceutical company 
that supported these trials. The use of PFCs can still be attractive, however, for their 
anti-inflammatory effects and their potent to clear the airway from debris and stabilize 
the lung [28]. However currently the routine use of perfluorocarbons cannot be recom-
mended, but its use in very special circumstances, for example to stimulate lung growth 
in neonates with congenital diaphragmatic hernia, might prove to be of benefit [29, 
30]. We used PFCs to recruit lung volume in one case during prolonged ECMO (chapter 
7). To prevent ongoing lung injury other strategies can include the acceptance of mild 
hypoxia and hypercapnia in these patients. Ultimately the least harmful way to ventilate 
a lung is obviously to refrain from artificial ventilation, and to use other means of gas 
exchange to sustain life whereby hypercarbia and/or acidosis is avoided.
Extra corporeal membrane oxygenation (EcMO)
The Pediatric Acute Lung Injury Consensus Conference Group strongly recommends the 
use of ECMO when respiratory failure is believed to be reversible and lung protective 
strategies result in inadequate gas exchange [31]. For children older than 4 weeks the 
type of ECMO to be used, the optimal way of vascular access and the optimal duration 
of ECMO are not yet well defined. 
The first reported use of ECMO in the neonatal population dates from 1977 [32]. Since 
then over 36,000 neonates have been treated with ECMO [33]. In 2008 a Cochrane re-
view of four randomized neonatal ECMO trials demonstrated strong benefit of ECMO on 
mortality compared to conventional ventilation, in that one death could be prevented 
with a number needed to treat of only three [34]. Over the last five years the number of 
neonates treated with ECMO for non-CDH respiratory failure has been slowly declining 
[35]. ECMO treatment for meconium aspiration syndrome (MAS) has decreased since the 
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end of the last century due to improvements in obstetric and neonatal intensive care [36, 
37]. For a long time MAS was the most frequent non-CDH indication for ECMO resulting 
in the highest survival rate of all neonatal ECMO indications. To prevent reperfusion 
injury the care for children with MAS with an oxygenation index of 25 or higher is best 
discussed with or undertaken in an ECMO center [37]. Regarding CDH the role of ECMO 
is still not completely clear as many centers use ECMO either according to strict criteria 
or as a last attempt to save an individual newborn’s life. In the VICI trial no definitive 
advantage of ECMO could be identified but survival was statistically better in patients 
treated in the ECMO centers without the actual use of ECMO [38].
In chapter 4 we describe the current indications and contraindications of non-neona-
tal ECMO. In the case of children older than 4 weeks a tailored ECMO approach is needed 
to account for the wider diversity of disease. Furthermore, care for these patients needs 
to be centralized. The 2014 version 1.8 ELSO guidelines for ECMO centers states that a 
minimum of six ECMO cases per year is a criterion for quality of care. The arguments used 
are strong and self-explanatory arguments: Both the cost effectiveness and the clinical 
expertise are endangered with fewer than six cases per year. Recently a minimum of 20 
cases per year was suggested for centers that offer ECMO for adult patients with adult 
acute respiratory failure [39]. Pediatric ECMO centers with a caseload of 22 or more show 
improved survival [40].
Due to the diverse nature of cardio-pulmonary failure it is difficult to define when 
ECMO is indicated. Evidence based criteria are even lacking for the initiation of ECMO 
in the case of pediatric acute respiratory distress syndrome (PARDS), which is a com-
mon indication for ECMO. The best indices for defining the severity of PARDS are the 
oxygenation index and PaO2/FiO2, although their ability to predict poor outcome for 
individual patients is poor [31].
Lactate as a biomarker
Increased arterial lactate, one of the end products of carbohydrate metabolism, was 
shown to be related to increased risk for mortality in critically ill adult patients [41, 42]. 
A study of goal-directed therapy in adult septic shock patients used lactate as a primary 
endpoint and showed improved outcome [43]. Reperfusion of tissue can result in a rise in 
arterial lactate because energy is needed for lactate formation [44]. Differences in lactate 
level can also be related, however, to age, time or other non-disease related situations 
[45, 46]. To account for these confounding factors, dynamic lactate indices have been 
developed that take into account duration of elevated lactate level and trend over time 
[47, 48]. A study presented in chapter 5 evaluated the predictive value for mortality of 
static lactate and dynamic lactate indices in the prediction of. We found that in neonatal 
ECMO lactate did not predict mortality and that in pediatric ECMO static arterial lactate 
was the better predictor for mortality in patients with primary respiratory disease. In this 
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study, however, repeat measurements were not performed on the guidance of changes 
in clinical parameters, which should be done in future investigations. The same holds 
true for the concept of lactate-based therapy, which was successful in adult patients 
with sepsis who did not receive ECMO treatment. Apart from changes in lactate there are 
many descriptive studies about the latest and most predictive biomarkers for individual 
diseases and age groups. For example, more than 20 different biomarkers have been 
suggested to predict the development of bronchopulmonary dysplasia in prematurely 
born neonates, without finding the Holy Grail so far. 
ECMO and Transposition of the great arteries (TGA)
Of all congenital heart defects, 5 to 9% are diagnosed as “simple” D-transposition of 
the great arteries (TGA) and this is the most frequent type of congenital cyanotic heart 
lesions. In this situation two parallel circulations exist: deoxygenated blood is re-circu-
lated through the systemic circulation and oxygenated blood keeps circulating in the 
pulmonary circulation [49]. Profound hypoxemia may occur when the two circulations 
are inadequately mixed, resulting in death. Under these circumstances intra-cardiac, 
atrial or ventricular connections and a patent ductus arteriosus facilitate mixing of both 
circulations. If inadequate mixing occurs in the pre-operative postnatal period, urgent 
pharmacologic or interventional therapy, such as a balloon septostomy (Rashkind pro-
cedure), may be needed to provide adequate tissue oxygenation. When these measures 
fail to achieve adequate oxygenation two options remain. The first option is a so-called 
emergency arterial switch operation (ASO), which carries increased risks. The second op-
tion is to oxygenate the blood by using an extra corporeal circuit. In chapter 6 we report 
six pre-operative ECMO patients with TGA. Five of those had pulmonary hypertension 
and one had persistent inadequate mixing of both circulations. These patients are not 
the first reported cases to receive pre-operative ECMO in TGA [50] but we provided 
additional information and were the first to show one year follow-up results of these 
patients. We discussed the difference between venovenous and venoarterial ECMO in 
this condition and argued that venovenous ECMO might be a good alternative to urgent 
ASO. To demonstrate a benefit of either treatment option in a prospective randomized 
clinical trial will be difficult as the reported incidence of severe pulmonary hypertension 
in TGA is only 5.3% [51]. Therefore a large number of pediatric cardiac centers would be 
needed to statistically prove differences in outcome between both treatment options.
Prolonged ECMO
Despite the enormous amount of patient data in the ELSO database this database has 
its limitations. 
Although outcome is registered no detailed information is available on how this was 
achieved. Moreover, data on diagnostic and therapeutic interventions are not consis-
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tently registered and no internal control of the data is provided or obligatory. It is there-
fore difficult to evaluate individual therapies during ECMO, especially during long ECMO 
runs where timing of interventions might be crucial to their success or failure. In chapter 
7 we report our case series of patients treated with ECMO for 21 days or longer, which 
occurs increasingly nowadays. Special attention was paid to the diagnostic procedures 
to assess reversibility of disease and to interventions needed, as the management and 
prognostication of these patients remains a challenge.
Most of these patients are so-called respiratory ECMO patients. The initial diagnosis 
may vary widely but for most patients ECMO is initiated to reduce the risk of ventilator-
induced lung injury (VILI) or to maintain oxygenation or decarboxylation with failing 
mechanical ventilation. In practice it appears that most patients experience a period of 
extremely low or even no tidal volumes. There is currently no clear guideline on how to 
ventilate these patients.
CT scanning of the chest either in combination with abdominal scanning can provide 
quick and reliable information and can guide surgical or other interventions during 
ECMO [52]. When contrast is used during CT scanning, attention should be paid to the 
additional circulating blood volume and in case of venoarterial ECMO, to the amount of 
blood bypassing the lung through the ECMO system [53, 54]. 
Like in ARDS patients, for patients treated with ECMO interventions can be initiated 
to recruit lung volume or to improve oxygenation [55]. Few of those have been proven 
beneficial and some, like prone positioning, are inherently more dangerous for patients 
on ECMO. To date no good data exist about the usefulness of these interventions in 
extreme respiratory failure patients on ECMO, in which standard lung protective set-
tings even after prolonged therapy do not seem to improve the patients’ condition. In 
a prolonged ECMO setting these attempts to improve gas exchange might prove to be 
beneficial as the risks and costs of ECMO could be reduced by reducing time on ECMO. 
However it is as yet unclear whether this is beneficial and if so, what would be the ap-
propriate timing of these procedures.
The reduction in sedatives consumption can lead to more interactive patients. Some 
patients can thus become eligible for extubation. This so-called awake type of ECMO 
in combination with minimal sedation is one of the newest insights in ECMO treat-
ment,  which can possibly help to prevent critical illness myopathy and neuropathy 
(CRIMYNE) [56-58]. In some cases, however, efforts to minimize sedation and to extubate 
the patient do not seem to be successful. Despite adequate gas exchange and reducing 
hypercarbic breathing drive some patients seem to be in respiratory distress. They show 
signs of dyspneic breathing or nasal flaring although when asked they report to feel fine. 
This situation requires a different mindset of the healthcare team and the parents [59].
Most patients experience a period with very low to no tidal volumes. In our cohort of 
patients on prolonged ECMO, tracheal occlusion or bronchial occlusion occurred fre-
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quently as a complication and routine bronchoscopy in these patients seems indicated 
to optimize ventilation. Other restricting factors to lung recruitment should be evalu-
ated. Timing of these interventions remains controversial, especially since recoverability 
of the primary disease as well as the potential to add secondary damage need to be 
balanced.
When ECMO has been started but there are still uncertainties about the nature or 
reversibility of disease, both a CT scan and an open lung biopsy can help to classify the 
disease and guide therapy.
Based on our experience described in chapter 7 we propose that in patients on ECMO 
high ventilator settings leading to increased risk of VILI should be avoided. In the early 
phase peak pressures as well as tidal volumes should be kept low. Appropriate PEEP 
levels to keep the lung open should be chosen but in many patients no ventilation 
will be possible for several days or even weeks. All patients should be evaluated for 
potential airway obstruction and restrictive pleural, thoracic or abdominal abnormali-
ties that might be treated. Future research should focus on long-term recoverability of 
lung function. Evaluating lungs function by standardized recruitment maneuvers once 
every week and supplemented by standardized CT scans on days 14 and 28 in all ELSO 
ECMO centers could provide a better categorization of lung pathology and potential 
lung recoverability, especially if this data is consistently added to the ELSO registry.
Surgery and ECMO
In chapter 8 we show the potential benefit and feasibility of open lung biopsy on 
ECMO. All open lung biopsies during ECMO from the two designated Dutch neonatal 
ECMO centers were analyzed as well as the clinical impact of the biopsy results. There 
is a major difference in this regard between newborns and older children. In the new-
born the main diagnosis to be ruled out is alveolar capillary dysplasia/misalignment of 
pulmonary veins (ACD/MPV), which is a reason to consider continuation of ECMO as 
futile. For obvious reasons this diagnosis should ideally be made prior to the institution 
of ECMO but unfortunately in many cases the clinical condition of the individual child 
is not stable enough to justify such an approach. Genetic evaluation predominantly 
focusing on the FOXF1 gene mutation can support the diagnosis but as approximately 
only 50% of patients carry this mutation, false negative cases do occur. Other diagnoses 
leading to reconsidering the continuation of ECMO are lymphangiomatosis of the lung 
and the very rare cases of interstitial glycogenosis. In most reports from high volume 
ECMO centers we can find cases of withdrawal of therapy. Another diagnosis that should 
be proven or ruled out is a surfactant-B deficiency as the cause of the respiratory failure, 
preferably before starting ECMO treatment by DNA analysis of blood and/or tracheal 
aspirates. Deciding on futility of treatment in non-neonatal ECMO can be very difficult 
or even impossible [60] Biopsy of the lung could guide therapy, however, seeing that the 
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result was a reason for a change in therapy in most adult patients, but not in all pediatric 
patients. It may be the only option to obtain a diagnosis while the patient is alive [61, 
62]. In case no biopsy result is available before death of the patient it is essential to ob-
tain a postmortem tissue specimen in the first hours after death by open biopsy. When 
postmortem lung biopsy is performed, it preserves the opportunity for the parents to 
take their child home, as is done frequently in the Netherlands.
In chapter 9 we analyzed the surgical pitfalls of the correction of CDH on ECMO, 
notably the risk of bleeding, and found that despite anticoagulation this practice is safe 
and feasible.
There is no consensus on the optimal timing of surgical correction of a diaphragmatic 
defect although in general the risk of bleeding is higher during ECMO then after ECMO 
[63]. In our institution over the years we shifted from late repair to repair 48-72 hours 
after the initiation of ECMO so as to profit from ECMO support in case of surgical com-
plications, decreased lung volume and possible pulmonary hypertension. There are no 
RCTs evaluating the best timing of the procedure and many clinics are probably not 
willing to participate in such a trial against the background of their best practice ”gut 
feeling” on this subject. Besides timing of repair, also expertise in repairing such as the 
optimal patch material and the determination of the size of the patch are points to 
investigate systematically. In principle a classic laparotomy provides the best view on 
the defect. The treatment of bleeding sites during and after repair is a fundamental part 
of the success rate and no guidelines are at present available to determine best practice. 
Newer ECMO systems may provide for absence of systemic anticoagulation during the 
surgical correction of the diaphragmatic defect.
Pharmacotherapy and ECMO
ECMO in itself is not a cure, it is merely a life-sustaining therapy on the way to recovery. 
Pharmacotherapy plays an important role in both the management and treatment of 
ECMO patients. Analgesics and sedatives, inotropes, anticoagulants and antibiotics 
are routinely given to almost all patients. Furthermore antivirals, anticonvulsants and 
anti-inflammatory drugs may be administered during the course of ECMO. Although 
by now we have a fair amount of knowledge on the changes of pharmacokinetics (PK) 
in children, clear pediatric data are still lacking for most drugs [64]. Dosing is mostly 
based on adult healthy volunteer data and extrapolated to children. Ontogeny plays an 
important role in the changes of PK and pharmacodynamics (PD) in children [65]. With 
maturation of organ and enzyme functions the PK and PD change rapidly over time 
from the newborn to the adolescent age [65, 66]. Besides ontogeny critical illness and 
multiple organ dysfunction will change PK and thereby total drug exposure. Fluid loss, 
fluid overload and changes in protein content can influence volume of distribution, e.g. 
how the drug disperses in the body. While organ perfusion will change in accordance 
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with cardiac function, renally cleared drugs will be influenced by renal function. For 
hepatically cleared drugs it is more difficult to estimate clearance. The most important 
mechanism of liver clearance is via the cytochrome P450 enzyme system. Several authors 
have shown that this system is inhibited during critical illness [67-70]. Vet et al. recently 
showed a clear correlation of midazolam clearance and CRP in that high CRP levels were 
associated with a reduced midazolam clearance [69, 71]. Adding ECMO to this already 
complex system complicates the situation further. The earliest reports of altered PK dur-
ing ECMO date from the 1980s and 1990s, showing altered PK for fentanyl and morphine 
[72, 73]. The ECMO system itself was shown to adsorp considerable amounts of drugs in 
either the membrane or tubing [72-74]. There seems to be a clear relationship between 
lipophilicity and adsorption rates where highly lipophilic drugs such as midazolam and 
midazolam are almost completely adsorped in silicone based membranes [75]. Still, 
the new smaller ECMO circuits with hollow fiber membranes considerably reduced the 
amount of loss of the more lipophilic drugs [75]. Thus, changes in ECMO system design 
may have profound effects on drug availability indicating the need to study drug ad-
sorption in newly designed circuits. Changes in coating may also affect drug adsorption 
and should be taken into account when changing ECMO circuits [76, 77].
Recently Shekar et al. performed a series of in vitro studies showing variable adsorp-
tion rates of antibiotic and antimycotic drugs [78]. Furthermore both lipophilicity and 
the amount of protein binding were associated with the amount of drug loss [78]. Mulla 
et al. showed that both the membrane and the tubing can be saturated with drugs al-
though in vitro studies contradict each other on differences in drug adsorption between 
used and new ECMO circuits [74, 75].
In chapter 10 we give an overview of the different aspects of PK and PD in ECMO 
patients by reviewing the literature. 
Initial reports show increased volume of distribution with decreased clearance, sug-
gesting increased loading doses and reduced maintenance doses. Increasingly there are 
reports on increased clearance on ECMO [79, 80]. Several mechanisms may play a role 
here. Compared to pre ECMO conditions patients rapidly improve on ECMO with both 
hemodynamics and oxygenation being restored. Improvements in organ perfusion may 
result in improved drug clearance over time. Secondly, some drugs such as meropenem 
are sensitive to light if exposed for more than three hours [81]. In the normal clinical set-
ting this may be irrelevant but it may have played a role in a study by Shekar et al. who 
found increased clearance of meropenem in ECMO patients [79]. In vivo case reports and 
cohort studies are increasingly showing PK in individual drugs. For some drugs such as 
oseltamivir or cefotaxim no change in dosing seems to be necessary, which is valuable 
information [80, 82]. For other drugs the clearance is significantly altered necessitating 
dose changes, but more often data is conflicting as both decreased and increased clear-
ance over time is reported [79, 83-85]. 
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For sedatives and analgesics it is clear that lipophilic drugs such as fentanyl, propofol 
and midazolam are adsorped to a large extent and several studies show increased dosing 
requirements for these drugs. Initial drop in sedatives will result in high doses. Changes 
in clearance over time may subsequently result in overdosing and drug dependency 
with severe withdrawal syndrome as a result. Efforts to wake our ECMO patients and 
have them extubated are sometimes frustrated by this problem necessitating prolonged 
intubation during weaning of sedatives.
Especially with prolonged ECMO treatment it is difficult to predict the changes in PK 
over time. Changing ECMO systems, changes in fluid overload, organ function and in-
flammation all influence PK and may result in either under or oversedation. The current 
efforts to identify specific drug characteristics that predict PK changes in ECMO patients 
should be continued supplemented by case reports on rare drugs. Ultimately larger 
cohorts such as the ASAPECMO initiative are needed to identify covariates that predict 
changes over time. To increase the accuracy of these models this should be evaluated 
in conjunction with non- ECMO data. By combining non-ECMO and ECMO data Krekels 
et al. demonstrated that a non-ECMO model would predict ECMO drug levels accurately 
showing that for morphine ECMO itself is not a relevant covariate [86]. 
In vitro testing should be done on all new ECMO circuits and coatings to predict drug 
adsorption with an added focus on saturation and potential reversal of adsorption dur-
ing prolonged ECMO. Then possible routine measurement of frequently used drugs will 
enable accurate dosing in these patients. 
A new mini pump for ECMO
In chapter 11 we describe a case series of 241 consecutive ECMO patients treated with 
a newly developed mini pump with a very small priming volume. In comparison with 
the classic ECMO therapy using a roller pump, a significant priming volume of the ECMO 
circuit and a different material of the membranes, the results of the use of the mini pump 
system are at least comparable with the ”old” system. It would have been ideal to have 
had a different design of our study such as a comparative effectiveness design of our 
prospective data collection. However the use of a new system places treatment teams 
for other challenges and the effect of a learning curve should not be underestimated 
before a real comparative approach could be tested. Our study describes the largest 
international data collection within a reasonable time frame and forms as such a refer-
ence for future studies regarding the feasibility, efficacy and complications during the 
use of this mini pump system. An additional advantage given the size of the system is 
the opportunity for transport of patients on ECMO and its ease of use in emergency situ-
ations such as rescue therapy during resuscitation either inside or outside the hospital. 
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In chapter 12 we discuss the current status of the use of perfluorocarbons (PFCs) in re-
spiratory failure. Our editorial comments on the paper by Herber-Jonat, which describes 
the prenatal Intrapulmonary instillation of PFCs in rabbits with induced congenital 
diaphragmatic hernia and shows that the use of PFCs resulted in an improvement of 
lung-to-body weight ratio of these lungs.
considerations and perspectives 
Primum non nocere, meaning “first do no harm” and often attributed to Hippocrates but 
traceable to Thomas Inman (1820-1876), is in itself the guidance for medical care [87]. 
In the treatment of patients with failure of gas exchange, the stakes are high and “harm” 
lurks around the corner. Too little is known about the “harm” inflicted by mechanical 
ventilation, ECMO, or both in synergy. As ECMO is a high-tech treatment modality, 
there is considerable risk of ”iatrogenesis” on top of the potential unwanted effects for 
the individual patient. Focus on survival as outcome parameter still drives the current 
literature although ECMO seems to have evolved from a rescue therapy to a means of 
chronic support for failing gas exchange and even as a means to prevent secondary 
lung damage. Super acute ECMO resuscitation or ECPR represents the other end of the 
spectrum where the primary focus still lies on increasing survival. Management of ECMO 
patients is still highly experience based. Large databases like the ELSO registry report on 
worldwide averages in outcome of different patient groups, but cannot explain differ-
ences in outcome between different centers. Moreover there is no adequate system of 
quality control of the data provided by the centers. The offered possibility to benchmark 
the individual results of the participating centers does not benefit the group as a whole. 
Data on diagnostics and therapeutic interventions are not consistently registered in the 
ELSO registry. Individual centers have to focus on all items and must draw conclusions 
from the available information. This approach therefore cannot lead to a universal set of 
treatment guidelines. More detailed data collection might make it possible to conduct 
larger comparative effectiveness trials to identify effective treatment modalities or care 
bundles associated with better outcome, as is currently done in the field of traumatic 
brain injury [88-90].
Another option is to reduce the number of centers treating these “difficult” cases. In 
the Netherlands the balance between centralization and individual freedom to treat 
is changing. Over the last decade ECMO patients on adult ICUs have been centralized, 
whereas PICUs more and more start their own ECMO programs and individual patients 
are consequently subject to the learning curve effects of these centers. At present ECMO 
is offered in the four pediatric cardiac centers in the Netherlands as a way of postop-
erative cardiac support in direct relation to cardio pulmonary bypass. However, patient 
with other indications should all be treated in the two designated ECMO centers in the 
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Netherlands as approved by the Dutch Healthcare Authority NZA. Before widespread 
use can be deployed several issues need to be clarified.
Device technology
Despite progress in design, reliability and costs, the manufacturers of ECMO related 
equipment should take their responsibility to manufacture state of the art equipment 
specialized for neonatal and pediatric use. One of the “big three” issues in ECMO care is 
cannula technology and availability of these cannulas. Recently many types of ECMO 
cannula have been withdrawn from the market and especially the availability of heparin 
coated types has become minimal. As with other medical products, the vulnerability of 
production processes frequently results in shortages in cannulas. Whether surgical or 
echo-guided percutaneous cannulation is preferable needs to be investigated. Innova-
tions such as a Dacron cuff might help to stabilize ECMO cannula position in prolonged 
ECMO runs and possibly prevent infection.
Anticoagulation technology
The traditional use of heparin as the major drug for anticoagulation will remain. How-
ever the amount of anticoagulation will need to be targeted to age, disease severity and 
type of equipment. The way of testing the level of anticoagulation needs to become 
universal, as only then international comparisons become valid. Unfortunately, struc-
tured collaboration between ECMO treatment teams and hematologists is still minimal 
in many institutions. Multicenter approaches are essential to tackle this problem [91]. 
Patient selection
In analogy to the results of the CESAR trial in adults, where referral to an ECMO center 
resulted in improved survival, it would be worthwhile to know which pediatric patients 
with what diagnoses will benefit from referral to an ECMO center [92]. Compiling a list of 
diagnoses with dismal outcome is equally important. Alternatively the conclusion could 
be that contraindications are disappearing [93]. Up to then liberal communication about 
early referral between centers is desired. This will for the individual patient not result in 
automatically start of ECMO in the centers upon arrival. In our experience, ECMO was 
not started in about 40% of the non-neonatal patients transferred for ECMO. A change 
in supportive therapy and/or reevaluation of the indication or contraindication deter-
mined whether ECMO was started. Even today no international consensus exists on the 
indications for non-neonatal ECMO candidates and many centers are not aware of the 
relative contribution in the mortality rates of patients with isolated respiratory failure 
in their respective units over the last five years. These data could determine the role of 
ECMO in the prevention of mortality. 
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With the increasing complexity of ECMO patients, a multidisciplinary approach is 
essential to manage these patients successfully [94]. The entire ECMO process starts 
with the indication for ECMO, but continues far longer than the eventual decannula-
tion. Long-term follow up care must form an integral part of an ECMO program. The 
risks and benefits for the individual patients of diagnostic or therapeutic interventions 
during ECMO need to be weighed by an experienced team with members from a wide 
range of disciplines and obviously the infrastructure should allow for performing these 
interventions as safely as possible. Concentration of ECMO patients does therefore not 
only pertain to the ECMO physicians, perfusionists and ECMO nurses but should involve 
the whole range of pediatric specialists, rehabilitation and physiotherapists. 
In conclusion: ECMO has found a place in the contemporary arsenal to treat the in-
dividual pediatric patient but is still a modality with inherent high risk factors. ECMO 
should therefore be applied only in designated centers with experienced teams. Fur-
thermore, survivors should be included in a long-term follow-up program to establish 
any long term morbidity. It is the responsibility of the ECMO teams to share the informa-
tion obtained with the medical and layman communities.
ECMO is a fascinating relatively new technology to which the words of Spinoza may 
still apply:
“Be not astonished at new ideas; for it is well known to you that a thing does not therefore 
cease to be true because it is not accepted by many.” - Spinoza (1632-1677)
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suMMARy
The overall aim of this thesis is to provide scientific data that will help to guide the treat-
ment of failing gas exchange in pediatric patients.
Part 1. Mechanical ventilation for failing gas exchange in children 
In chapter 2 we search the literature for evidence to provide the optimal ventilatory 
modes for artificial ventilation of pediatric patients. We show that the available litera-
ture does not provide sufficient evidence on the best ventilation mode in critically ill 
children beyond the newborn period. With regards to high-frequency ventilation we 
found that it provided better oxygenation after 72 hours than conventional ventilation. 
However, there is no evidence that high-frequency ventilation would reduce mortality 
and length of ventilation. With this knowledge we defined our institutional algorithm 
for ventilation of critically ill children. In chapter 3 we describe the implementation of 
such an algorithm for use at our PICU. This algorithm improves physician’s adherence to 
the ventilation algorithm and the effect was shown to be sustainable over time.
When lung protective ventilation does not provide sufficient gas exchange an alterna-
tive way to supply oxygen and to remove carbon dioxide is Extracorporeal Membrane 
Oxygenation (ECMO). In chapter 4 we describe the available evidence for the use of 
pediatric ECMO in respiratory and circulatory failure. With this evidence at hand we 
propose indications and contraindications for non-neonatal ECMO that can for the base 
for international collaboration. 
Part 2. Extracorporeal Membrane Oxygenation to assist gas exchange in 
children
In chapter 5 we focus on the predictive value of lactate measurements. Lactate, is an 
end product of carbohydrate metabolism and correlates to both severity of illness and 
mortality. We evaluated the significance of static lactate and dynamic lactate indices in 
the prediction of mortality. The outcome of this study illustrated that in neonatal ECMO 
lactate did not predict mortality and in pediatric ECMO static arterial lactate was the 
better predictor for mortality in patients with primary respiratory disease.
In chapter 6 we present a retrospective analysis of the potential role of preoperative 
ECMO in neonates born with transposition of the great arteries with severe hypoxemia 
despite conventional measures. We show that despite interventions to improve oxygen-
ation, critical hypoxemia does occur and that preoperative ECMO can help to stabilize 
the patient and allows for subsequent surgical correction of the defect.
With more and more patients on ECMO for increasing periods of time, well defined 
guidelines in the literature how to manage these patients are missing. We reported 
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in chapter 7 our patients on ECMO for 21 days or longer. We show that especially in 
respiratory ECMO cases survival to discharge can be 44%. We show that both medication 
and interventions play an important role in the management of these prolonged ECMO 
cases.
One of those interventions during ECMO is open lung biopsy. This technique is used 
to determine the origin of the disease and sometimes can be used to guide therapy of 
to determine futility. In chapter 8 we report on the feasibility and safety and results of 
open lung biopsy during ECMO. We show that biopsy is recommended after seven days 
of ECMO, except when ACD/MPV or another lethal congenital pulmonary abnormality is 
highly suspected. In that case biopsy is recommended within the first week of ECMO or 
ideally before ECMO is initiated. Another intervention during ECMO is surgery. Surgery 
during a status of anticoagulation can be troublesome. In chapter 9 we show that with 
slight adjustments in the level of anticoagulation surgical correction of congenital dia-
phragmatic hernia can safely be performed during ECMO.
chapter 10 gives an overview of the available pharmacokinetic (PK) and pharmaco-
dynamics (PD) studies in neonates and children on ECMO, suggesting a number of pos-
sible mechanisms of altered PK. PK of several drugs is altered in neonates and children 
on ECMO. Changes in PK are drug and circuit dependent with more dramatic changes 
found for lipophilic drugs and in case the circuit contains silicone oxygenators. But basi-
cally this chapter shows that evidence based dose regimens are still largely lacking for 
many regularly used drugs in neonates and older children on ECMO. 
In chapter 11 we describe a case series of 241 consecutive ECMO patients, treated 
with a new diagonal centrifugal mini pump with a very small priming volume. The 
results of this study are at least comparable with the” old” system and shows the largest 
international data collection within a reasonable time frame. As such it can form a refer-
ence for future studies
chapter 12 contains amongst others an editorial paper based on a laboratory study 
in rabbits with induced congenital diaphragmatic hernia (CDH), in which we discuss the 
future perspectives of the use of perfluorocarbons in CDH. 
In chapter 13 the main results of our studies are discussed within the context of the 
international literature and considerations and perspectives are defined for the future 
management of pediatric ECMO patients including a plea for international evidence 
based guidelines and collaboration. chapter 14 contains the summary. 
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sAMEnVAtting
Het doel van dit proefschrift is om wetenschappelijke gegevens te genereren die helpen 
om de behandeling van falende gasuitwisseling bij kinderen te verbeteren.
deel 1. Mechanische beademing voor falende gasuitwisseling bij kinderen
In hoofdstuk 2 zoeken we in de literatuur naar bewijzen voor optimale beademingsin-
stellingen tijdens kunstmatige beademing bij kinderen. De beschikbare literatuur voor-
ziet niet in voldoende bewijs voor de beste ventilatiemodus bij ernstig zieke kinderen 
buiten de pasgeboren periode. Met betrekking tot hoogfrequente beademing vonden 
we dat dit een betere oxygenatie geeft na 72 uur dan conventionele beademing. Er is 
echter geen bewijs dat hoogfrequente beademing de mortaliteit en beademingsduur 
zou verminderen. Met deze kennis werd op onze afdeling een algoritme voor beade-
mingsinstellingen van ernstig zieke kinderen vastgesteld. In hoofdstuk 3 beschrijven 
we de implementatie van een dergelijk algoritme voor het gebruik op onze kinderIC. 
Dit algoritme verbetert de uitvoering door artsen van het beademingsalgoritme en dit 
effect bleek duurzaam te zijn.
Wanneer long beschermende beademing niet voldoende gasuitwisseling geeft, is een 
alternatieve manier om zuurstof to te dienen en kooldioxide te verwijderen, Extracor-
porele Membraanoxygenatie (ECMO). In hoofdstuk 4 beschrijven we het beschikbare 
bewijs voor het gebruik van ECMO buiten de pasgeboren leeftijdsperiode voor respira-
toir en circulatoir falen. Met dit bewijs stellen wij indicaties en contra-indicaties op voor 
niet-neonatale ECMO, die de basis kunnen vormen voor internationale samenwerking.
deel 2. Extracorporele membraanoxygenatie om gasuitwisseling bij kinderen 
te ondersteunen
In hoofdstuk 5 richten we ons op de voorspellende waarde van lactaat metingen. 
Lactaat is een eindproduct van koolhydraatmetabolisme en correleert met zowel de 
ernst van ziekte als de sterfte. We evalueerden de betekenis van lactaat; statische en 
dynamische lactaat indices in de voorspelling van mortaliteit. De resultaten van deze 
studie hebben aangetoond dat bij pasgeborenen tijdens ECMO lactaat niet voorspel-
lend was voor de kans op overlijden en bij oudere ECMO patiënten statische arteriële 
lactaat meting een hogere voorspellende waarde heeft voor het overlijden bij patiënten 
met primair falen van de longen.
In hoofdstuk 6 presenteren we een retrospectieve analyse naar de mogelijke rol van 
preoperatieve ECMO bij neonaten, geboren met een transpositie van de grote vaten, 
met een ernstige hypoxemie ondanks conventionele maatregelen. We laten zien dat 
ondanks interventies om de oxygenatie te verbeteren, kritische hypoxemie optreedt en 
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dat preoperatieve ECMO kan helpen de patiënt te stabiliseren en zo de mogelijkheid 
biedt voor verdere chirurgische correctie van het hart.
Met meer en meer patiënten aan ECMO, voor steeds langere perioden, ontbreken in de 
literatuur goed gedefinieerde richtlijnen voor de behandeling van deze patiënten. We 
beschrijven in hoofdstuk 7 onze patiënten, die gedurende 21 dagen of langer ECMO-
behandeling kregen. We laten zien dat met name bij patiënten met respiratoire ECMO , 
overleving tot ontslag 44% kan zijn. We tonen aan dat zowel medicatie als interventies 
een belangrijke rol spelen bij de behandeling van deze langdurige ECMO patiënten.
Een van de interventies tijdens ECMO is “open longbiopsie”. Deze techniek wordt 
gebruikt om de oorsprong van de ziekte te bepalen en soms wordt de uitkomst gebruikt 
om de therapie aan te passen of om vast te stellen dat de behandeling uitzichtloos is. In 
hoofdstuk 8 beschrijven we de haalbaarheid en de veiligheid en de resultaten van de 
“open longbiopsie” tijdens ECMO. We laten zien dat biopsie wordt aanbevolen na zeven 
dagen ECMO, tenzij Alveolaire Capillaire Dysplasie (ACD / MPV) of een andere dodelijke 
aangeboren longafwijking sterk wordt vermoed. In dat geval wordt biopsie aanbevolen 
binnen de eerste week van ECMO of idealiter voor de start van ECMO. Een andere inter-
ventie tijdens ECMO is een operatie. Chirurgie tijdens het gebruik van ontstolling kan 
lastig zijn. 
In hoofdstuk 9 laten we zien dat met kleine aanpassingen in het antistollingsniveau, 
chirurgische correctie van een congenitale hernia diafragmatica veilig kan worden 
uitgevoerd tijdens ECMO. 
Hoofdstuk 10 geeft een overzicht van de beschikbare farmacokinetische (PK) en 
farmacodynamische (PD) studies bij pasgeborenen en kinderen aan ECMO en beschrijft 
een aantal mogelijke mechanismen voor veranderingen in de farmacokinetiek De PK 
van verschillende geneesmiddelen verandert bij pasgeborenen en kinderen aan ECMO. 
Veranderingen in de PK zijn medicatie en circuit afhankelijk, waarbij grotere verande-
ringen gevonden worden bij zogenaamde lipofiele geneesmiddelen en bij het gebruik 
van systemen met siliconen membraanlongen. Maar vooral laat dit hoofdstuk zien dat 
evidence-based doseringsschema’s nog grotendeels ontbreken voor veel van de regel-
matig gebruikte medicijnen bij pasgeborenen en oudere kinderen aan ECMO.
In hoofdstuk 11 beschrijven we een serie van 241 opeenvolgende ECMO patiënten, 
behandeld met een nieuwe diagonale mini centrifugaalpomp met een zeer klein 
volume. De resultaten van deze studie zijn ten minste vergelijkbaar met de “oude” 
systemen en tonen aan dat een grote verzameling internationale gegevens binnen een 
redelijke termijn te verkrijgen is. Als zodanig kan dit een referentie voor toekomstige 
studies vormen.
Hoofdstuk 12 bevat een editorial naar aanleiding van een experimentele studie bij 
konijnen met geïnduceerde congenitale hernia diafragmatica, waarin we het gebruik 
van perfluorocarbons bij congenitale hernia diafragmatica evalueren.
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In hoofdstuk 13 worden de belangrijkste resultaten van onze onderzoeken besproken 
in de context van de internationale literatuur. Overwegingen en perspectieven worden 
gedefinieerd voor de toekomstige behandeling van kinderen met ECMO, waaronder 
een pleidooi voor internationale evidence-based richtlijnen en samenwerking. 
Hoofdstuk 14 bevat de samenvatting.
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list Of AbbREViAtiOns
AaDO2  Alveolar-arterial oxygen tension difference 
ACD/MPV Alveolar capillary dysplasia/misalignment of pulmonary veins
ACT  Activated clotting time 
ARDS  Acute respiratory distress syndrome
ASO   Arterial switch operation
BAS   Balloon atrial septostomy
BSI  Blood stream infections
CDC  Centre for disease control
CLD  Chronic lung disease
CPB  Cardio pulmonary bypass
CPR  Cardio pulmonary resuscitation
ECMO  Extracorporeal Membrane Oxygenation
ECLS  Extracorporeal life Support
ELSO  Extracorporeal life support organization
FiO2  Fraction of inspired oxygen
ICU  Intensive care unit
IQR  Inter quartile range
LCOS  Low cardiac output state
LC-MS  Liquid chromatography-mass spectrometry
LOV  Length of ventilation
MCS  Mechanical cardiac support 
NO   Nitric oxide
NONMEM Nonlinear mixed effect modelling
NRS  Numeric rating scale
O.I.  Oxygenation index 
pCO2  Partial arterial pressure of carbondioxide
PD  Pharmacodynamics
PDMS  Patient data management system
PF  Pao2/Fio2 ratio
PFC  Perfluorocarbon
PH  Pulmonary hypertension.
(P)ICU  (Pediatric) intensive care unit
PK  Pharmacokinetics
pO2  Partial pressure of oxygen
RRT  Renal replacement therapy 
SaO2   Saturation of oxygen
VA  Venoarterial
VAD (R)(L) Ventricular assist device (R)ight, (L)eft 
VA-ECMO Venoarterial extracorporeal membrane oxygenation
VV  Venovenous
VV- ECMO Venovenous extracorporeal membrane oxygenation
VVDL  Venovenous double lumen 
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voor je vernieuwende inzichten in de neonatale zorg. Nou maar een keer zeilen.
Dr. Van Heijst, beste Arno, “when east meets west you get the best”. Wanneer gaan we 
weer van de piste in Keystone? Hartelijk dank voor alles wat je voor mij hebt gedaan. 
Overige leden van de promotiecommissie, dank voor jullie interesse in mijn proefschrift 
en voor het feit dat jullie de tijd vrijgemaakt hebben om mij hierover te bevragen.
Professor Lachmann, beste Burkhard, jij hebt mij als jonge student meegenomen in 
jouw ”Open-Lung” concept. Het was mij een voorrecht om samen met jou jaren lang 
dit concept te mogen overbrengen op honderden collega’s overal op de wereld. Nog 
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steeds ben ik blij dat ik het echt begrepen heb en “er mit klar komm”. Je hebt voor altijd 
de standaard gezet voor het geven van een kerstborrel. Dank voor alles.
Judith Visser, mijn steun en toeverlaat, zonder wie de uitvoering van mijn taken al lang 
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Miranda in het bijzonder. Dank voor de zorgzaamheid voor onze patiënten en voor mij. 
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